研究者総覧

山口 博紀 (ヤマグチ ヒロノリ)

  • 博士課程地域医療学系専攻腫瘍医学専攻分野地域がん総合医学専攻科 教授
Last Updated :2021/12/07

研究者情報

学位

  • 医学博士(東京大学)

ホームページURL

J-Global ID

研究キーワード

  • Clinical Oncology   臨床腫瘍学   

研究分野

  • ライフサイエンス / 腫瘍診断、治療学

研究活動情報

論文

  • Kobayashi D, Ishigami H, Kanda M, Tanaka C, Yamaguchi H, Kitayama J, Kodera Y
    Oncology 98 1 1 - 5 2019年09月 [査読有り][通常論文]
     
    INTRODUCTION: Intraperitoneal (IP) chemotherapy is a promising treatment option for gastric cancer (GC) with peritoneal metastasis (PM). Recently, superiority of IP administration of paclitaxel (PTX) combined with S-1 and intravenous PTX over conventional systemic chemotherapy was suggested in a phase III study, although the difference in overall survival did not reach statistical significance in the primary analysis. Thus, attempts to combine IP PTX with other systemic therapies with higher efficacy are warranted. We designed a new regimen combining IP PTX with S-1 plus cisplatin (SP), which is regarded as the standard first-line treatment for metastatic GC in Japan, and subsequently carried out a dose-escalation study. METHODS: The combination was a 5-weekly regimen. IP PTX was to be administered on days 1, 8, and 22 with an initial dose of 15 mg/m2 at level 1 and 20 mg/m2 at level 2. S-1 was to be administered orally at a fixed dose of 80 mg/m2 b.i.d. for 21 days followed by a -14-day rest. Cisplatin was to be administered intravenously at a dose of 60 mg/m2 on day 8. Dose-limiting toxicities (DLTs) were defined as grade 4 leukopenia, grade 3 (G3) febrile neutropenia, G3 thrombocytopenia, and G3 nonhematological toxicity. RESULTS: A total of 9 patients with macroscopic PM were enrolled. No DLTs were observed among the 3 patients at level 1 and 6 patients at level 2. No adverse events or technical problems associated with the IP administration were observed. Consequently, the maximum-tolerated dose was not reached, and the dose for further clinical trials of IP PTX was determined as 20 mg/m2. As for efficacy, peritoneal lavage cytology turned negative after the first course in 4 of 7 patients who had positive cytology before treatment. CONCLUSION: The present study determined the dose for further clinical trials of IP PTX to be 20 mg/m2, when combined with the 5-weekly SP regimen.
  • Kaneko Y, Saito S, Takahashi K, Kanamaru R, Hosoya Y, Yamaguchi H, Kitayama J, Niki T, Lefor AK, Sata N
    Clinical journal of gastroenterology 12 6 534 - 538 2019年05月 [査読有り][通常論文]
     
    A 68-year-old male was referred with dysphagia. Endoscopic findings showed circular stenosis with a protruding mass in the lower esophagus. Biopsy showed adenocarcinoma and there was no evidence of distant metastases. A subtotal esophagectomy was performed. The resected specimen revealed a mixed neuroendocrine carcinoma with adenocarcinoma. The adenocarcinoma component was on the surface of the tumor and the neuroendocrine component invaded the deeper portion. Immunohistochemically, the neuroendocrine carcinoma component stained positive for cytokeratin 7 and cytokeratin 20, suggesting that the neuroendocrine carcinoma originated from the adenocarcinoma. The adenocarcinoma component stained positive for MUC2, which suggests that the adenocarcinoma component originated from Barrett's epithelium. Taken together, the neuroendocrine carcinoma may have originated from Barrett's epithelium. A metastasis to the liver was found 2 months after the surgical resection. Chemotherapy was administered, but there was no response. Most esophageal neuroendocrine carcinomas are accompanied by adenocarcinoma or squamous cell components, suggesting that these carcinomas originate from pluripotent cells in squamous or Barrett's epithelium. Appropriate chemotherapy for these lesions should be considered based on the cell of origin.
  • Atsumi T, Seki Y, Yamaguchi H
    Disasters 43 2 355 - 371 2019年04月 [査読有り][通常論文]
  • Kaneko Y, Saito S, Takahashi D, Ui T, Haruta H, Kurashina K, Yamaguchi H, Hosoya Y, Kitayama J, Lefor AK, Sata N
    International journal of surgery case reports 62 140 - 143 2019年 [査読有り][通常論文]
     
    INTRODUCTION: Immune thrombocytopenic purpura is an acquired thrombocytopenia. Preoperative management of thrombocytopenia is important in patients with gastric cancer. Partial splenic embolization can be effective for patients with thrombocytopenia, but could lead to ischemic necrosis of the remnant stomach when performing subtotal gastrectomy with splenectomy. PRESENTATION OF CASE: The patient is an 84-year old woman evaluated for anemia. Endoscopy revealed an advanced gastric cancer with bleeding. The patient also had immune thrombocytopenic purpura with a platelet count <50,000/μL. Administration of platelets did not increase the platelet count. Partial splenic embolization was performed followed by administration of high-dose immunoglobulin. The platelet count was over 50,000/μL preoperatively. The patient underwent combined subtotal gastrectomy and splenectomy, followed by an uneventful course. DISCUSSION: Patients with immune thrombocytopenic purpura and advanced gastric cancer can have anemia. Partial splenic embolization has been used to treat patients with refractory immune thrombocytopenic purpura as an alternative to splenectomy. Preoperative partial splenic embolization and high-dose immunoglobulin therapy resulted an increased platelet count in this patient. Elderly patients with gastric cancer have a high risk of postoperative complications. Patients with gastric cancer undergoing total gastrectomy have an impaired postoperative quality of life compared to those who undergo subtotal gastrectomy. We performed a subtotal gastrectomy and splenectomy as a function-preserving operation, completed safely by maintaining blood flow to the remnant stomach. CONCLUSION: Partial splenic embolization is effective for patients with immune thrombocytopenic purpura and gastric cancer. Combined subtotal gastrectomy and splenectomy is achieved by preserving blood flow to the remnant stomach.
  • Takahashi K, Saito S, Kaneko Y, Matsumoto S, Yamaguchi H, Kitayama J, Hosoya Y, Kawata H, Lefor AK, Sata N
    International journal of surgery case reports 64 180 - 183 2019年 [査読有り][通常論文]
     
    INTRODUCTION: Gastric hyperplastic polyps are common stomach lesion and these polyps are generally benign. However, they can undergo malignant transformation. Most reported cases of malignant transformation of gastric hyperplastic polyps have been to well or moderately differentiated adenocarcinoma, and those transformed into poorly differentiated adenocarcinoma are extremely rare. No case has been reported that has changed to diffuse type adenocarcinoma with lymphatic invasion. PRESENTATION OF CASE: A 48-year-old woman presented with worsening anemia. A polyp was seen in the gastric cardia seven years prior to presentation. Helicobacter pylori infection was also found at that time. She underwent upper gastrointestinal endoscopy and biopsy of the polyp revealed signet ring cell carcinoma. Total gastrectomy was performed due to concern about possible invasion into the submucosal layer and there was no evidence of distant metastases. Histologic examination revealed both poorly differentiated adenocarcinoma and signet ring cell carcinoma surrounded by hyperplastic epithelium at the head of the polyp. Lymphatic invasion was also found, and malignant cells were limited to the mucosa. DISCUSSION: Gastric hyperplastic polyps are commonly associated with chronic gastritis which is related to Helicobacter pylori infections. Gastric hyperplastic polyps are generally benign and rarely undergo malignant transformation to adenocarcinoma with differentiated histology. The gastric hyperplastic polyp in this patient transformed to poorly differentiated adenocarcinoma with lymphatic invasion. CONCLUSION: Even small polyps may become poorly differentiated adenocarcinoma with invasion, so close follow-up or endoscopic resection are recommended as well as eradication of Helico Pylori infection when appropriate.
  • Rihito Kanamaru, Hideyuki Ohzawa, Hideyo Miyato, Shiro Matsumoto, Hidenori Haruta, Kentaro Kurashina, Shin Saito, Yoshinori Hosoya, Hironori Yamaguchi, Hiroharu Yamashita, Yasuyuki Seto, Alan Kawarai Lefor, Naohiro Sata, Joji Kitayama
    Scientific Reports 8 1 632  2018年12月 [査読有り][通常論文]
     
    Many types of immune cells appear in peritoneal cavity after abdominal surgery. In patients who underwent laparotomy due to gastric cancer, peritoneal lavages were obtained before and after surgical procedure. Cells were recovered from intermediate layer after Ficoll-Hypaque centrifugation and analyzed for phenotypes and functions, especially focused on low density neutrophils (LDN). The number of CD66b (+) LDN with mature phenotype was markedly elevated in postoperative as compared with preoperative lavages. Short term culture of the purified LDN produced many threadlike structures positive for SYTOX, nucleic acid staining, as well as histone and myeloperoxidase, suggesting the NETs formation. Human gastric cancer cells, MKN45, OCUM-1 and NUGC-4, were selectively attached on the NETs, which was totally abolished by the pretreatment of DNAse I. Intraperitoneal (IP) co-transfer of the LDN with MKN45 in nude mice strongly augments the metastasis formation on peritoneum, which was strongly suppressed by the following IP administration of DNAse I. Many NETs-like structures were detected on the surface of human omental tissue resected by gastrectomy. NETs on peritoneal surface can assist the clustering and growth of free tumor cells disseminated in abdomen. Disruption of the NETs by DNAse might be useful to prevent the peritoneal recurrence after abdominal surgery.
  • Kanamaru R, Ohzawa H, Miyato H, Yamaguchi H, Hosoya Y, Lefor AK, Sata N, Kitayama J
    Journal of visualized experiments : JoVE 138 2018年08月 [査読有り][通常論文]
     
    Activated neutrophils release neutrophil extracellular traps (NETs), which can capture and destroy microbes. Recent studies suggest that NETs are involved in various disease processes, such as autoimmune disease, thrombosis, and tumor metastases. Here, we show a detailed in vitro technique to detect NET activity during the trapping of free tumor cells, which grow after attachment to NETs. First, we collected low density neutrophils (LDN) from postoperative peritoneal lavage fluid from patients who underwent laparotomies. Short-term culturing of LDN resulted in massive NET formation that was visualized with green fluorescent nuclear and chromosome counterstain. After co-incubation of human gastric cancer cell lines MKN45, OCUM-1, and NUGC-4 with the NETs, many tumor cells were trapped by the NETs. Subsequently, the attachment was completely abrogated by the degradation of NETs with DNase I. Time-lapse video revealed that tumor cells trapped by the NETs did not die but instead grew vigorously in a continuous culture. These methods may be applied to the detection of adhesive interactions between NETs and various types of cells and materials.
  • Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 36 19 1922 - 1929 2018年07月 [査読有り][通常論文]
     
    Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its superiority over standard systemic chemotherapy in overall survival. Patients and Methods This randomized phase III trial enrolled patients with gastric cancer with peritoneal metastasis who had received no or short-term (< 2 months) chemotherapy. Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 plus S-1 80 mg/m2 per day on days 1 to 14 for a 3-week cycle) or S-1 plus cisplatin (SP; S-1 80 mg/m2 per day on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 for a 5-week cycle), stratified by center, previous chemotherapy, and extent of peritoneal metastasis. The primary end point was overall survival. Secondary end points were response rate, 3-year overall survival rate, and safety. Results We enrolled 183 patients and performed efficacy analyses in 164 eligible patients. Baseline characteristics were balanced between the arms, except that patients in the IP arm had significantly more ascites. The median survival times for the IP and SP arms were 17.7 and 15.2 months, respectively (hazard ratio, 0.72; 95% CI, 0.49 to 1.04; stratified log-rank P = .080). In the sensitivity analysis adjusted for baseline ascites, the hazard ratio was 0.59 (95% CI, 0.39 to 0.87; P = .008). The 3-year overall survival rate was 21.9% (95% CI, 14.9% to 29.9%) in the IP arm and 6.0% (95% CI, 1.6% to 14.9%) in the SP arm. Both regimens were well tolerated. Conclusion This trial failed to show statistical superiority of intraperitoneal paclitaxel plus systemic chemotherapy. However, the exploratory analyses suggested possible clinical benefits of intraperitoneal paclitaxel for gastric cancer.
  • Kensuke Otani, Soichiro Ishihara, Keisuke Hata, Koji Murono, Kazuhito Sasaki, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Hiroaki Nozawa, Hironori Yamaguchi, Toshiaki Watanabe
    Asian Journal of Surgery 41 3 197 - 202 2018年05月 [査読有り][通常論文]
     
    Colorectal cancer is seldom accompanied by venous tumor thrombosis, and little is known about the features of venous tumor thrombosis in colorectal cancer. However, some reports show that colorectal cancer patients can develop venous tumor thrombosis and warn clinicians not to overlook this complication. In this report, we perform a review of 43 previously reported cases and investigate the characteristics of colorectal cancer accompanied by venous tumor thrombosis. The histological type of more than half of the cases was moderately differentiated adenocarcinoma, which is known to be aggressive. Among 41 cases with available data on liver metastasis, eight patients had synchronous liver metastasis, and liver metastatic recurrence after surgical resection was indicated in 10 patients. This liver metastatic rate was high compared to general colorectal cancer. However, 11 of 43 patients with venous tumor thrombosis could survive for more than 2 years after the diagnosis, although five of the 11 patients had liver metastasis. A long survival can be anticipated for patients following complete tumor resection and adjuvant chemotherapy. A greater accumulation of cases will help elucidate the characteristics of colorectal cancer with venous tumor thrombosis and improve the treatment strategy.
  • Kitayama J, Ishigami H, Yamaguchi H, Sakuma Y, Horie H, Hosoya Y, Lefor AK, Sata N
    Annals of gastroenterological surgery 2 2 116 - 123 2018年03月 [査読有り][通常論文]
     
    Despite recent advances in chemotherapy, outcomes of patients with peritoneal metastases (PM) from gastric cancer are still very poor and standard treatment has not been established. Although oral S-1 appears to be effective for patients with PM, the effects of systemic chemotherapy are limited. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) yield fewer benefits in patients with PM from gastric cancer than in patients with PM from other malignancies. In comparison, repeated intraperitoneal chemotherapy (RIPEC) with taxanes using an implantable peritoneal access port has a pharmacokinetic advantage for the control of peritoneal lesions and in combination with systemic chemotherapy can result in surprisingly long-term survival in patients with PM from gastric cancer. Herein, we review the results of recent clinical studies specifically targeting PM from gastric cancer and discuss future prospects for an intraperitoneal approach to the ideal treatment of patients with gastric cancer with peritoneal involvement.
  • Yuzo Harada, Shinsuke Kazama, Teppei Morikawa, Koji Murono, Koji Yasuda, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Hiroaki Nozawa, Hironori Yamaguchi, Soichiro Ishihara, Toshiaki Watanabe
    ONCOLOGY LETTERS 14 6 7791 - 7798 2017年12月 [査読有り][通常論文]
     
    Preoperative chemoradiotherapy has been performed as a standard therapy for advanced low rectal cancer. Cancer stem cells (CSCs) have been reported to contribute to resistance to treatment and patient prognosis. Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) and cluster of differentiation (CD133) are putative markers for CSCs. However, their prognostic ability remains unknown, and evaluation of a single marker can be insufficient due to the heterogeneity of cancer. LGR5 and CD133 expression was immunohistochemically evaluated in surgical specimens of 56 patients who received curative resection following chemoradiotherapy for advanced low rectal cancer. In addition, the correlations between their expression levels, and clinicopathological features and patient prognosis were asessed. LGR5 expression was significantly correlated with lymphatic invasion, lymph node metastasis, and tumor node metastasic (TNM) stage. CD133 expression was significantly correlated with vascular invasion and the tumor regression grade. Combined expression was significantly correlated with lymphatic invasion, tumor regression grade and TNM stage, but not with overall, and disease-free survival. LGR5 and CD133 expressions may represent useful markers associated with tumor progression and resistance to chemoradiotherapy in patients with low rectal cancer. Furthermore, combined expression of these markers may be a more useful marker compared with the expression of each single marker.
  • Hirofumi Sonoda, Kazushige Kawai, Hironori Yamaguchi, Koji Murono, Manabu Kaneko, Takeshi Nishikawa, Kensuke Otani, Kazuhito Sasaki, Koji Yasuda, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Soichiro Lshihara, Susumu Aikou, Hiroharu Yamashita, Tetsuo Ushiku, Yasuyuki Seto, Masashi Fukayama, Toshiaki Watanabe
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY 41 6 E81 - E86 2017年12月 [査読有り][通常論文]
     
    Metastases to the colon are rare and a high-frequency primary region is the stomach. In cases of metastases to the colon, the morphological type of the metastatic region is mostly the infiltrating type of poorly differentiated or undifferentiated adenocarcinoma with lymph and blood vessel invasion. A case of cancer metastasis to the transverse colon that originated from advanced gastric cancer, which shows the difficulties in the precise diagnosis of metastases to the colon, is presented. In the present case, the gastric carcinoma was determined to be an advanced infiltrative ulcerative adenocarcinoma and the colon carcinoma was determined to be a superficial depressed adenocarcinoma. After surgery, the colon carcinoma was diagnosed as a metastatic adenocarcinoma from gastric adenocarcinoma with high invasion of vessels, by immunohistopathological analysis of CK7, CK20, p53 and HER-2. In this report, previously reported cases of metastases to the colon from gastric cancer were reviewed and their morphological characteristics were analyzed. (C) 2017 Elsevier Masson SAS. All rights reserved.
  • Hironori Yamaguchi, Masataka Okada, Yohei Kono, Shunichiro Kittaka, Toshiro Sakakibara, Toshiki Okabe, Yoshiki Iwasaki, Yuko Hosokoshi
    SCIENTIFIC REPORTS 7 1 16144  2017年11月 [査読有り][通常論文]
     
    Quantum entanglement in magnetic materials is expected to yield a quantum spin liquid (QSL), in which strong quantum fluctuations prevent magnetic ordering even at zero temperature. This topic has been one of the primary focuses of condensed-matter science since Anderson first proposed the resonating valence bond state in a certain spin-1/2 frustrated magnet in 1973. Since then, several candidate materials featuring frustration, such as triangular and kagome lattices, have been reported to exhibit liquid-like behavior. However, the mechanisms that stabilize the liquid-like states have remained elusive. Here, we present a QSL state in a spin-1/2 honeycomb lattice with randomness in the exchange interaction. That is, we successfully introduce randomness into the organic radialbased complex and realize a random-singlet (RS) state (or valence bond glass). All magnetic and thermodynamic experimental results indicate the liquid-like behaviors, which are consistent with those expected in the RS state. Our results suggest that the randomness or inhomogeneity in the actual systems stabilize the RS state and yield liquid-like behavior.
  • Kazuhito Sato, Toshiaki Tanaka, Jiro Sato, Eisuke Shibata, Yuzo Nagai, Koji Murono, Koji Yasuda, Kensuke Otani, Takeshi Nishikawa, Junichiro Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Kuni Ohtomo, Toshiaki Watanabe
    Asian Journal of Surgery 40 6 438 - 443 2017年11月 [査読有り][通常論文]
     
    Background Computed tomographic colonography (CTC) is reported to be feasible for screening of colorectal polyps however, its efficacy in preoperative workup remains unknown. This study was done to define our CTC methodology and assess CTC's potential for preoperative examination in patients with colon cancer. Methods A total of 86 colon cancer patients underwent CTC prior to laparoscopic colectomy in our department from February 2014 to November 2015. The location of primary colon cancer determined by CTC was compared with that confirmed during the surgery. CTC was performed just after preoperative colonoscopy for a small colon cancer, we performed clipping during colonoscopy to enhance CTC detectability. We classified wall deformities and compared them with the pathological T stage. Results CTC accurately located all 87 primary colon cancers prior to surgery. No patient experienced complications associated with CTC. The deformity classification correlated significantly with the pathological T stage (p < 0.001, Kruskal–Wallis nonparametric tests). CTC provided reconstructed images depicting the feeding artery of the primary colon cancer feeding artery information obtained by CTC facilitated precise lymph node dissection. Conclusion CTC appears to be a feasible and useful preoperative examination modality for colon cancer treatment.
  • Hiroshi Nagata, Hironori Yamaguchi, Toshiaki Watanabe
    ANZ JOURNAL OF SURGERY 87 10 844 - 845 2017年10月 [査読有り][通常論文]
  • Hironori Yamaguchi, Yumiko Satoh, Hironori Ishigami, Makiko Kurihara, Yutaka Yatomi, Joji Kitayama
    ANNALS OF SURGICAL ONCOLOGY 24 11 3345 - 3352 2017年10月 [査読有り][通常論文]
     
    The outcome of gastric cancer patients with peritoneal metastasis remains poor. We treated these patients with intraperitoneal and intravenous paclitaxel plus oral S-1 (tegafur/gimeracil/oteracil), followed by gastrectomy in responders. We evaluated the clinical significance of peritoneal lavage carcinoembryonic antigen (CEA) messenger RNA (mRNA) levels as a biomarker for indication of conversion gastrectomy. The peritoneal lavage of 68 patients who received the above regimen as induction chemotherapy was repeatedly collected via intraperitoneal access ports. Gastrectomy was considered when improvement of peritoneal metastasis was confirmed by a second laparoscopic examination with negative peritoneal cytology. CEA and porphobilinogen deaminase mRNAs were chronologically quantified using the transcription reverse-transcription concerted reaction method. The CEA mRNA index (CmRI) was calculated as CEA mRNA/porphobilinogen deaminase mRNA x 10,000. Thirty-nine patients underwent gastrectomy and 29 patients did not (median survival time, 27.8 vs. 10.7 months, respectively; P < 0.001). In gastrectomy-positive patients, the outcome largely differed according to CmRI values immediately prior to surgery. Patients with a preoperative CmRI value < 100 (n = 20) were associated with a significantly longer survival than those with a preoperative CmRI value > 100 (n = 19) (41.8 vs. 20.1 months, respectively; P < 0.001). A preoperative CmRI value < 100 was confirmed as an independent predictor of survival for gastrectomy-positive patients in the multivariate analysis. The CmRI reflects the response of peritoneal metastases to induction intraperitoneal chemotherapy. It may be a useful biomarker for indicating gastrectomy in gastric cancer patients with peritoneal metastasis.
  • Chieko Hirao, Naoko Mikoshiba, Tomomi Shibuta, Reiko Yamahana, Aki Kawakami, Ryosuke Tateishi, Hironori Yamaguchi, Kazuhiko Koike, Noriko Yamamoto-Mitani
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 47 9 786 - 794 2017年09月 [査読有り][通常論文]
     
    Objective: The purpose of this study was to investigate medication adherence to oral chemotherapy medications and determinants of medication non-adherence to them among gastroenterological cancer patients. Methods: A cross-sectional study was conducted on 117 consecutive, consenting, eligible patients visiting an outpatient clinic of university hospital in Japan. Good medication adherence was defined as taking 100% of the prescribed dose. Medication adherence was measured via self-report. We hypothesized that there was a significant relationship between medication non-adherence and the five factors defined by the World Health Organization: patient-related, socioeconomic-related, condition-related, treatment-related, and healthcare-system/provider-related factors. Multiple logistic regression models were used to identify factors associated with oral chemotherapy medication non-adherence. Results: The proportion of patients showing good medication adherence was 56.4%. The multiple logistic regression analysis revealed that the determinants of medication non-adherence to oral chemotherapy medications included having a history of patient-caused treatment interruptions due to worsening of symptoms (adjusted odds ratio [AOR] = 9.59, 95% confidence interval [CI] = 1.38-66.47), having diarrhea (AOR = 3.25, 95% CI = 1.13-9.34), experiencing pain (AOR = 0.17, 95% CI = 0.05-0.55), taking oral chemotherapy medication every 8 h (AOR = 5.52, 95% CI = 1.71-17.81), and diminished sense of priority for medication (AOR = 1.40, 95% CI = 1.21-1.63). Conclusions: This study suggests that many patients with gastroenterological cancer were non-adherent to oral chemotherapy medications. It might be necessary to conduct periodic screening and connect patients at a high risk of medication non-adherence to appropriate support.
  • Seiichi Ohta, Shota Hiramoto, Yuki Amano, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, Joji Kitayama, Taichi Ito
    MOLECULAR PHARMACEUTICS 14 9 3105 - 3113 2017年09月 [査読有り][通常論文]
     
    Intraperitoneal administration of chemotherapeutics is expected for the treatment of peritoneally disseminated gastric cancer because of poor migration of the drugs from the systemic circulation to the peritoneal cavity. In this study, for intraperitoneal delivery of cisplatin (CDDP), we developed a hyaluronan (HA)-based hybrid system in which CDDP-loaded HA nanogels were either physically encapsulated in or chemically conjugated to injectable HA hydrogels. Physical encapsulation enabled sustained release of HA nanogels from the HA hydrogel matrix for over a week. This was a longer release period than that of encapsulated free CDDP, which released 80% of the drug in 2 days. The longer release was attributed to delayed diffusion of HA nanogels from the hydrogel matrix network. The release profile could be tuned by modifying the chemical conjugation of HA nanogels to the HA hydrogel matrix, as well as the type of chelating ligands used to load CDDP to the nanogel. Furthermore, intraperitoneally administered hybrid had significant antitumor activity in a mouse model of peritoneally disseminated gastric cancer, especially for nodules smaller than 1.0 mm.
  • Kitayama J, Ishigami H, Yamaguchi H, Yamada J, Soma D, Miyato H, Kamei T, Lefor AK, Sata N
    Pleura and peritoneum 2 2 95 - 102 2017年06月 [査読有り][通常論文]
     
    Background: Repeated intraperitoneal (IP) administration of paclitaxel (PTX) with concurrent systemic chemotherapy is clinically effective for the treatment of peritoneal metastases (PM) from gastric cancer. However, it is unclear how biochemical modifications may affect the pharmacokinetics and bioavailability of IP administered PTX. Methods: In a xenograft PM model using human gastric cancer cells, MKN45, fluorescein-conjugated PTX (OG-PTX) was given IP and the intra-tumor distribution of PTX examined with fluorescein microscopy. Results: After IP injection, PTX was seen to directly infiltrate up to several hundred micrometers from the surface of the PM. Co-injection with 5 % non-animal stabilized hyaluronic acid increased PTX infiltration and suppressed the development of PM more efficiently than PTX alone. PTX solubilized with amphiphilic polymer composed of 2-methacryloyloxyethyl phosphorylcholine (MPC) and n-butyl methacrylate (BMA) efficiently formed a micellar formation 50-100 nm in diameter. IP injection of the nanomicellar PTX (PTX-30W) also showed significantly enhanced tumor infiltration and further inhibition of the growth of PM compared with PTX solubilized with Cremophor-ethanol (PTX-Cre). Finally, IP administration of NK105, another nanomicellar PTX, inhibited the growth of subcutaneous tumors as well as PM, compared with conventional PTX-Cre in the same murine model. Conclusions: PTX administered IP directly infiltrates PM and are thus a useful strategy for the treatment of PM. Drug modification with nanotechnology may further enhance penetration of PM resulting in improved clinical efficacy.
  • Hiroyuki Matsuzaki, Soichiro Ishihara, Kazushige Kawai, Koji Murono, Kensuke Otani, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Hironori Yamaguchi, Toshiaki Watanabe
    SURGERY TODAY 47 5 627 - 635 2017年05月 [査読有り][通常論文]
     
    Purpose To evaluate the advantages of laparoscopic surgery for rectal cancer in obese patients. Methods We collected clinical data from consecutive patients who underwent anterior resection for rectal cancer between 2008 and 2015 to compare the surgical outcomes of a laparoscopic surgery group (LG) with those of an open surgery group (OG) stratified by obesity. Obesity was defined as a body mass index >= 25. Results A total of 268 patients were analyzed, with 157 in the LG (44 obese and 113 non-obese) and 111 in the OG (25 obese and 86 non-obese). The rates of complications between the LG and the OG were 18.5 vs. 11.6 % (p = 0.18) for the non-obese patients and 18.2 vs. 20.0 % (p = 1.0) for the obese patients, respectively, without a significant difference. Operative time was longer in the LG than in the OG, but the difference between the non-obese and obese patients was not significant, being 266 vs. 189 min (p < 0.0001) and 260 vs. 254 min (p = 0.96), respectively. Blood loss was much lower in the LG for both obese and non-obese patients, being 10 vs. 435 mL (p < 0.0001) and 10 vs. 275 mL (p < 0.0001), respectively. Conclusions There were no significant differences between LG and OG in operative time or complications for obese patients with rectal cancer, and blood loss was much lower in the LG. Thus, laparoscopic surgery is a safe and minimally invasive approach for obese patients with rectal cancer.
  • Shigenobu Emoto, Hironori Ishigami, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    SURGERY TODAY 47 3 280 - 283 2017年03月 [査読有り][通常論文]
     
    Although the incidence of port-site metastasis after laparoscopic surgery for colorectal cancer has markedly decreased since laparoscopic colectomy was first reported in 1991, it still has not reached zero. In colorectal cancer, the safety of laparoscopic surgery, including the low incidence of port-site metastasis, has been proven in large, randomized trials. In gastric cancer, reports of port-site metastasis are extremely rare, but we should await the results of ongoing trials. This brief review summarizes the current knowledge regarding port-site metastasis after laparoscopic surgery for colorectal and gastric cancer.
  • Takahide Shinagawa, Soichiro Ishihara, Hiroaki Nozawa, Koji Murono, Takeshi Nishikawa, Kensuke Otani, Kazuhito Sasaki, Koji Yasuda, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hironori Yamaguchi, Akimasa Hayashi, Mariko Tanaka, Tetsuo Ushiku, Masashi Fukayama, Toshiaki Watanabe
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY 41 2 E19 - E23 2017年03月 [査読有り][通常論文]
     
    Colorectal cancer resembling submucosal tumor (SMT) is very rare. We herein report two cases of small colon carcinoma resembling SMT (80-year-old female and 67-year-old male), which massively invaded into the submucosal layer and accompanied marked lymphatic invasion and lymph node metastasis. We also reviewed the reported cases of colorectal carcinoma resembling SMT (SMT-like group, n = 70) and analyzed the clinicopathological characteristics of this group compared with typical colorectal carcinoma cases operated at our institution (control group, n = 1723). Tumors in the SMT-like group were significantly smaller in size compared with the control group; the median diameter measured 22 mm vs. 37 mm (P < 0.01), respectively. Histologically, although the tumors in the SMT-like group were small in diameter, they almost all invaded into the submucosal (T1) or deeper layer (T2-4), and the rate of poorly differentiated adenocarcinoma or mucinous adenocarcinoma was significantly higher than that in the control group (48.6% vs. 7.7%; P < 0.01). In the subgroup analysis of T1 tumors, the rate of lymphatic invasion in the SMT-like group was also significantly higher than that in the control group (43.8% vs. 15.4%; P < 0.01). Carcinoma resembling SMT appears to be invasive and has a high risk of lymphatic invasion even if small in size. Therefore, surgical treatment with dissection of the regional lymph nodes might be necessary in cases with any signs of massive submucosal invasion. (C) 2016 Elsevier Masson SAS. All rights reserved.
  • Hironori Ishigami, Hironori Yamaguchi, Hiroharu Yamashita, Masahiro Asakage, Joji Kitayama
    GASTRIC CANCER 20 Suppl 1 S128 - S134 2017年03月 [査読有り][通常論文]
     
    Background Despite recent progress in systemic chemotherapy, the prognosis of gastric cancer patients with peritoneal metastasis (P1) or positive peritoneal cytology findings (CY1) is still poor. We developed a regimen combining intraperitoneal (IP) paclitaxel (PTX) with S-1 and PTX, which can produce notable efficacy with regard to peritoneal lesions. Surgery after response to combination chemotherapy is a promising option for P1 or CY1 gastric cancer. A retrospective study was performed to evaluate the safety and efficacy. Methods This study enrolled 100 primary P1 or CY1 gastric cancer patients treated with IP PTX plus S-1 and PTX at the University of Tokyo Hospital between 2005 and 2011. Radical gastrectomy was performed when peritoneal cytology findings became negative, and the disappearance or obvious shrinkage of peritoneal metastasis was confirmed by laparoscopy. The same chemotherapy regimen was restarted after surgery and repeated with appropriate dose reduction. Results Gastrectomy was performed in 64 (P1 56, P0CY1 8) of 100 (P1 90, P0CY1 10) patients. R0 resection was achieved in 44 patients (69%). The median survival time was 30.5 months [95% confidence interval (CI) 23.6-37.7 months] from the initiation of intraperitoneal chemotherapy and 34.6 months (95% CI 26.8-39.4 months) from the diagnosis of gastric cancer. Postoperative complications included anastomotic leakage and pancreatic fistula, each in two patients, which were cured conservatively. There were no treatment-related deaths. The median survival time of the 36 patients who did not undergo surgery was 14.3 months (95% CI 10.0-17.8 months). Conclusions Surgery after response to intraperitoneal and systemic chemotherapy is safe and may prolong the survival of P1 and CY1 gastric cancer patients.
  • Kensuke Otani, Soichiro Ishihara, Hironori Yamaguchi, Koji Murono, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Toshiaki Watanabe
    SURGERY TODAY 47 2 151 - 158 2017年02月 [査読有り][通常論文]
     
    Colorectal cancer is an obesity-related malignancy. Adiponectin is an adipokine produced exclusively by adipose tissue, and its concentration in the serum is reduced in obesity. A low serum level of adiponectin is associated with an increased risk of various types of malignancies including colorectal cancer. These facts suggest that the epidemiological link between obesity and cancer may have a significant association with adiponectin. Although numerous studies of colorectal cancer have been reported, the results are conflicting about the anti-cancer effect of adiponectin, and how adiponectin affects carcinogenesis or cancer development remains controversial. Because adiponectin has multiple systemic effects and exists as a high serum concentration protein, the main role of adiponectin should be regulation of homeostasis, and it would not likely act as an anti-cancerous hormone. However, as epidemiological evidence shows, a low adiponectin level may be a basic risk factor for colorectal cancer. We speculate that when the colonic epithelium is stimulated or damaged by another carcinogen under the condition of a low adiponectin level, carcinogenesis is promoted and cancer development is facilitated. In this report, we summarize recent findings of the correlation between adiponectin and colorectal cancer and investigate the effect of adiponectin on colorectal cancer.
  • Tomomichi Kiyomatsu, Soichiro Ishihara, Koji Murono, Kensuke Otani, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Hironori Yamaguchi, Toshiaki Watanabe
    SURGERY TODAY 47 1 14 - 19 2017年01月 [査読有り][通常論文]
     
    The middle rectal artery is a very important anatomical structure in rectal cancer surgery. It is the only vessel that penetrates through the proper rectal fascia into the pelvic cavity, and therefore threatens the integrity of total mesorectal excision. Moreover, it is very closely related to the lateral lymphatic drainage root. The definition of the middle rectal artery is ambiguous, and different frequencies, origins, and trajectories have been reported in various papers. The frequency of the middle rectal artery is reported to range from 12 to 97 %. Traditionally, the middle rectal artery is described as an artery that penetrates the pelvic plexus from the lateral side along with the lateral ligament; the frequency of this lateral type of middle rectal artery ranges from 20 to 30 %. However, the reports that describe higher frequency values also consider another type of middle rectal artery, which penetrates the neuro-vascular bundle from the antero-lateral direction; this antero-lateral type of middle rectal artery tends to be a small vessel, and frequently forms a common trunk with the prostatic artery. With advancements in endoscopic surgery, the knowledge of the precise anatomy of this structure is becoming more crucial for optimal rectal cancer surgery.
  • Tsuyoshi Ozawa, Soichiro Ishihara, Kazushige Kawai, Hiroaki Nozawa, Hironori Yamaguchi, Joji Kitayama, Toshiaki Watanabe
    Clinical Colorectal Cancer 15 4 E157 - E163 2016年12月 [査読有り][通常論文]
     
    We retrospectively evaluated the prognostic power of the preoperative serum carbohydrate antigen (CA) 19-9 level in stage IV colorectal cancer patients who had undergone curative resection. The preoperative serum CA 19-9 level was associated with poor relapse-free survival and overall survival on multivariate analysis (P = .035 and P = .023, respectively) and might be a good predictive marker of the prognosis in these patients. Introduction: Carbohydrate antigen (CA) 19-9 is a widely used tumor marker in colorectal cancer (CRC). However, its prognostic impact in patients with stage IV CRC who have undergone curative resection is not clear. We evaluated the prognostic power of preoperative serum CA 19-9 in these patients. Patients and Methods: We performed a retrospective review of 173 patients with stage IV CRC who had undergone curative resection at our institution. Patients were categorized into normal and high CA 19-9 groups, and relapse-free survival and overall survival were compared using Kaplan-Meier curves. Multivariate analyses were performed using a Cox proportional hazard model. Results: The preoperative serum CA 19-9 level was elevated in 80 patients (46%). The 3-year relapse-free survival of the high CA 19-9 group was significantly worse than that of the normal CA 19-9 group (18% vs. 28%, respectively; P = .026). The 3-year overall survival of the high CA 19-9 group was significantly lower than that of the normal CA 19-9 group (75% vs. 82%; P = .047). Multivariate analyses indicated that elevated preoperative serum CA 19-9 level was an independent prognostic factor for poor relapse-free survival and overall survival, with a hazard ratio of 1.46 (95% confidence interval, 1.03-2.06; P = .035) and 1.90 (95% confidence interval, 1.10-3.29; P = .023), respectively. Conclusion: The preoperative serum CA 19-9 level is a good predictive marker of tumor recurrence and prognosis in patients with stage IV CRC who have undergone curative resection.
  • Takeshi Nishikawa, Soichiro Ishihara, Keisuke Hata, Koji Murono, Koji Yasuda, Kensuke Otani, Toshiaki Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Hiroaki Nozawa, Hironori Yamaguchi, Toshiaki Watanabe
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES 30 12 5550 - 5557 2016年12月 [査読有り][通常論文]
     
    Along with an aging society, the number of elderly patients with colorectal cancer treated with a surgical modality has gradually increased. Our purpose is to verify the safety and effectiveness of laparoscopic surgery for the treatment of colorectal cancer in elderly patients. We compared the short-term outcomes of open versus laparoscopic surgery in patients aged 80 years or older with colorectal cancer between 2007 and 2014. Of 150 elderly colorectal patients, 62 patients received laparoscopic surgery, and 88 patients, open surgery. In the laparoscopic surgery group, two patients were converted to open surgery due to extensive adhesion. The amount of blood loss was smaller in patients treated with laparoscopic surgery than those with open surgery (44.0 +/- 86.5 vs. 329.9 +/- 482.1 ml, P < 0.01). In the laparoscopic surgery group, days until oral intake (5.3 +/- 1.9 vs. 7.0 +/- 3.0 days, P < 0.01) and hospital stay (17.2 +/- 6.8 vs. 22.0 +/- 14.0 days, P < 0.01) were shorter. Morbidity (30.6 vs. 42.0 %) and mortality (1.6 vs. 1.1 %) in laparoscopic and open surgery groups were similar. Laparoscopic surgery in elderly patients with colorectal cancer was a safe and less invasive alternative to open surgery, with less blood loss and shorter hospital stay.
  • Tanaka T, Kawai K, Abe H, Murono K, Otani K, Nishikawa T, Kiyomatsu T, Hata K, Nozawa H, Yamaguchi H, Ishihara S, Fukayama M, Watanabe T
    Surgical case reports 2 1 117 - 117 2016年12月 [査読有り][通常論文]
     
    We present the first ever report on a colonic mucocele observed at the distal stump of a transverse loop colostomy caused by neoplasia. A 37-year-old female consulted us because of abdominal pain and vomiting caused by cystic lesions in the upper left abdominal quadrant. A preoperative checkup revealed no sign of neoplastic lesions; however, tumor resection was performed because of the symptoms. The tumor was a mucocele of the distal stump of the transverse colon with obstruction interposed between the mucocele and stoma. Pathological diagnosis was low-grade adenoma; however, it appeared like low-grade mucinous neoplasia of the appendix rather than a normal colonic adenoma. The neoplasia existed in the transitional segment between obstruction and dilatation. As this is the first case of colonic mucocele caused by mucinous neoplasia, no definite consensus for diagnosis and treatment exists. With reference to low-grade mucinous neoplasia, we propose that complete surgical resection be performed for diagnosis and a favorable outcome.
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • Naoko Mikoshiba, Noriko Yamamoto-Mitani, Takamasa Ohki, Yoshinari Asaoka, Hironori Yamaguchi, Shuntaro Obi, Kazuki Sato, Kazuhiko Koike, Mitsunori Miyashita
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 46 11 979 - 985 2016年11月 [査読有り][通常論文]
     
    We developed a simple, sensitive and specific self-monitoring tool for identifying Common Terminology Criteria for Adverse Events grade 2 or higher hand-foot syndrome symptoms, which can cause treatment discontinuation, that can be used at home by patients with cancer.Development of hand-foot syndrome symptoms, which is a common adverse effect of several cancer chemotherapy agents, can result in patient withdrawal from treatment. Its early identification allows appropriate modification of chemotherapy regimens and can avert treatment withdrawal by minimizing the impact on quality of life and duration of discontinued therapy. We sought to develop a simple home-based self-monitoring tool to facilitate reliable early identification of hand-foot syndrome, based on the self-administered quality of life questionnaire hand-foot syndrome-14. We modified the hand-foot syndrome-14 to create a simple tool with binary responses ('yes' or 'no') for patients to self-evaluate subjective hand-foot syndrome symptoms daily. We evaluated this tool with 187 consecutive, consenting, eligible adult patients attending four centers and treated with capecitabine, sorafenib or sunitinib for various cancers. Univariate and multivariate logistic regression analyses were used to select the items with the greatest discrimination for detecting Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or 3 reactions, which indicate the need to modify the treatment regimen. There were four items that were most strongly associated with Common Terminology Criteria for Adverse Events grade 2 or higher symptoms. 'Pain associated with hand-foot syndrome' was the most strongly associated with moderate hand-foot syndrome. For detecting moderate hand-foot syndrome symptoms, the sensitivity was 100.0%, specificity was 94.6%, positive predictive value was 82.6% and area under the curve was 0.98 by a sum of the scores of four-item self-monitoring tool with cut-off value. We present a simple self-monitoring tool that can be used at home with high sensitivity and specificity for identifying grade 2 hand-foot syndrome. In addition, this tool might facilitate self-care.
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • A simple home-based self-monitoring tool for early detection of hand-foot syndrome in cancer patients(和訳中)
    Mikoshiba Naoko, Yamamoto-Mitani Noriko, Ohki Takamasa, Asaoka Yoshinari, Yamaguchi Hironori, Obi Shuntaro, Sato Kazuki, Koike Kazuhiko, Miyashita Mitsunori
    Japanese Journal of Clinical Oncology 46 11 979  Oxford University Press 2016年11月 [査読無し][通常論文]
  • Keisuke Hata, Yoko Yamamoto, Tomomichi Kiyomatsu, Toshiaki Tanaka, Shinsuke Kazama, Hiroaki Nozawa, Kazushige Kawai, Junichiro Tanaka, Takeshi Nishikawa, Kensuke Otani, Koji Yasuda, Junko Kishikawa, Yuzo Nagai, Hiroyuki Anzai, Takahide Shinagawa, Keiichi Arakawa, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    SURGERY TODAY 46 10 1115 - 1122 2016年10月 [査読有り][通常論文]
     
    Gastrointestinal (GI) cancer, including gastric and colorectal cancer, is a major cause of death worldwide. A substantial proportion of patients with GI cancer have a familial history, and several causative genes have been identified. Gene carriers with these hereditary GI syndromes often harbor several kinds of cancer at an early age, and genetic testing and specific surveillance may save their lives through early detection. Gastroenterologists and GI surgeons should be familiar with these syndromes, even though they are not always associated with a high penetrance of GI cancer. In this review, we provide an overview and discuss the diagnosis, genetic testing, and management of four major hereditary GI cancers: familial adenomatous polyposis, Lynch syndrome, hereditary diffuse gastric cancer, and Li-Fraumeni syndrome.
  • Naminatsu Takahara, Hiroyuki Isayama, Yousuke Nakai, Hironori Ishigami, Sohei Satoi, Suguru Mizuno, Hirofumi Kogure, Saburo Matsubara, Natsuyo Yamamoto, Hironori Yamaguchi, Minoru Tada, Joji Kitayama, Toshiaki Watanabe, Kazuhiko Koike
    INVESTIGATIONAL NEW DRUGS 34 5 636 - 642 2016年10月 [査読有り][通常論文]
     
    Objectives The aim of this study was to evaluate the safety and efficacy of intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for treatment of gemcitabine-refractory pancreatic cancer with malignant ascites. Methods After the feasibility of this regimen was first confirmed in an interim analysis in 10 patients, a total of 35 patients were enrolled between April 2011 and December 2014. PTX was administered intravenously (50 mg/m(2)) and intraperitoneally (20 mg/m(2)) on days 1 and 8, and 80 mg/m(2) S-1 was administered on days 1-14 every 3 weeks. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), the objective tumor response, efficacy against malignant ascites, and safety. Result In all 35 patients, the median OS and PFS were 4.8 (95 % confidence interval [CI], 2.1-5.3) months and 2.8 (95 % CI, 0.9-4.1) months, respectively. The 26 patients who were evaluable for efficacy achieved a response rate of 8 % and a disease control rate of 69 %. Malignant ascites had disappeared or decreased in 18 (69 %) patients, including complete resolution in 4 (15 %), and a negative change in cytological status was achieved in 8 (31 %) patients. The major grade 3/4 adverse events included neutropenia (34 %), anemia (31 %), nausea (9 %), and catheter-related infections (6 %). Conclusion Combination chemotherapy consisting of intravenous and intraperitoneal PTX with S-1 showed acceptable toxicity and favorable efficacy in pancreatic cancer patients with malignant ascites. (Clinical trial registration number: UMIN000005306).
  • Yuzo Nagai, Sinsuke Kazama, Daisuke Yamada, Takuya Miyagawa, Koji Murono, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Yuri Masui, Hiroaki Nozawa, Hironori Yamaguchi, Soichiro Ishihara, Takafumi Kadono, Toshiaki Watanabe
    ANNALS OF DERMATOLOGY 28 5 624 - 628 2016年10月 [査読有り][通常論文]
     
    Treatment of perianal and vulvar extramammary Paget disease (EMPD), rare intraepithelial malignancies, is often challenging because of its potential to spread into the anal canal. However, there is still no consensus regarding the optimal resection margin within the anal canal. Between 2004 and 2014, six patients (three with perianal EMPD and three with vulvar EMPD) in which the spread of Paget cells into the anal canal was highly suspected were referred to our department. To evaluate the disease extent within the anal canal, preoperative mapping biopsy of the anal canal was performed in five out of six patients. Two patients were positive for Paget cells within the anal canal (one at the dentate line and the other at 0.5 cm above the dentate line), whereas in three patients, Paget cell were present only in the skin of the anal verge. Using 1 cm margin within the anal canal from the positive biopsy sites, we performed anal-preserving wide local excision (WLE), and negative resection margins within the anal canal were confirmed in all five patients. The remaining one patient with perianal EMPD did not undergo mapping biopsy of the anal canal because preoperative colonoscopy revealed that the Paget cells had spread into the lower rectum. Therefore, WLE with abdominoperineal resection was performed. During the median follow-up period of 37.3 months, no local recurrence was observed in all patients. Our small case series suggest the usefulness of mapping biopsy of the anal canal for the treatment of perianal and vulvar EMPD.
  • Hereditary gastrointestinal cancer(和訳中)
    Hata Keisuke, Yamamoto Yoko, Kiyomatsu Tomomichi, Tanaka Toshiaki, Kazama Shinsuke, Nozawa Hiroaki, Kawai Kazushige, Tanaka Junichiro, Nishikawa Takeshi, Otani Kensuke, Yasuda Koji, Kishikawa Junko, Nagai Yuzo, Anzai Hiroyuki, Shinagawa Takahide, Arakawa Keiichi, Yamaguchi Hironori, Ishihara Soichiro, Sunami Eiji, Kitayama Joji, Watanabe Toshiaki
    Surgery Today 46 10 1115  シュプリンガー・ジャパン(株) 2016年10月 [査読無し][通常論文]
  • Hereditary gastrointestinal cancer(和訳中)
    Hata Keisuke, Yamamoto Yoko, Kiyomatsu Tomomichi, Tanaka Toshiaki, Kazama Shinsuke, Nozawa Hiroaki, Kawai Kazushige, Tanaka Junichiro, Nishikawa Takeshi, Otani Kensuke, Yasuda Koji, Kishikawa Junko, Nagai Yuzo, Anzai Hiroyuki, Shinagawa Takahide, Arakawa Keiichi, Yamaguchi Hironori, Ishihara Soichiro, Sunami Eiji, Kitayama Joji, Watanabe Toshiaki
    Surgery Today 46 10 1115  シュプリンガー・ジャパン(株) 2016年10月 [査読無し][通常論文]
  • Kazushige Kawai, Yuuki Iida, Soichiro Ishihara, Hironori Yamaguchi, Hiroaki Nozawa, Keisuke Hata, Tomomichi Kiyomatsu, Toshiaki Tanaka, Takeshi Nishikawa, Koji Yasuda, Kensuke Otani, Koji Murono, Toshiaki Watanabe
    DIGESTIVE ENDOSCOPY 28 6 633 - 640 2016年09月 [査読有り][通常論文]
     
    The use of intraoperative colonoscopy has increased alongside progress in the development of colonoscopy-associated devices and techniques, including the colonoscope itself. In the present review, we focus on four circumstances in which intraoperative colonoscopy is beneficial to colorectal surgery: (i) intraoperative determination of a tumor's location; (ii) observation of the proximal colon in cases of obstructive colorectal cancer; (iii) confirmation of the integrity of anastomosis; and (iv) novel surgical techniques that combine laparoscopic and endoscopic surgery. In light of the findings of our review, a combination of colonoscopy and surgery-especially laparoscopic surgery-is expected to facilitate the optimal handling of a variety of colorectal tumors, ranging from benign cases to advanced and obstructive cases.
  • Koji Murono, Kazushige Kawai, Soichiro Ishihara, Kensuke Otani, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Hironori Yamaguchi, Toshiaki Watanabe
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE 31 9 1633 - 1638 2016年09月 [査読有り][通常論文]
     
    The requisite for a rigorous preoperative understanding of vascular branching continues to grow in parallel with the implementation of laparoscopic surgery. Three-dimensional (3D)-computed tomography (CT) angiography is a less-invasive modality than traditional angiographic examination. Therefore, we aimed to evaluate branching patterns of the superior mesenteric artery (SMA). In the present study, 536 consecutive patients who underwent preoperative 3D-CT angiography from April 2012 to March 2014 were prospectively enrolled. The branching pattern of the right colic artery (RCA) and the intersectional patterns of the RCA, ileocolic artery (ICA), and superior mesenteric vein (SMV) were evaluated. The RCA existed in only 179 cases (33.4 %); the remaining 357 patients (66.6 %) lacked evidence of the RCA. The ICA was detected in all cases. The RCA ran ventral to the SMV in the majority of cases (89.4 %). Conversely, the ICA ran ventral to the SMV in only half of the cases (50.6 %). When the RCA was observed to pass dorsal to the SMV, the ICA also ran dorsal to SMV in all cases. 3D-CT angiography can aid surgeons in identifying and understanding the anatomical vascular variations and intersectional patterns of the RCA, ICA, and SMV. Developing awareness of these variations can aid in the prevention of unexpected vascular injury during laparoscopic right-sided colon surgery.
  • Soichiro Ishihara, Yukihide Kanemitsu, Koji Murono, Kensuke Otani, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Hioaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Kenichi Sugihara, Toshiaki Watanabe
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE 31 7 1315 - 1321 2016年07月 [査読有り][通常論文]
     
    We aimed to clarify the prognostic impact of lateral pelvic lymph node (LPN) dissection (LPND) for rectal cancer through a multicenter retrospective study using propensity score analysis. A total of 1238 patients with pathological T2-4, M0 rectal cancer who had undergone curative operation between 2007 and 2008 were examined. Majority of the patients (96 %) were treated without preoperative chemoradiotherapy (CRT). Clinical background data of the patients treated with LPND and those treated without LPND were matched using propensity scores, and hazard ratios (HRs) for cancer-specific mortality were compared. LPND was performed more frequently for lower rectal cancers and in patients with more advanced disease, and 29 % of the patients were treated with LPND. After matching background features by propensity scores, LPND did not correlate with improved cancer-specific survival (CSS) among the entire study population [HR, 0.73; 95 % confidence interval (CI) 0.41-1.31; P = 0.28]; however, LPND was correlated with significantly improved CSS in female patients (HR, 0.23; 95 % CI, 0.06-0.89; P = 0.04) but not in male patients (HR, 0.95; 95 % CI, 0.48-1.89; P = 0.89). The results were similar when patients treated with LPND finally diagnosed as pathologically negative for LPN metastasis were compared with those curatively treated without LPND. It is suggested that the prognostic impact of LPND for rectal cancer treated without CRT might be different between sexes, and LPND should be considered for female rectal cancer patients although they are diagnosed as clinically negative for LPN metastasis.
  • Keiichi Arakawa, Soichiro Ishihara, Kazushige Kawai, Junichi Shibata, Kensuke Otani, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    WORLD JOURNAL OF SURGICAL ONCOLOGY 14 1 180  2016年07月 [査読有り][通常論文]
     
    Background: We present a case of asynchronously occurring adenocarcinomas 29 and 36 years after ureterosigmoidostomy for bladder cancer, respectively, at both anastomosis sites. Case presentation: A colonoscopy that was performed on a 69-year-old man because of bloody stool and an elevated carcinoembryonic antigen (CEA) level revealed a polypoid lesion at the right ureterosigmoid anastomosis site 29 years after the patient's ureterosigmoidostomy. Endoscopic resection was performed, and the lesion was diagnosed as adenocarcinoma. Seven years later (36 years after ureterosigmoidostomy), an elevated lesion was detected at the left ureterosigmoid anastomosis site by colonoscopy performed after detection of high CEA levels. Biopsy revealed an adenocarcinoma that was immunohistologically positive for CDX2; sigmoidectomy and ureterectomy were subsequently performed. The pathological diagnosis of the second tumor was adenocarcinoma arising in the ureterosigmoid anastomosis site and invading the left ureter. Conclusions: Diligent long-term follow-up of patients who underwent ureterosigmoidostomy is essential.
  • Junko Kishikawa, Shinsuke Kazama, Koji Oba, Kiyoshi Hasegawa, Hiroyuki Anzai, Yuzo Harada, Hiroyuki Abe, Keisuke Matsusaka, Kumiko Hongo, Masaru Oba, Koji Yasuda, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Tetsuo Ushiku, Joji Kitayama, Masashi Fukayama, Norihiro Kokudo, Toshiaki Watanabe
    Annals of surgical oncology 23 6 1916 - 23 2016年06月 [査読有り][通常論文]
     
    BACKGROUND: CD133 is a transmembrane protein that is proposed to be a stem cell marker of colorectal cancer (CRC); however, the correlation between CD133 expression and survival of CRC patients with liver metastasis has not been fully examined. METHODS: CD133 expression was evaluated immunohistochemically, both in primary tumors and synchronous liver metastases of 88 consecutive CRC patients, as well as recurrent lesions in the remnant liver of 27 of these 88 patients. The relationship between CD133 expression and clinicopathological characteristics, recurrence-free survival, and overall survival (OS) was analyzed. RESULTS: CD133 expression in liver metastases (mCD133) was detected in 50 of 88 patients (56.8 %), and had significant correlation with CD133 expression in primary lesions (pCD133) (p < 0.001). CD133 expression in liver recurrent lesions (recCD133) also had a significant correlation with mCD133 (p < 0.001). mCD133+ patients had significantly longer disease-free survival (p = 0.043) and OS (p = 0.014) than mCD133- patients. In addition, mCD133+ patients had a significantly lower rate of extrahepatic recurrence (p < 0.001). CONCLUSIONS: Patients without CD133 expression in liver metastasis had significantly shorter survival, perhaps because mCD133- patients had a significantly higher rate of extrahepatic recurrence.
  • Soichiro Ishihara, Kensuke Otani, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Hioaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Kenichi Sugihara, Toshiaki Watanabe
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE 31 6 1149 - 1155 2016年06月 [査読有り][通常論文]
     
    Colon cancers in male and female patients are suggested to be oncologically different. The aim of this study is to elucidate the prognostic impact of lymph node dissection (LND) in male and female colon cancer patients. A total of 5941 stage I-III colon cancer patients who were curatively operated on during the period from 1997 to 2007 were retrospectively studied. Cancer-specific survival (CSS) was individually compared between for male and female patients treated with D3, D2, and D1 LND. Background differences of the patients were matched using propensity scores. D3, D2, and D1 LND were performed in 3756 (63 %), 1707 (29 %), and 478 (8 %), respectively, and more extensive LND was indicated for younger patients and more advanced disease. D2 LND was significantly associated with decreased cancer-specific mortality compared to D1 LND in male patients (HR 0.54, 95 % CI 0.32-0.89, p = 0.04), but not in female patients. D3 LND did not correlate to an improved prognosis compared to D2 LND both in male and female patients. D2 LND was associated with an improved CSS in male, but not female colon cancer patients, compared to D1 LND. This suggested that colon cancer in male and female patients might be oncologically different, and that the prognostic impact of the extent of surgical intervention for colon cancer might therefore be different between sexes.
  • Joji Kitayama, Hironori Yamaguchi, Hironori Ishigami, Keisuke Matsuzaki, Naohiro Sata
    PLOS ONE 11 5 e0154542  2016年05月 [査読有り][通常論文]
     
    The human peritoneal cavity contains a small number of free cells of mesenchymal cell lineage. Intraperitoneal mesenchymal cells (PMC) play supportive roles in metastasis formation on the peritoneum. In this study, we found that PMC, when co-cultuerd with human gastric cancer cells, MKN45, enhanced the proliferation of MKN45 when cultured at low, but not high, cellular density. Also, PMC suppressed apoptotic cell death of MKN45 only under low density culture conditions. Time-lapse videoanalysis clearly demonstrated that PMC randomly migrated more vigorously than did MKN45, and strongly enhanced the migration behavior of co-cultured MKN45. In fact, the majority of MKN45 migrated together in direct physical contact with PMC, and the sum of migration lengths from original position of co-cultured MKN45 for 48 hours was approximately 10 times longer than that of MKN45 cultured alone. Our data suggest that enhanced migration can increase the chance of direct contact or positional proximity among sparcely distributed MKN45, which may bring survival advantages to tumor cells. This may be one of the important mechanisms of peritoneal metastasis, since only a small number of tumor cells are considered to be disseminated in the early step of metastasis formation on the peritoneum.
  • Keisuke Hata, Junko Kishikawa, Hiroyuki Anzai, Takahide Shinagawa, Shinsuke Kazama, Hiroaki Ishii, Hiroaki Nozawa, Kazushige Kawai, Tomomichi Kiyomatsu, Junichiro Tanaka, Toshiaki Tanaka, Takeshi Nishikawa, Kensuke Otani, Koji Yasuda, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    DIGESTIVE ENDOSCOPY 28 3 260 - 265 2016年04月 [査読有り][通常論文]
     
    Long-standing ulcerative colitis patients are known to be at high risk for the development of colorectal cancer. Therefore, surveillance colonoscopy has been recommended for these patients. Because colitis-associated colorectal cancer may be difficult to identify even by colonoscopy, a random biopsy method has been recommended. However, the procedure of carrying out a random biopsy is tedious and its effectiveness has also not yet been demonstrated. Instead, targeted biopsy with chromoendoscopy has gained popularity in European and Asian countries. Chromoendoscopy is generally considered to be an effective tool for ulcerative colitis surveillance and is recommended in the guidelines of the British Society of Gastroenterology and the European Crohn's and Colitis Organisation. Although image-enhanced endoscopy, such as narrow-band imaging and autofluorescence imaging, has been investigated as a potential ulcerative colitis surveillance tool, it is not routinely applied for ulcerative colitis surveillance in its present form. The appropriate intervals of surveillance colonoscopy have yet to be determined. Although the Japanese and American guidelines recommend annual or biannual colonoscopy, the British Society of Gastroenterology and the European Crohn's and Colitis Organisation stratified their guidelines according to the risks of colorectal cancer. A randomized controlled trial comparing random and targeted biopsy methods has been conducted in Japan and although the final analysis is still ongoing, the results of this study should address this issue. In the present review, we focus on the current detection methods and characterization of dysplasia/cancer and discuss the appropriate intervals of colonoscopy according to the stratified risks.
  • Koji Yasuda, Kazushige Kawai, Soichiro Ishihara, Koji Murono, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Hironori Yamaguchi, Shigeo Aoki, Hideyuki Mishima, Tsunehiko Maruyama, Akihiro Sako, Toshiaki Watanabe
    WORLD JOURNAL OF SURGICAL ONCOLOGY 14 99  2016年04月 [査読有り][通常論文]
     
    Background: Curative resection of sigmoid colon and rectal cancer includes "high tie" of the inferior mesenteric artery (IMA). However, IMA ligation compromises blood flow to the anastomosis, which may increase the leakage rate, and it is unclear whether this confers a survival advantage. Accordingly, the IMA may be ligated at a point just below the origin of the left colic artery (LCA) "low tie" combined with lymph node dissection (LND) around the origin of the IMA (low tie with LND). However, no study has investigated the detailed prognostic results between "high tie" and "low tie with LND." The aim of this study was to assess the utility of "low tie with LND" on survival in patients with sigmoid colon or rectal cancer. Methods: A total of 189 sigmoid colon or rectal cancer patients who underwent curative operation from 1997 to 2007 were enrolled in this study. The patient's medical records were reviewed to obtain clinicopathological information. Overall survival (OS) and relapse-free survival (RFS) rates were calculated using the Kaplan-Meier method, with differences assessed using log-rank test. Results: Forty-two and 147 patients were ligated at the origin of the IMA (high tie) and just below the origin of the LCA combined with LND around the origin of the IMA (low tie with LND), respectively. No significant differences were observed in the complication rate and OS and RFS rates in the two groups. Further, no significant difference was observed in the OS and RFS rates in the lymph node-positive cases in the two groups. Conclusions: "Low tie with LND" is anatomically less invasive and is not inferior to "high tie" with prognostic point of view.
  • Ota Y, Ishihara S, Otani K, Yasuda K, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Kazama S, Yamaguchi H, Sunami E, Kitayama J, Watanabe T
    Molecular and clinical oncology 4 4 607 - 610 2016年04月 [査読有り][通常論文]
  • Takayuki Okuno, Hironori Yamaguchi, Joji Kitayama, Hironori Ishigami, Takeshi Nishikawa, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Kazushige Kawai, Shinsuke Kazama, Soichiro Ishihara, Eiji Sunami, Toshiaki Watanabe
    WORLD JOURNAL OF SURGICAL ONCOLOGY 14 107  2016年04月 [査読有り][通常論文]
     
    Background: Clinical studies of intraperitoneal chemotherapy with paclitaxel in patients of gastric cancer with peritoneal carcinomatosis is well tolerated and effective, and rare cases of metastasis and recurrence have experienced during the treatment. Disseminated carcinomatosis of the bone marrow is highly rare in gastric cancer and associated with a poor prognosis. Case presentation: A 59-year-old woman of gastric cancer with peritoneal carcinomatosis received five courses of chemotherapy with intraperitoneal administration of paclitaxel, and laparoscopy showed disappearance of the peritoneal carcinomatosis. She subsequently underwent total gastrectomy, and the histopathological findings showed a complete response to the chemotherapy. Postoperatively, chemotherapy with intraperitoneal administration of paclitaxel was continued for 30 months, without apparent recurrence. However, the gastric cancer recurred as disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation, and we hence changed the chemotherapy regimen to weekly irinotecan. Remission was achieved, and she did not experience any major symptoms; however, she died 6 months after the diagnosis of disseminated carcinomatosis of the bone marrow. Conclusions: Since intraperitoneal paclitaxel administration can strongly suppress peritoneal carcinomatosis of gastric cancer, careful attention should be paid not only to peritoneal recurrence but also for rare site metastases, such as bone marrow metastases.
  • Seiichi Ohta, Syota Hiramoto, Yuki Amano, Mayu Sato, Yukimitsu Suzuki, Marie Shinohara, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, Yasuyuki Sakai, Joji Kitayama, Taichi Ito
    BIOCONJUGATE CHEMISTRY 27 3 504 - 508 2016年03月 [査読有り][通常論文]
     
    Hyaluronan (HA) is a promising drug carrier for cancer therapy because of its CD44 targeting ability, good biocompatibility, and biodegradability. In this study, cisplatin (CDDP)-incorporating HA nanogels were fabricated through a chelating ligand metal coordination cross-linking reaction. We conjugated chelating ligands, iminodiacetic acid or nalonic acid, to HA and used them as a precursor polymer. By mixing the ligand-conjugated HA with CDDP, cross-linking occurred via coordination of the ligands with the platinum in CDDP, resulting in the spontaneous formation of CDDP-loaded HA nanogels. The nanogels showed pH-responsive release of CDDP, because the stability of the ligand platinum complex decreases in an acidic environment. Cell viability assays for MKN45P human gastric cancer cells and Met-5A human mesothelial cells revealed that the HA nanogels selectively inhibited the growth of gastric cancer cells. In vivo experiments using a mouse model of peritoneal dissemination of gastric cancer demonstrated that HA nanogels specifically localized in peritoneal nodules after the intraperitoneal administration. Moreover, penetration assays using multicellular tumor spheroids indicated that HA nanogels had a significantly higher ability to penetrate tumors than conventional, linear HA. These results suggest that chelating-ligand conjugated HA nanogels will be useful for targeted cancer therapy.
  • Hiroaki Ishii, Keisuke Hata, Junko Kishikawa, Hiroyuki Anzai, Kensuke Otani, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Hiroaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    WORLD JOURNAL OF SURGICAL ONCOLOGY 14 75  2016年03月 [査読有り][通常論文]
     
    Background: The incidence of neoplasia after surgery has not been sufficiently evaluated in patients with ulcerative colitis (UC), particularly in the Japanese population, and it is not clear whether surveillance endoscopy is effective in detecting dysplasia/cancer in the remnant rectum or pouch. The aims of this study were to assess and compare postoperative development of dysplasia/cancer in patients with UC who underwent ileorectal anastomosis (IRA) or ileal pouch-anal anastomosis (IPAA) and to evaluate the effectiveness of postoperative surveillance endoscopy. Methods: One hundred twenty patients who received postoperative surveillance endoscopy were retrospectively reviewed for development of dysplasia/cancer in the remnant rectal mucosa or pouch. Results: Three hundred seventy-nine endoscopy sessions were conducted for 30 patients after IRA, while 548 pouch endoscopy sessions were conducted for 90 patients after IPAA. In the IRA group, 5 patients developed dysplasia/cancer during postoperative surveillance and in all cases, neoplasia was detected at an early stage. In the IRA group, no patient developed neoplasia within 10 years of diagnosis; the cumulative incidence of neoplasia after disease onset was 7.2, 12.0, and 23.9 % at 15, 20, and 25 years, respectively. In one case after stapled IPAA, dysplasia was found at the ileal pouch; a subsequent 9 endoscopy sessions in 8 years did not detect any dysplasia. Neoplasia was found more frequently during postoperative surveillance in the IRA group than in the IPAA group (p =.0028). The cumulative incidence of neoplasia after IRA was 3.8, 8.7, and 21.7 % at 10, 15, and 20 years, respectively, and that after IPAA was 1.6 % at 20 years. Conclusions: The cumulative incidence of neoplasia after IPAA was minimal. Those who underwent IRA had a greater risk of developing neoplasia than those who underwent IPAA, although postoperative surveillance endoscopy was able to detect dysplasia/cancer at an early stage. IRA can be the surgical procedure of choice only in selected cases in which it would be of benefit to the patient, with more careful surveillance.
  • Yuichiro Yoshioka, Hiroaki Nozawa, Junichiro Tanaka, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    ONCOLOGY LETTERS 11 3 2137 - 2139 2016年03月 [査読有り][通常論文]
     
    Patients with hereditary hemorrhagic telangiectasia (HHT) are reportedly at a lower overall risk of malignancies, and small bowel adenocarcinoma (SBA) arising in a HHT patient is extremely rare. In this study, the case of a 37-year-old female with HHT who developed a poorly differentiated jejunal adenocarcinoma five years after ileocecal resection for multiple colonic adenomas is presented. The patient underwent curative resection of the cancer invading the ileum and the mesentery of the transverse colon, but had to overcome critical complications perioperatively, stemming from HHT-associated peripheral capillary dilatation and arteriovenous malformation, including nosebleeds and possible infusion-induced air embolism through pulmonary shunts. The patient subsequently received adjuvant chemotherapy including capecitabine and oxaliplatin for 6 months, and currently remains alive without any evidence of recurrence 12 months after the second surgery. This patient with SBA was an instructive case demonstrating the necessity of careful attention during major surgery in HHT.
  • Hiroaki Nozawa, Soichiro Ishihara, Koji Murono, Koji Yasuda, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hironori Yamaguchi, Toshiaki Watanabe
    SPRINGERPLUS 5 287  2016年03月 [査読有り][通常論文]
     
    Laparoscopy-assisted surgery has been widely accepted in the treatment of colorectal cancer. The aim of the present study was to investigate the feasibility and outcomes of laparoscopy-assisted combined resection for multiple colorectal cancers in comparison to open surgery. We retrospectively reviewed patients with synchronous multiple colorectal cancers who underwent combined resection resulting in two anastomotic sites by either open or laparoscopy-assisted surgery in the University of Tokyo Hospital between April 2005 and March 2015. Nine patients underwent laparoscopic surgery using five ports, whereas 16 underwent open surgery. Blood loss was less (median 65 vs 295 mL, p = 0.0015), but the operative time was longer (median 429 vs 310 min, p = 0.09) in the laparoscopic surgery group than in the open surgery group. No intergroup difference was observed in the number of lymph nodes retrieved (median 32 vs 27, p = 0.50). The frequency of clinically significant postoperative complications was also similar between the two groups. Our results suggest that laparoscopy-assisted combined resection is an acceptable alternative to open surgery for multiple colorectal cancers.
  • Hironori Yamaguchi, Joji Kitayama, Hironori Ishigami, Shigenobu Emoto, Takeshi Nishikawa, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Hiroaki Nozawa, Shinsuke Kazama, Soichiro Ishihara, Eiji Sunami, Toshiaki Watanabe
    Journal of Medical Case Reports 10 1 14  2016年01月 [査読有り][通常論文]
     
    Background: Peritoneal dissemination of gastric cancer is still a dismal disease and has extremely poor prognosis even with systemic intensive chemotherapy. However, intraperitoneal chemotherapy using paclitaxel has recently shown good results. In order to perform optimal intraperitoneal chemotherapy, laparoscopic examination is necessary to assess the condition of peritoneal disseminated lesions. This is the first report of a case of a patient with gastric cancer with massive peritoneal metastasis treated with intraperitoneal administration of paclitaxel and repeated laparoscopic examinations who survived more than 5 years. Case presentation: Here we report a case of a 60-year-old Japanese woman with peritoneal carcinomatosis of gastric cancer who underwent intraperitoneal chemotherapy receiving repeated laparoscopic examinations. The patient was referred to our institution for the treatment of peritoneal carcinomatosis of gastric cancer. The staging laparoscopy showed peritoneal metastasis in the whole peritoneal space with a peritoneal cancer index score of 23. An intraperitoneal access port was subcutaneously implanted. Paclitaxel was intraperitoneally and intravenously administered with oral administration of S-1. The second-look laparoscopy, which was performed after nine courses of intraperitoneal chemotherapy, revealed the disappearance of peritoneal carcinomatosis. A total gastrectomy with D2 lymphadenectomy was performed and intraperitoneal chemotherapy was continued after the surgery. The third laparoscopic examination, which was performed after 67 courses of intraperitoneal chemotherapy showed bilateral ovarian metastasis without recurrence of peritoneal carcinomatosis. Since multiple bone metastases developed after the third-look laparoscopy, bilateral adnexectomy was not performed and the chemotherapy was changed to the regimen including CPT-11. Our patient survived more than 5 years since the intraperitoneal chemotherapy started. Conclusions: Sequential intraperitoneal chemotherapy could strongly suppress the development of peritoneal metastasis for several years. Repeated laparoscopic examinations are considered to be essential to evaluate the efficacy of intraperitoneal chemotherapy on peritoneal carcinomatosis of gastric cancer.
  • Yuichi Tachikawa, Hiroaki Nozawa, Junichiro Tanaka, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Madoka Fujisawa, Katutoshi Takahashi, Yoshiki Sakaguchi, Tetsuo Ushiku, Masashi Fukayama, Toshiaki Watanabe
    International Journal of Surgery Case Reports 23 70 - 73 2016年 [査読有り][通常論文]
     
    Introduction Cytomegalovirus (CMV) infection of the gastrointestinal tract is an uncommon illness, but can be observed in immunocompromised patients. Systemic lupus erythematosus (SLE) patients are generally at high risk of CMV infection. Here we report a subacute progressive case of colitis in SLE accompanied by cytomegalovirus infection. Presentation of case The patient, a 79-year-old woman, was hospitalized complaining of fever, polyarthritis, and skin ulcer that had lasted seven days. She additionally manifested vomiting, high fever, and right abdominal pain within two weeks thereafter, and was diagnosed with perforation of the intestine. Emergency operation was carried out for panperitonitis due to perforation of one of the multiple colon ulcers. Multidisciplinary postoperative treatment could not save her life. Pathological examination suggested that cytomegalovirus infection as well as cholesterin embolization contributed to the rapid progression of colitis. Discussion There have been only a limited number of case reports of CMV enteritis in SLE. Moreover, only two SLE patients on multiple medications have been reported to experience gastrointestinal perforation. Viral infections, including CMV, can induce clinical manifestations resembling SLE and for this reason we suspect that there are potentially many more patients misdiagnosed and/or unreported. Conclusion Our case underscores the importance of exploring the possibility of CMV infection as a differential diagnosis in SLE patients with obvious gastrointestinal symptoms who were treated by immunosuppressive drugs.
  • Yuzo Nagai, Keisuke Hata, Kazushige Kawai, Koji Murono, Koji Yasuda, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Hiroaki Nozawa, Hironori Yamaguchi, Soichiro Ishihara, Toshiaki Watanabe
    DIGESTION 93 4 272 - 279 2016年 [査読有り][通常論文]
     
    Background/Aims: The incidence of colorectal cancer (CRC) in young people is increasing, indicating an urgent need for understanding young-onset CRC. This study serves to clarify the characteristics and prognosis of young CRC patients. Methods: Using a detailed database, various clinicopathological findings including symptoms, family history and prognosis of 70 young CRC patients under 50 years who underwent surgical resection between 2005 and 2011 were compared to 786 old CRC patients over 50 years. For the comparison of prognosis, a matched 1: 4 case-control study adjusting for gender, tumor location, tumor differentiation type, and Union For International Cancer Control stage was conducted. Results: The young group had a higher proportion of rectal cancer (51.4 vs. 36.4%, p = 0.004) and a higher positive rate for the Amsterdam criteria II (7.1 vs. 1.9%, p = 0.02) than the old group. There was no significant difference in overall survival (OS) or cancer-specific survival (CSS) between the young and old groups (5-year OS: 84.7 vs. 76.9%, p = 0.18; 5-year CSS: 84.7 vs. 82.8%, p = 0.55). Conclusion: This study may add a new perspective to understanding young-onset CRC. The prognosis of young CRC patients was equivalent to that of old CRC patients. (C) 2016 S. Karger AG, Basel
  • Keiichi Arakawa, Tomomichi Kiyomatsu, Soichiro Ishihara, Masako Ikemura, Daisuke Hojo, Hirotoshi Takiyama, Koji Murono, Kensuke Otani, Koji Yasuda, Takeshi Nishikawa, Toshiaki Tanaka, Kazushige Kawai, Keisuke Hata, Hiroaki Nozawa, Hironori Yamaguchi, Toshiaki Watanabe
    International Journal of Surgery Case Reports 24 206 - 210 2016年 [査読有り][通常論文]
     
    Introduction We report our experience involving a case of relatively rare anorectal malignant melanoma with skipped lesion. Presentation of case The patient was a 72-year-old man who had visited a local clinic complaining of a mass in the anal region, whereupon he was referred to our hospital on suspicion of a malignant melanoma. Close examination revealed a 25-mm black type 1 tumor one-third the size of the circumference of the anal canal and located externally to it. We performed transanal resection of the tumor and confirmed a diagnosis of malignant melanoma. Notably, multiple macular black lesions spaced away from the main lesion were observed during surgery in half of the circumference of the anal canal, from the tumor to the pectinate line. A biopsy of the area also revealed malignant melanoma therefore, we performed abdominoperineal resection. Pathological diagnosis indicated a submucosal depth the patient was thus diagnosed with T4 N2c M0 stage IIIb malignant melanoma and was followed on an outpatient basis. Discussion Patients with anorectal malignant melanoma have very poor prognoses owing to early lymph node metastasis and hematogenous metastasis. Our case illustrates that small anorectal malignant melanoma lesions can spread from the main lesion and invade the mucosa examinations may sometimes miss such skipped lesions. Conclusion Skipped lesions can occur in anorectal melanomas thus, careful scrutiny of such lesions is required. Moreover, lesion resection is critical for anorectal malignant melanomas.
  • Tsuyoshi Ozawa, Soichiro Ishihara, Kazushige Kawai, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    JOURNAL OF SURGICAL RESEARCH 199 2 386 - 392 2015年12月 [査読有り][通常論文]
     
    Background: Recent studies have proposed that the use of the lymphocyte-to-monocyte ratio (LMR) is a good prognostic indicator for patients with nonmetastatic colorectal cancer (CRC). In the present study, we aimed to evaluate the prognostic impact of the LMR in stage IV CRC patients who have undergone curative resection. Methods: We performed a retrospective review of 117 stage IV CRC patients who underwent curative resection at our institute between 1997 and 2012. Patients were divided into a lowLMR group and a high-LMR group according to their LMR. The cutoff value of the LMR was determined based on receiver operating characteristics curve analysis. The relationships between the LMR and disease-free survival (DFS) and cancer-specific survival (CSS) rates were assessed. Results: The cutoff value for LMR was 3.00. DFS was not significantly different between the high-and low-LMR groups (P = 0.277). By contrast, CSS was significantly better in the high-LMR group than in the low-LMR group (P = 0.001). Multivariate analysis indicated that the LMR was an independent prognostic factor for CSS in patients with stage IV CRC who had undergone curative resection (hazard ratio: 2.75; 95% confidence interval: 1.40-5.44; P = 0.004), but not for DFS. Conclusions: The preoperative LMR is a simple and useful prognostic indicator in patients with stage IV CRC who have undergone curative resection. (C) 2015 Elsevier Inc. All rights reserved.
  • Junichi Shibata, Kazushige Kawai, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Kenichi Sugihara, Toshiaki Watanabe
    ANNALS OF SURGICAL ONCOLOGY 22 S621 - S629 2015年12月 [査読有り][通常論文]
     
    Background. This study aimed to clarify differences in prognostic factors, metastatic features, and recurrence rates between histologic types in patients with stage 4 colorectal cancer (CRC) who had undergone curative resection. Methods. The data from 1131 patients with stage 4 colorectal cancer from the databases of referral institutions were analyzed. The patients were divided into two groups according to histologic types as follows: patients with poorly differentiated adenocarcinoma, mucinous adenocarcinoma, or signet-ring cell carcinoma (Por/Muc/Sig) and patients with well-differentiated or moderately differentiated adenocarcinoma (Wel/Mod). Differences in clinicopathologic features, relapse-free survival (RFS) rates, and cancer-specific survival (CSS) rates between the groups were evaluated. Results. Although RFS did not differ between the Por/Muc/Sig and Wel/Mod groups, CSS was significantly shorter in the Por/Muc/Sig group's than in the Wel/Mod group, and survival after recurrence was significantly worse in the Por/Muc/Sig group than in theWel/Mod group. The incidence of peritoneal or local recurrence was significantly higher for the Por/Muc/Sig patients, whereas the resection recurrence rate was 16.4 %. Multivariate analysis suggested that histologic type was an independent prognostic factor for survival after recurrence. Conclusions. The patients with Por/Muc/Sig CRC synchronous metastasis had significantly shorter survival times than the patients with other CRC histologies, even if the metastases were curatively resected.
  • Shinsuke Kazama, Junko Kishikawa, Koji Yasuda, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Hiroaki Nozawa, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Toshiaki Watanabe
    ANTICANCER RESEARCH 35 12 6599 - 6605 2015年12月 [査読有り][通常論文]
     
    Background: Recently, two meta-analysis reports have suggested that CD133 expression in the primary tumor is significantly associated with shorter survival in colorectal cancer (CRC), and that CD133 may play an important role in CRC progression. However, the expression of CD133 in lymph node metastases as well as in primary tumors in CRC remains to be elucidated. Materials and Methods: We analyzed CD133 expression in both primary tumors and lymph node metastases in stage III CRC by immunohistochemistry, and its correlation with clinicopathological factors and outcomes. Results: Through immunohistochemistry we demonstrated that 69.6% of CRC primary tumors and 62.3% of lymph node metastases were CD133-positive. High CD133 expression in lymph node metastases was significantly associated with the number of lymph node metastases. Moreover, patients with CD133-negative staining of either primary tumor or lymph node metastases had a higher overall survival rate than those with CD133-positive staining, although this finding was not statistically significant. Conclusion: CD133-positive cancers may be more aggressive than CD133-negative ones during the process of lymph node metastasis. Further investigation of the role of CD133-positive cells in lymph node metastases in CRC is required.
  • Kazushige Kawai, Eiji Sunami, Hironori Yamaguchi, Soichiro Ishihara, Shinsuke Kazama, Hiroaki Nozawa, Keisuke Hata, Tomomichi Kiyomatsu, Junichiro Tanaka, Toshiaki Tanaka, Takeshi Nishikawa, Joji Kitayama, Toshiaki Watanabe
    WORLD JOURNAL OF GASTROENTEROLOGY 21 41 11877 - 11886 2015年11月 [査読有り][通常論文]
     
    AIM: To assist in the selection of suitable nomograms for obtaining desired predictions in daily clinical practice. METHODS: We conducted electronic searches for journal articles on colorectal cancer (CRC)-associated nomograms using the search terms colon/rectal/colorectal/nomogram. Of 174 articles initially found, we retrieved 28 studies in which a nomogram for CRC was developed. RESULTS: We discuss the currently available CRC-associated nomograms, including those that predict the oncological prognosis, the short-term outcome of treatments, such as surgery or neoadjuvant chemoradiotherapy, and the future development of CRC. Developing nomograms always presents a dilemma. On the one hand, the desire to cover as wide a patient range as possible tends to produce nomograms that are too complex and yet have C-indexes that are not sufficiently high. Conversely, confining the target patients might impair the clinical applicability of constructed nomograms. CONCLUSION: The information provided in this review should be of use in selecting a nomogram suitable for obtaining desired predictions in daily clinical practice.
  • Hironori Yamaguchi, Joji Kitayama, Hironori Ishigami, Shinsuke Kazama, Hiroaki Nozawa, Kazushige Kawai, Keisuke Hata, Tomomichi Kiyomatsu, Toshiaki Tanaka, Junichiro Tanaka, Takeshi Nishikawa, Kensuke Otani, Koji Yasuda, Soichiro Ishihara, Eiji Sunami, Toshiaki Watanabe
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY 7 11 285 - 291 2015年11月 [査読有り][通常論文]
     
    The effect of chemotherapy on peritoneal carcinomatosis (PC) of gastric cancer remains unclear. Recently, the intraperitoneal (IP) administration of taxanes [e.g., paclitaxel (PTX) and docetaxel (DOC)] during the perioperative period has shown promising results. Herein, we summarized the rationale and methodology for using IP chemotherapy with taxanes and reviewed the clinical results. IP administered taxanes remain in the IP space at an extremely high concentration for 48-72 h. The drug directly infiltrates peritoneal metastatic nodules from the surface and then produces antitumor effects, making it ideal for IP chemotherapy. There are two types of perioperative IP chemotherapy with taxanes: neoadjuvant intraperitoneal and systemic chemotherapy and sequential perioperative intraperitoneal chemotherapy (SPIC). In SPIC, patients receive neoadjuvant IP chemotherapy and the same regimen of IP chemotherapy after cytoreductive surgery (CRS) until disease progression. Usually, a taxane dissolved in 500-1000 mL of saline at ordinary temperature is administered through an IP access port on an outpatient basis. According to phase. studies, the recommended doses (RD) are as follows: IP DOC, 45-60 mg/m(2); IP PTX [without intravenous (IV) PTX], 80 mg/m(2); and IP PTX (with IV PTX), 20 mg/m(2). Phase. studies have reported a median survival time of 14.4-24.6 mo with a 1-year overall survival of 67%-78%. A phase. study comparing S-1 in combination with IP and IV PTX to S-1 with IV cisplatin started in 2011. The prognosis of patients who underwent CRS was better than that of those who did not; however, this was partly due to selection bias. Although several phase. studies have shown promising results, a randomized controlled study is needed to validate the effectiveness of IP chemotherapy with taxanes for PC of gastric cancer.
  • Hironori Yamaguchi, Tsuyoshi Okubo, Shunichiro Kittaka, Toshiro Sakakibara, Koji Araki, Kenji Iwase, Naoki Amaya, Toshio Ono, Yuko Hosokoshi
    SCIENTIFIC REPORTS 5 15327  2015年10月 [査読有り][通常論文]
     
    Geometric frustration, in which competing interactions give rise to degenerate ground states, potentially induces various exotic quantum phenomena in magnetic materials. Minimal models comprising triangular units, such as triangular and Kagome lattices, have been investigated for decades to realize novel quantum phases, such as quantum spin liquid. A pentagon is the second-minimal elementary unit for geometric frustration. The realization of such systems is expected to provide a distinct platform for studying frustrated magnetism. Here, we present a spin-1/2 quantum pentagonal lattice in the new organic radical crystal alpha-2,6-Cl-2-V [=alpha-3-(2,6-dichlorophenyl)-1,5-diphenylverdazyl]. Its unique molecular arrangement allows the formation of a partially corner-shared pentagonal lattice (PCPL). We find a clear 1/3 magnetization plateau and an anomalous change in magnetization in the vicinity of the saturation field, which originate from frustrated interactions in the PCPL.
  • Hirotoshi Takiyama, Shinsuke Kazama, Yusuke Tanoue, Koji Yasuda, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Takuya Miyagawa, Daisuke Yamada, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Toshiaki Watanabe
    International Journal of Surgery Case Reports 15 107 - 111 2015年09月 [査読有り][通常論文]
     
    Background Perianal hidradenitis suppurativa (PHS) is a chronic recurrent inflammatory disease of the apocrine glands present in the skin and soft tissue adjacent to the anus. It is often misdiagnosed or treatment is delayed, resulting in the formation of an abscess or, in the worst case, leading to sepsis. It is difficult to treat perianal lesions merged with fistulae completely due to its high recurrence rate. Therefore, we should diagnose it correctly and treat it with appropriate methods. Presentation of case We report two cases of PHS with anal fistulae that were examined preoperatively using magnetic resonance imaging (MRI) and treated safely by surgery without any recurrence. Discussion The anal sphincter area cannot be visualized and evaluated directly by fistulography. Also CT has only limited resolution, making it difficult to distinguish between soft tissues and inflammatory streaks. Endosonography is not suitable for the examination of supra-sphincteric or extra-sphincteric extensions, as it is limited by insufficient penetration of the ultrasonic beams. MRI can demonstrate the entire course of the fistulae owing to its high contrast resolution. Conclusion Our findings support the idea that PHS with complicated anal fistulae can be diagnosed accurately using MRI and treated safely and completely with surgery.
  • Tsuyoshi Ozawa, Soichiro Ishihara, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE 30 9 1165 - 1171 2015年09月 [査読有り][通常論文]
     
    The platelet to lymphocyte ratio (PLR) is a potential prognostic marker in a number of different cancers. The aim of this study was to evaluate the prognostic impact of the PLR in patients with stage II colorectal cancer (CRC) who have undergone curative resection but not adjuvant chemotherapy. A retrospective review was performed on 234 patients with stage II CRC who underwent curative resection, but not adjuvant chemotherapy, in our institute. The patients were divided into low and high PLR groups, and patient survival as well as several clinicopathological factors were compared between the groups. Disease-free survival (DFS) and cancer-specific survival (CSS) were analyzed by using the Kaplan-Meier method, and multivariate analysis was performed by using the Cox proportional hazard model. The cutoff value of the PLR determined by using a receiver-operating characteristic curve analysis was 25.4. DFS and CSS were significantly better in patients with a low PLR compared to patients with a high PLR (P = 0.002 and P = 0.011, respectively). On multivariate analysis, we identified the PLR as an independent prognostic factor for DFS and CSS, with a hazard ratio of 2.65 (95 % confidence interval [CI], 1.26-5.45; P = 0.011) and 3.61 (95 % CI, 1.08-12.64; P = 0.038, respectively). The PLR is a good prognostic indicator in patients with stage II CRC who have undergone curative surgery but not adjuvant chemotherapy.
  • Hiroaki Nozawa, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    ANTICANCER RESEARCH 35 9 5073 - 5078 2015年09月 [査読有り][通常論文]
     
    Aim: The postoperative administration of oxaliplatin reduces the frequency of relapse in selected patients with colorectal cancer following surgical resection. However, factors associated with recurrence despite adjuvant therapy are largely unknown. Patients and Methods: We investigated 68 patients who were pathologically diagnosed with stage II or III colorectal cancer and received oxaliplatin-including chemotherapy, FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) or CapeOX (capecitabine and oxaliplatin), after curative surgery. Results: Nineteen patients developed recurrence during the median follow-up period of 17.8 months. Multivariate analyses using the Cox proportional-hazards model revealed that primary tumor size >= 45 mm was a significant predictor of recurrence (hazard ratio = 3.16, 95% confidence interval = 1.06-11.54, p = 0.039). A primary tumor of 45 mm or more in size was associated with poor recurrence-free survival. Conclusion: Our results suggest that large colorectal carcinoma needs to be recognized as a high-risk factor for recurrence even after surgery and subsequent treatment with oxaliplatin.
  • Nozawa H, Tanaka J, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Hata K, Kazama S, Yamaguchi H, Ishihara S, Sunami E, Kitayama J, Nakajima J, Kokudo N, Watanabe T
    Molecular and clinical oncology 3 5 1041 - 1047 2015年09月 [査読有り][通常論文]
  • Keisuke Hata, Shinsuke Kazama, Hiroaki Nozawa, Kazushige Kawai, Tomomichi Kiyomatsu, Junichiro Tanaka, Toshiaki Tanaka, Takeshi Nishikawa, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    SURGERY TODAY 45 8 933 - 938 2015年08月 [査読有り][通常論文]
     
    Despite the development of new therapies, including anti-TNF alpha antibodies and immunosuppressants, a substantial proportion of patients with ulcerative colitis (UC) still require surgery. Restorative proctocolectomy with ileal-pouch anal anastomosis is the standard surgical treatment of choice for UC. With the advent of laparoscopic techniques for colorectal surgery, ileal-pouch anal anastomosis has also been performed laparoscopically. This paper reviews the history and current trends in laparoscopic surgery for UC. The accumulation of experience and improvement of laparoscopic devices have shifted the paradigm of UC surgery towards laparoscopic surgery over the past decade. Although laparoscopic surgery requires a longer operation, it provides significantly better short and long-term outcomes. The short-term benefits of laparoscopic surgery over open surgery include shorter hospital stays and fasting times, as well as better cosmesis. The long-term benefits of laparoscopy include better fecundity in young females. Some surgeons favor laparoscopic surgery even for severe acute colitis. More efforts are being made to develop newer laparoscopic methods, such as reduced port surgery, including single incision laparoscopic surgery and robotic surgery.
  • Yuzo Nagai, Yoko Yamamoto, Takaaki Yasuhara, Keisuke Hata, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Hiroaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Takeharu Yamanaka, Kiyoshi Miyagawa, Toshiaki Watanabe
    ONCOTARGET 6 25 21064 - 21073 2015年08月 [査読有り][通常論文]
     
    We recently reported a specific mechanism that RAD54B, an important factor in homologous recombination, promotes genomic instability via the degradation of p53 protein in vitro. However, clinical significance of RAD54B in colorectal cancer (CRC) remains unclear. Thus we analyzed RAD54B gene expression in CRC patients. Using the training set (n = 123), the optimal cut-off value for stratification was determined, and validated in another cohort (n = 89). Kaplan-Meier plots showed that distant recurrence free survival was significantly lesser in high RAD54B expression group compared with that of low expression group in both training (P = 0.0013) and validation (P = 0.024) set. Multivariate analysis using Cox proportional-hazards model showed that high RAD54B expression was an independent predictor in both training (hazard ratio, 4.31; 95% CI, 1.53-13.1; P = 0.0060) and validation (hazard ratio, 3.63; 95% CI, 1.23-10.7; P = 0.021) set. In addition, a negative significant correlation between RAD54B and CDKN1A, a target gene of p53, was partially confirmed, suggesting that RAD54B functions via the degradation of p53 protein even in clinical samples. This study first demonstrated RAD54B expression has potential to serve as a novel prognostic biomarker, particularly for distant recurrence in CRC patients.
  • Soichiro Ishihara, Kensuke Otani, Koji Yasuda, Takeshi Nishikawa, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 20 4 633 - 640 2015年08月 [査読有り][通常論文]
     
    Robotic technology, which has recently been introduced to the field of surgery, is expected to be useful, particularly in treating rectal cancer where precise manipulation is necessary in the confined pelvic cavity. Robotic surgery overcomes the technical drawbacks inherent to laparoscopic surgery for rectal cancer through the use of multi-articulated flexible tools, three-dimensional stable camera platforms, tremor filtering and motion scaling functions, and greater ergonomic and intuitive device manipulation. Assessments of the feasibility and safety of robotic surgery for rectal cancer have reported similar operation times, blood loss during surgery, rates of postoperative morbidity, and circumferential resection margin involvement when compared with laparoscopic surgery. Furthermore, rates of conversion to open surgery are reportedly lower with increased urinary and male sexual functions in the early postoperative period compared with laparoscopic surgery, demonstrating the technical advantages of robotic surgery for rectal cancer. However, long-term outcomes and the cost-effectiveness of robotic surgery for rectal cancer have not been fully evaluated yet; therefore, large-scale clinical studies are required to evaluate the efficacy of this new technology.
  • Hiroaki Nozawa, Soichiro Ishihara, Teppei Morikawa, Junichiro Tanaka, Koji Yasuda, Kensuke Ohtani, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Masashi Fukayama, Toshiaki Watanabe
    DIAGNOSTIC PATHOLOGY 10 139  2015年08月 [査読有り][通常論文]
     
    Anal canal adenoma is an extremely rare disease that has the potential to transform into a malignant tumor. We herein presented a rare case of metachronous multiple adenomas of the anal canal. A 48-year-old woman underwent total colonoscopy following a positive fecal blood test. A 9-mm villous polyp arising from the posterior wall of the anal canal was removed by snare polypectomy. Histologically, the tumor was tubulovillous adenoma with high-grade dysplasia and the cut end was negative for tumor cells. Six years later, an elevated lesion, macroscopically five millimeters in size, was detected in the left wall of the anal canal in a follow-up colonoscopy. Local excision of the tumor was performed, and the lesion was pathologically confirmed to be tubular adenoma with high-grade dysplasia limited to the mucosa. The patient is currently alive without any evidence of recurrence for six months after surgery. Although she had a past history of cervical cancer, the multiple tumors arising in the anal canal were unlikely to be related to human papilloma virus infection. Our case report underscores the importance of careful observations throughout colonoscopy to detect precancerous lesions, particularly in anatomically narrow segments.
  • Joji Kitayama, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, Haruna Onoyama, Hiroharu Yamashita, Yasuyuki Seto, Keisuke Matsuzaki, Toshiaki Watanabe
    ANNALS OF SURGICAL ONCOLOGY 22 7 2336 - 2342 2015年07月 [査読有り][通常論文]
     
    The frequency of intraperitoneal free tumor cells (IPTC) is considered to reflect the severity of peritoneal metastasis (PM). We quantified the relative number of IPTC against leukocytes in peritoneal fluid and evaluated its clinical relevance in gastric cancer (GC) patients, particularly those with PM. Cells recovered from ascites or peritoneal lavage fluid were immunostained with monoclonal antibodies (mAb) to CD45 and CD326 (EpCAM). Using flow cytometry (FACS), CD326(+) and CD45(+) cells were classified as either tumor cells (T) or leukocytes (L) and the T/L ratio (TLR) was calculated in a total of 506 samples obtained from 300 patients with GC and 33 patients with liver cirrhosis (LC). Median (M) of the TLR of the initial samples obtained from 199 patients with PM(+) GC was 1.32 % (0-1,868.44 %), which was significantly higher than that in patients with PM(-) GC (M = 0 %, 0-0.35 %; n = 101) or LC (M = 0 %, 0-0.031 %; n = 33). In 104 PM(+) patients who received combination chemotherapy including intraperitoneal paclitaxel, the TLR was repeatedly measured in peritoneal fluid obtained from the port. In these patients, the TLR showed a strong correlation with clinical features as well as cytological findings and carcinoembryonic antigen messenger RNA status. Finally, the median survival time of the 11 patients with initial TLR > 10 % was significantly shorter than that of the 52 patients with TLR < 10 % (271 vs. 627 days; p = 0.0002). The TLR excellently reflected tumor burden in the peritoneal cavity, and could be a reliable biomarker to determine the outcome, as well as the effectiveness, of chemotherapy in patients with PM(+) GC.
  • Hiroaki Ishii, Kazushige Kawai, Keisuke Hata, Yasutaka Shuno, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Hiroaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    INTERNATIONAL SURGERY 100 7-8 1169 - 1176 2015年07月 [査読有り][通常論文]
     
    Total proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the standard surgical treatment for patients with ulcerative colitis (UC). The purpose of this study was to investigate the long-term functional outcomes and quality of life (QOL) associated with hand-sewn and stapled IPAA. Ninety-one patients with UC had undergone IPAA using hand-sewn anastomosis with mucosectomy (32 patients) or stapled anastomosis (59 patients) from January 1988 to May 2010. Patients were evaluated according to patient characteristics, postoperative complications, functional outcomes and QOL. The QOL of patients were evaluated using the Medical Outcomes Study Short Form 36 (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ). Numbers of patients with colorectal cancer or dysplasia were significantly greater in the hand-sewn IPAA group (P < 0.01). These patients had longer disease durations and were older (both P < 0.01). There was no difference in the incidence of complications between the groups, except for a greater incidence of postoperative anal fistula in the stapled group (P = 0.03). In the early postsurgery period, both the frequency of bowel movements and the rate of soiling were significantly higher in the hand-sewn group, but in a later period, there was no difference in these events >3 years after surgery. The SF-36 and IBDQ results were similar in the two groups, indicating that hand-sewn and stapled IPAA result in similar QOL in the late postoperative period. Postoperative complications, functional outcomes, and long-term QOL were similar in patients who had received hand-sewn or stapled IPAA.
  • Soichiro Ishihara, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Hioaki Nozawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Kenichi Sugihara, Toshiaki Watanabe
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE 30 6 807 - 812 2015年06月 [査読有り][通常論文]
     
    Retrospective studies have shown that primary tumor resection improves the prognosis of patients with colorectal cancer (CRC) with unresectable metastasis (mCRC). The aim of this study was to investigate the prognostic impact of primary tumor resection in various subgroups of mCRC patients. A total of 1982 patients with mCRC from January 1997 to December 2007 were retrospectively evaluated. The impact of primary tumor resection on cancer-specific survival (CSS) was analyzed using propensity score analysis to mitigate selection bias. Covariates in the models for propensity scores included treatment period, age, gender, tumor location, depth, lymph node metastasis, number of metastatic organs, and carcinoembryonic antigen (CEA) levels. Among the whole patient population, primary tumor resection significantly improved CSS [hazard ratio (HR) 0.46, 95 % confidence interval (CI) 0.32-0.66, p < 0.01]. However, primary tumor resection did not significantly improve CSS in the following subgroups: patients treated in the first 5 years of the study (HR 0.56, 95 % CI 0.28-1.13, p = 0.08), patients aged > 65 years (HR 0.72, 95 % CI 0.36-1.42, p = 0.31), female patients (HR 0.60, 95 % CI 0.31-1.17, p = 0.13), patients with right-sided colon cancer (HR 0.68, 95 % CI 0.39-1.20, p = 0.17), and patients without nodal involvement (HR 0.54, 95 % CI 0.25-1.17, p = 0.09). Our study suggests that primary tumor resection improves the survival of patients with mCRC. However, the prognostic benefit is different among patient subpopulations.
  • Junichiro Tanaka, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Shinsuke Kazama, Hiroaki Nozawa, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    Annals of Medicine and Surgery 4 2 183 - 186 2015年06月 [査読有り][通常論文]
     
    Background: The incidence of anastomotic leakage in rectal surgery is around 10 percent. Poor blood supply to the anastomosis, high anastomotic pressure and tension, increased operative blood loss, long operative time, and male sex are risk factors of anastomotic leakage. In the present study, we examined anastomotic leakage cases in rectal surgery at our institute and tried to ascertain the risk factors. Methods: Three hundred fifty-seven consecutive patients who underwent rectal resection with anastomosis between January 2008 and October 2013 were included in the study. Patients were divided into two groups according to the existence of anastomotic leakage. Clinicopathological features, operative procedures, and intraoperative outcomes were compared between the two groups. Regarding intraoperative procedure, we focused on the ligation level of the inferior mesenteric artery, installing a transanal drainage tube in the rectum, and constructing a diverting stoma. Results: Anastomotic leakage occurred in eight patients. All of them were male (p=0.0284). There were no statistical differences in other characteristics of the patients or tumors, in operative procedures, or in intraoperative outcomes. Conclusions: In the present study, no statistically significant risk factors for anastomotic leakage in rectal surgery were detected, except for male sex. However, the rate of anastomotic leakage at our institute was revealed to be rather low. Our exertion to preserve good blood flow and to prevent high tension and pressure on the anastomosis in operation may have led to this result.
  • Ozawa T, Ishihara S, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Kanazawa T, Nozawa H, Kazama S, Yamaguchi H, Sunami E, Kitayama J, Watanabe T
    Hepato-gastroenterology 62 140 853 - 858 2015年06月 [査読有り][通常論文]
  • Kazushige Kawai, Soichiro Ishihara, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Hiroaki Miyata, Toshiaki Watanabe
    ANNALS OF SURGERY 261 5 926 - 932 2015年05月 [査読有り][通常論文]
     
    Objective: To construct a predictive model of postoperative colorectal neoplasm development using a nomogram. Background: Although patients with colorectal cancer (CRC) are known to be at high risk of developing metachronous adenoma or CRC, no statistical model for predicting the incidence of postoperative colorectal lesions has been reported. Methods: A total of 309 CRC patients who underwent surgical resection received regular endoscopic follow-up to detect the development of metachronous adenoma or adenocarcinoma. The patients were divided into the derivation set (n = 209) and the validation set (n = 100). The nomogram to predict the 3- and 5-year adenoma-free survival rates was constructed using the derivation set, and a calibration plot and concordance index (c-index) were calculated. The predictive utility of the nomogram was validated in the validation set. Results: Sex, age, and number of synchronous lesions at the time of surgery for primary CRC were adopted as variables for the nomogram. The nomogram showed moderate calibration, with a c-index of 0.709 in the derivation set and 0.712 in the validation set. Conclusions: A nomogram based on sex, age, and number of synchronous lesions at the time of surgery has the ability to predict postoperative adenoma-free survival.
  • Tsuyoshi Ozawa, Soichiro Ishihara, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Takamitsu Kanazawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    ANNALS OF SURGICAL ONCOLOGY 22 5 1513 - 1519 2015年05月 [査読有り][通常論文]
     
    The lymph node ratio (LNR) was proposed as a prognostic indicator in Stage III colorectal cancer (CRC) patients in recent studies. The purpose of this study was to evaluate the prognostic impact of the LNR in Stage IV CRC patients who have undergone curative resection. A retrospective review of 119 Stage IV CRC patients who underwent curative resection in our institute from 1997 to 2009 was performed. Patients were divided into two groups (low LNR and high LNR) by means of their median LNR. A disease-free survival (DFS) and an overall survival (OS) were analyzed using the Kaplan-Meier curve; multivariate analysis was performed using the Cox proportional hazard model. The cutoff value for the LNR was 0.111. For the entire study group, the 5-year DFS was 22 % and the 5-year OS was 65 %. DFS was not significantly different between patients in the low LNR group and the high LNR group (25 and 19 %, respectively; P = 0.317), but OS was significantly higher in the low LNR group patients compared with the high LNR group patients (77 and 54 %, respectively; P < 0.001). Using multivariate analysis, we identified the LNR as an independent prognostic factor for OS, with a hazard ratio of 3.08 (95 % CI 1.38-8.19; P = 0.005). LNR is a potent prognostic indicator for stratification in Stage IV CRC patients who have undergone curative resection.
  • Junko Kishikawa, Kazushige Kawai, Nelson H. Tsuno, Soichiro Ishihara, Hironori Yamaguchi, Eiji Sunami, Toshiaki Watanabe
    INTERNATIONAL SURGERY 100 5 783 - 789 2015年05月 [査読有り][通常論文]
     
    It is well known that host immunity plays an important role in the defense against colorectal cancer (CRC) progression. The effects of autoimmune diseases, such as rheumatic disease (RD) in which the immune system is deregulated, on this immunity have not been fully investigated. The medical records of 1299 consecutive patients diagnosed with primary colorectal cancer who underwent surgical resection were retrospectively reviewed. The clinicopathologic factors of 28 subjects with RD (RD group) were compared with those of 1271 patients without RD (non-RD group). Compared to the non-RD group, the RD group was typified by a predominance of females (P < 0.01), older age (P < 0.01), and a lower incidence of rectal cancer (P = 0.02). Although no difference was observed between the groups in terms of TNM classification, disease-free and overall survival were significantly poorer in the RD group in both univariate and multivariate analyses. Subjects who had RD for more than 10 years tended to have a higher frequency of lymph node metastasis (P = 0.06) and a significantly higher incidence of synchronous distant metastasis (P = 0.035) at the time of cancer diagnosis. RD was associated with a significantly poorer prognosis of colorectal cancer, suggesting that deregulation of the immune system by autoimmune diseases may adversely affect the host immune defense against colorectal cancer progression.
  • Hiroyuki Anzai, Shinsuke Kazama, Tomomichi Kiyomatsu, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Keisuke Hata, Kazushige Kawai, Hironori Yamaguchi, Hiroaki Nozawa, Takamitsu Kanazawa, Tetsuo Ushiku, Soichiro Ishihara, Eiji Sunami, Masashi Fukayama, Toshiaki Watanabe
    WORLD JOURNAL OF SURGICAL ONCOLOGY 13 180  2015年05月 [査読有り][通常論文]
     
    Background: Alpha-fetoprotein (AFP)-producing rectal cancer is very rare, and this type of cancer frequently metastasizes to the liver with a poor prognosis. To date, only 11 cases of AFP-producing colorectal cancer have been reported. Case presentation: A 41-year-old woman was first presented to the hospital for anal bleeding. An elevated tumor with a central shallow depression in the lower rectum was detected by colonoscopy. Transanal excision was performed, and the histology revealed adenocarcinoma. Further immunohistopathological examination revealed that the tumor was an AFP-producing adenocarcinoma of the rectum. Although local resection was performed 2 months before the diagnosis of AFP tumor, the serum AFP level was normal. The depth of the submucosal invasion was 5,000 mu m, and there was venous invasion. Also, no lymphatic invasion was detected. Therefore, additional surgical resection with lymph node dissection was conducted, and the patient underwent laparoscopic intersphincteric resection. No residual cancer was identified in the surgical specimens, and there was no evidence of lymph node metastasis. The patient was discharged 18 days postoperatively, and 12 months after the operation, there are no signs of recurrence. Conclusion: To the best of our knowledge, this is the first case of an AFP-producing rectal cancer that was diagnosed at an early stage.
  • Shinsuke Kazama, Joji Kitayama, Masaya Hiyoshi, Yoshitaka Taketomi, Makoto Murakami, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Hironori Yamaguchi, Hiroaki Nozawa, Soichiro Ishihara, Eiji Sunami, Toshiaki Watanabe
    ANTICANCER RESEARCH 35 5 2983 - 2990 2015年05月 [査読有り][通常論文]
     
    Background: Although secretory phospholipase A2 (sPLA2) has been shown to be involved in various biological processes, its specific roles in sub-types of cancer development remain to be elucidated. Materials and Methods: We examined the expression of sPLA2 group III (GIII) in 142 patients with colorectal cancer using immunohistochemistry, and its correlation with clinicopathological features and outcomes. In addition, we examined the co-expression of sPLA2GIII and sPLA2GX using serial tissue sections to clarify the roles of both proteins in colorectal carcinogenesis. Results: In 66 cases, diffuse staining of sPLA2GIII was seen; this was defined as the group with high expression. High expression was associated with a significantly higher rate of lymph node metastasis (p=0.02) and poorer survival (p=0.03) compared with low expression. Patients with low sPLA2GIII and high sPLA2GX expression had a significantly higher survival rate than those with high sPLA2GIII and low sPLA2GX expression (p=0.038). Conclusion: sPLA2GIII expression may be used as a risk factor for lymph node metastasis and a prognostic marker in colorectal cancer. In addition, sPLA2GIII and sPLA2GX may play opposing roles in colorectal carcinogenesis.
  • Kensuke Kaneko, Kazushige Kawai, Nelson H. Tsuno, Soichiro Ishihara, Hironori Yamaguchi, Eiji Sunami, Toshiaki Watanabe
    INTERNATIONAL SURGERY 100 5 797 - 804 2015年05月 [査読有り][通常論文]
     
    Allogeneic blood transfusion (ABT) has been reported as a major risk factor for surgical site infection (SSI) in patients undergoing colorectal surgery. However, the association of ABT with SSI in patients undergoing abdominoperineal resection (APR) and total pelvic exenteration (TPE) still remains to be evaluated. Here, we aim to elucidate this association. The medical records of all patients undergoing APR and TPE at our institution in the period between January 2000 and December 2012 were reviewed. Patients without SSI (no SSI group) were compared with patients who developed SSI (SSI group), in terms of clinicopathologic features, including ABT. In addition, data for 262 patients who underwent transabdominal rectal resection at our institution in the same period were also enrolled, and their data on differential leukocyte counts were evaluated. Multivariate analysis showed that intraoperative transfusion was an independent predictive factor for SSI after APR and TPE (P = 0.004). In addition, the first-operative day lymphocyte count of patients undergoing APR, TPE, and transabdominal rectal resection was significantly higher in nontransfusion patients compared with transfusion ones (P = 0.026). ABT in the perioperative period of APR and TPE may have an important immunomodulatory effect, leading to an increased incidence of SSI. This fact should be carefully considered, and efforts to avoid allogeneic blood exposure while still achieving adequate patient blood management would be very important for patients undergoing APR and TPE as well.
  • Soichiro Ishihara, Keiji Matsuda, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Hiroaki Nozawa, Shinsuke Kazama, Takamitsu Kanazawa, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Yojiro Hashiguchi, Toshiaki Watanabe
    SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES 25 2 168 - 172 2015年04月 [査読有り][通常論文]
     
    The aim of this study was to clarify patient factors contributing to complications after laparoscopic surgery for colorectal cancers. A total of 333 colorectal cancer patients who underwent laparoscopic colorectal resection between January 2007 and December 2012 were enrolled. The association between patient factors and the incidence of complications were analyzed. Postoperative complications were divided into 2 categories: infectious complications and noninfectious complications. The overall complication rate was 13% and mortality rate 0%. Multivariate analysis showed that body mass index > 25 kg/m(2) [odds ratio (OR) = 3.02, P = 0.0254] and tumor location (right colon cancer/rectal cancer: OR = 0.11, P = 0.0083) were risk factors for infectious complications; in addition, male sex (OR = 3.91, P = 0.0102) and cancer stage (stage 2/stage 4: OR = 0.17, P = 0.0247) were risk factors for noninfectious complications. This study shows that different patient factors are associated with the risk of different types of complications.
  • Kazushige Kawai, Eiji Sunami, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Hiroaki Nozawa, Shinsuke Kazama, Takamitsu Kanazawa, Akihiro Hosaka, Soichiro Ishihara, Hironori Yamaguchi, Kunihiro Shigematsu, Toshiaki Watanabe
    INTERNATIONAL SURGERY 100 4 600 - 603 2015年04月 [査読有り][通常論文]
     
    Although the incidence of synchronous abdominal aortic aneurysm (AAA) and malignancies is increasing, there has been no clear consensus in the surgical treatment of such patients. The focus on surgical treatments with minimal invasiveness, such as endovascular aneurysm repair (EVAR) for AAA and laparoscopic colectomy for colorectal cancer, has increased; however, the clinical applicability of combination treatment with EVAR and laparoscopic colectomy has not been established. A 61-year-old man was diagnosed with AAA, advanced sigmoid colon cancer, and coronary artery stenosis. Because the patient also had chronic renal failure with nephrotic syndrome, among several other comorbidities, surgery was considered to be associated with high risks in this patent. Sequential treatments with percutaneous coronary intervention, EVAR, and laparoscopic colectomy were successfully performed. Staged treatment of EVAR followed by laparoscopic colectomy may be a promising strategy for high-risk patients with AAA associated with malignancy.
  • Yuichiro Yokoyama, Keisuke Hata, Takamitsu Kanazawa, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    WORLD JOURNAL OF SURGICAL ONCOLOGY 13 164  2015年04月 [査読有り][通常論文]
     
    Solitary fibrous tumors (SFTs) rarely develop in the pelvis. When they do arise, they are usually treated using surgery, although SFTs are often very large by the time of diagnosis, which makes surgical excision difficult. We report a case of a 63-year-old man who was referred to our hospital for the treatment of a giant tumor of the pelvis. Computed tomography (CT) revealed a 30 x 25 x 19 cm sized hypervascular tumor that almost completely filled the pelvic cavity. The diagnosis of SFT was made by CT-assisted needle biopsy. The feeding arteries of the tumor were embolized twice. The first embolization aimed to reduce the tumor volume, while the second one was planned a day prior to the surgery to obtain hematostasis during the operation. Tumor resection was then performed. The blood loss during the operation was 440 ml, and there was no uncontrollable bleeding. The postoperative course was uneventful. No recurrence of SFT was observed during a 2-year follow-up.
  • Shigenobu Emoto, Joji Kitayama, Hironori Ishigami, Hironori Yamaguchi, Toshiaki Watanabe
    ANNALS OF SURGICAL ONCOLOGY 22 3 780 - 786 2015年03月 [査読有り][通常論文]
     
    Background. A positive cytology of peritoneal lavage fluid (CY1) is a poor prognostic factor in patients with gastric cancer (GC). We have recently reported that CY1 often changes to negative (CY0) following combination chemotherapy including intraperitoneal (IP) paclitaxel (PTX), which results in marked prolongation of survival in GC patients with peritoneal dissemination (P1). Methods. A total of 95 P1 GC patients who received combination chemotherapy with S-1 and intravenous and IP PTX were enrolled. Peritoneal lavage fluid was periodically examined cytologically at the start of every cycle of chemotherapy, and the impact of CY status on patient outcome was retrospectively evaluated. Results. Seventy-three (76.8 %) of 95 patients were diagnosed as CY1 before initial treatment. Median survival time (MST) of the CY1 group was significantly shorter than that of the CY0 group (19.1 vs. 32.5 months, P = 0.033). Cytological status changed from CY1 to CY0 in 68 (93.2 %) of 73 CY1 patients during the whole treatment period and MST of patients who showed a negative change was significantly longer than that of the unchanged group (20.0 vs. 13.0 months, P = 0.0017). In 64 patients who achieved CY0 by IP PTX regimen, the median time to achieve CY0 was 1.4 months, and patients who achieved a negative change within 1 month showed a particularly good outcome (MST = 26.1 months). Conclusions. Periodic cytological examination of peritoneal lavage fluid is clinically useful to evaluate the efficacy of treatment as well as to predict the outcome of patients with P1 GC.
  • Yuuki Iida, Eiji Sunami, Hiroharu Yamashita, Masaya Hiyoshi, Soichiro Ishihara, Hironori Yamaguchi, Asuka Inoue, Kumiko Makide, Nelson H. Tsuno, Junken Aoki, Joji Kitayama, Toshiaki Watanabe
    ANTICANCER RESEARCH 35 3 1459 - 1464 2015年03月 [査読有り][通常論文]
     
    Background: The function of phosphatidylserine-specific phospholipase A1 (PS-PLA(1)), a phospholipase that acts specifically on phosphatidylserine and produces lysophosphatidylserine, a lysophospholipid mediator, has not been fully elucidated. We evaluated the role of PS-PLA(1) in oncogenesis and metastasis of colorectal cancer (CRC). Materials and Methods: Specimens from 85 patients with CRC were immunostained with a monoclonal antibody against PS-PLA(1). The correlation between PS-PLA(1) expression and the clinicopathological variables was analyzed. Results: Tumor depth and hematogenous metastasis independently positively correlated with PS-PLA(1) expression. High PS-PLA(1) expression was associated with shorter disease-free survival, although it was not an independent predictive factor. Conclusion: PS-PLA(1) expression in CRC is associated with tumor invasion and metastasis.
  • Noriko Tada, Kazushige Kawai, Nelson H Tsuno, Soichiro Ishihara, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Koji Oba, Toshiaki Watanabe
    World journal of surgical oncology 13 30 - 30 2015年02月 [査読有り][通常論文]
     
    BACKGROUND: Although neoadjuvant chemoradiotherapy (CRT) has become a standard procedure to downstage locally advanced rectal cancer prior to surgery, markers to predict the response to CRT have not been fully identified. The aim of this study was to identify predictive factors of response to CRT, especially focusing on peripheral blood leukocyte subsets. METHODS: A total of 45 consecutive patients diagnosed with primary rectal cancer were prospectively enrolled and received CRT followed by curative resection. The numbers of each lymphocyte subset in peripheral blood pre- and post-CRT were analyzed using flow cytometry. According to the pathological response to CRT, patients were classified into high (Hi-R) and low (Lo-R) response groups. RESULTS: Hi-R cases had significantly higher numbers of pre-CRT lymphocytes (p = 0.018), T lymphocytes (p = 0.009) and helper T lymphocytes (Th lymphocytes, p = 0.015) compared to the Lo-R cases. With the receiver-operating characteristic curve for numbers of pre-CRT T lymphocytes, the area under the curve (AUC) was 0.733, and the optimal cutoff value was 1196/μl, with 76.5% sensitivity, 67.8% specificity, 59.1% positive and 82.6% negative predictive values. The numbers of pre-CRT Th lymphocytes and cytotoxic lymphocytes were both independent predictors of the high CRT response in the multivariate analysis. CONCLUSIONS: In addition to the direct cytotoxicity of CRT, recent studies have demonstrated the induction of an immunological host response, which also contributed to the tumor regression induced by CRT. Our result suggested the potential role of circulating T lymphocytes in predicting the response to CRT in colorectal cancer patients.
  • Koji Murono, Shinsuke Kazama, Hironori Yamaguchi, Kazushige Kawai, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Yumiko Satoh, Makiko Kurihara, Yutaka Yatomi, Toshiaki Watanabe
    SURGERY 157 2 322 - 330 2015年02月 [査読有り][通常論文]
     
    Background. Peritoneal dissemination and positive peritoneal lavage cytology are associated with poor prognosis in colorectal cancer. Carcinoembryonic antigen (CEA) messenger RNA (mRNA) is often used as a marker to detect micrometastases. We aimed to evaluate the prognostic significance of CEA mRNA in the peritoneal lavage of colon cancer patients. Methods. Colon cancer patients (n = 201) who underwent curative operative resection between August 2009 and February 2013 were enrolled. CEA mRNA in peritoneal lavage was measured using the transcription-reverse transcription concerted method, a quantitative RNA amplification method. The correlation between CEA mRNA and overall and peritoneal recurrence-free survival was evaluated. Results. Positive CEA mRNA in peritoneal lavage was an independent risk factor for overall recurrence-free survival in colon cancer (1, < .0001). Positive CEA mRNA was a risk factor for poorer overall recurrence in stage II and III patients (P = .04 and P = .02, respectively). Moreover, among stage III patients with positive CEA mRNA, the postoperative chemotherapy group had significantly lower overall and peritoneal recurrence rates than the no postoperative chemotherapy group (P = .001). Conclusion. Positive cm mRNA in peritoneal lavage was associated with high overall recurrence rates in stage II and III colon cancer Further study is necessary to determinate the efficacy of aggressive postoperative chemotherapy for stage II and III colon cancerpatients with positive CEA mRNA.
  • Koji Murono, Kazushige Kawai, Shinsuke Kazama, Soichiro Ishihara, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    DISEASES OF THE COLON & RECTUM 58 2 214 - 219 2015年02月 [査読有り][通常論文]
     
    BACKGROUND: The branching of the inferior mesenteric artery and vein varies among individuals. Three-dimensional CT angiography is a less invasive modality than traditional angiographic examination to assess the artery and vein. OBJECTIVE: We aimed to demonstrate the clinical applicability of CT angiography by evaluating bifurcations of the inferior mesenteric artery and the positional relationship between the inferior mesenteric artery and vein. DESIGN: This was a prospective observational study of patients undergoing preoperative CT angiography. SETTINGS: This study was conducted at a single tertiary care institution in Japan. PATIENTS: A total of 471 consecutive patients who underwent preoperative CT angiography from April 2012 to December 2013 were prospectively enrolled. MAIN OUTCOME MEASURES: The branching pattern of the inferior mesenteric artery, the positional relationship between the inferior mesenteric artery and vein, and the associations between inferior mesenteric artery length and clinical features were evaluated. RESULTS: The length of the inferior mesenteric artery varied widely, from 10.1 to 82.2 mm. In 41.2% patients, the left colic artery arose independently from the sigmoid artery, and in 44.7% of the patients, the left colic artery and sigmoid artery had a common trunk, whereas the left colic artery did not exist in 5.1%. The left colic artery was located lateral to the inferior mesenteric vein at the level of the origin of the inferior mesenteric artery in 73.0% of the patients. The incidence of a short inferior mesenteric artery was significantly increased in men with high BMIs (75.0%). LIMITATIONS: Three-dimensional reconstruction was performed by the use of a single software, and angiographic examination was not performed. Therefore, accuracy and reliability of the 3-dimensional reconstruction could not be established for each modality. CONCLUSIONS: Using 3-dimensional CT angiography, preoperative understanding of the anatomic vascular variations can be easily obtained, which would help surgeons to safely perform laparoscopic surgery in the left-side colon and rectum.
  • Nirei T, Kazama S, Hiyoshi M, Tsuno NH, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Hata K, Kawai K, Nozawa H, Kanazawa T, Yamaguchi H, Ishihara S, Sunami E, Kitayama J, Watanabe T
    Journal of clinical medicine research 7 1 59 - 61 2015年01月 [査読有り][通常論文]
  • Tsuyoshi Ozawa, Hironori Yamaguchi, Tomomichi Kiyomatsu, Shinsuke Saito, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    INTERNATIONAL SURGERY 100 1 58 - 62 2015年01月 [査読有り][通常論文]
     
    A 57-year-old woman without any past medical history underwent abdominoperineal resection for rectal cancer in our department. On postoperative day 15, the patient complained of sudden abdominal pain, and high fever was noted in addition to the appearance of erythema around the stoma. The diagnosis of phlegmon was made, and antibiotic infusion was started. However, a few days later, the patient developed hypovolemic shock with hypoalbuminemia and hemoconcentration. Fasciotomy was performed to exclude the necrotizing fasciitis, though all cultures were negative. Upon exclusion of the differential diagnoses, idiopathic systemic capillary leak syndrome (ISCLS) was diagnosed. She was successfully treated with massive fluid infusion under ventilation and continuous hemodiafiltration. Here, we report the first case of ISCLS that occurred during the postoperative period of colorectal surgery.
  • Masaya Hiyoshi, Kazushige Kawai, Mihoko Shibuya, Tsuyoshi Ozawa, Junko Kishikawa, Takako Nirei, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Tomohiro Tada, Takamitsu Kanazawa, Shinsuke Kazama, Hirofumi Shoda, Shuji Sumitomo, Kanae Kubo, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Kazuhiko Yamamoto, Toshiaki Watanabe
    INTERNAL MEDICINE 54 7 749 - 753 2015年 [査読有り][通常論文]
     
    We herein report the case of a 42-year-old man with a one-year history of ulcerative colitis who presented with exacerbated bloody diarrhea, a productive cough and increasing breathing difficulties. Colonoscopy revealed typical deep ulcers in the rectosigmoid colon and atypical multiple sucker-like ulcers in the transverse colon, and computed tomography of the chest demonstrated wall thickening of the trachea and bronchi. In addition, bronchoscopy showed ulcers in the trachea, and histopathology disclosed findings of necrosis and inflammation of the subepithelial tissue of the trachea. Based on these findings, the patient's respiratory symptoms were strongly suspected to be due to ulcerative colitis-related tracheobronchitis. Treatment with systemic corticosteroids subsequently resulted in a rapid clinical improvement.
  • Hidemichi Kiyomatsu, Kazushige Kawai, Toshiaki Tanaka, Jyunichiro Tanaka, Tomomichi Kiyomatsu, Hiroaki Nozawa, Takamitsu Kanazawa, Shinsuke Kazama, Soichiro Ishihara, Hironori Yamaguchi, Eiji Sunami, Toshiaki Watanabe
    INTERNAL MEDICINE 54 13 1605 - 1608 2015年 [査読有り][通常論文]
     
    A 16-year-old boy was diagnosed with Crohn's disease. Treatment with oral mesalazine was started at 3 g per day; however, he complained of high fever, a nonproductive cough, and left shoulder pain after 2 weeks. His chest radiography and chest computed tomography showed cardiomegaly and left pleural effusion, while an echocardiogram revealed pericardial effusion. Because no infection was detected by thoracentesis and the drug lymphocyte stimulation tests for mesalazine were positive, the patient was diagnosed with mesalazine-induced pleuropericarditis. After the cessation of mesalazine, the clinical symptoms and laboratory findings quickly improved.
  • Shigenobu Emoto, Eiji Sunami, Hironori Yamaguchi, Soichiro Ishihara, Joji Kitayama, Toshiaki Watanabe
    SURGERY TODAY 44 12 2209 - 2220 2014年12月 [査読有り][通常論文]
     
    Intraperitoneal (IP) chemotherapy for peritoneal carcinomatosis (PC) from gastrointestinal cancer has been investigated and applied clinically for several decades. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy have been considered to be the optimal treatment options for selected patients with colorectal and gastric cancers with PC. Accumulating evidence suggests that the administration of IP paclitaxel for patients with PC from gastric cancer may improve the patient survival. The pharmacokinetics of such treatment should be considered to optimize IP chemotherapy. In addition, newly emerging molecular-targeted therapies and research into new drug delivery systems, such as nanomedicine or controlled absorption/release methods, are essential to improve the effects of IP chemotherapy. This review summarizes the current status and future prospects of IP chemotherapy for the treatment of gastrointestinal cancer.
  • Yuuki Iida, Kazushige Kawai, Nelson H. Tsuno, Soichiro Ishihara, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    CLINICAL COLORECTAL CANCER 13 4 213 - 218 2014年12月 [査読有り][通常論文]
     
    This study reviewed 1059 patients with colorectal cancers (CRCs) to evaluate the age-related changes in the clinicopathologic features, according to the gender. The presence of concomitant adenoma was the only independent age-related factor in men (P = .0044), whereas the presence of right-sided CRC was the only one in women (P < .0001). The results suggest the oncologic background difference between men and women among the elderly. Introduction: Although several reports have documented the increased incidence of right-sided colorectal cancer (CRC) in the elderly, especially in women, the gender-specific, age-related changes in the characteristics of CRCs, especially related to the cancer localization, have not been fully investigated. This study evaluated the age-related changes in the clinicopathologic features of CRCs, according to the gender. Materials and Methods: A total of 1059 consecutive patients with CRCs who were admitted to the authors' surgical department between February 2005 and June 2012 were retrospectively reviewed. The patients were divided into male (n = 632) and female (n = 427) groups and then according to the age group, and the correlation between the age group and the other clinicopathologic features was analyzed by univariate and multivariate analysis. Results: The number of concomitant adenomas found was significantly increased along with increasing age in men, and the presence of concomitant adenoma was the only independent age-related factor of male CRC in the multivariate analysis (P = .0044). In contrast, in women, the location of the CRC progressively shifted to the right side (proximal colon) with increasing age, and the presence of right-sided CRC was the only independent factor of female CRC in the multivariate analysis (P < .0001). Conclusion: There was a significant gender-specific difference in the age-related changes in the characteristics of CRC. Increasing the number of concomitant adenomas and the shift of CRC localization to the proximal colon were the gender-specific characteristics of male and female CRC, respectively.
  • Kazushige Kawai, Eiji Sunami, Takeshi Nishikawa, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Shinsuke Kazama, Soichiro Ishihara, Hironori Yamaguchi, Joji Kitayama, Toshiaki Watanabe
    SPRINGERPLUS 3 681  2014年11月 [査読有り][通常論文]
     
    Introduction: We report a rare case of delayed abdominal wall abscess after abdominoperineal resection (APR) for rectal cancer. Case description: A 63-year-old woman was diagnosed with rectal cancer and received chemo-radiotherapy, followed by APR. One year after surgery, the patient complained of pain and skin redness in the lower abdomen. A low-density mass lesion with 5.9-cm diameter was found in the lower abdominal wall by computed tomography, which showed high uptake on positron-emission tomography. These findings suggested the possibilities of either delayed abscess formation or abdominal wall recurrence of rectal cancer with central necrosis. Percutaneous drainage was performed. The content was a purulent exudate, without neoplastic cells in the cytology. The lesion quickly disappeared after the drainage, and no recurrence of the tumor was observed for more than 2 years. Discussion and evaluation: In this case, the un-absorbable yarn, such as silk, has not been used during the operation, no foreign body was retained in the abdominal wall, and there was no associated inflammatory bowel disease. Use of neoadjuvant chemoradiotherapy was the only possible cause of delayed abscess formation in this case. Conclusion: In case local recurrence is suspected by imaging modalities in the postoperative of colorectal cancer, especially those with precedent chemoradiotherapy or radiotherapy, although rare, the possibility of a delayed abscess formation should also be considered.
  • Yuuki Iida, Nelson H. Tsuno, Junko Kishikawa, Kensuke Kaneko, Koji Murono, Kazushige Kawai, Toshiyuki Ikeda, Soichiro Ishihara, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Yutaka Yatomi, Toshiaki Watanabe
    ANTICANCER RESEARCH 34 10 5465 - 5472 2014年10月 [査読有り][通常論文]
     
    Background: Lysophosphatidylserine (lysoPS) is a type of lysophospholipid mediator, which is involved in allergic conditions and tumor progression. We investigated the physiological function of lysoPS on colorectal cancer (CRC) cell lines, as well as the involved receptor and signaling pathways. Materials and Methods: Expression of lysoPS receptors on six cell lines was examined by reverse transcription-polymerase chain reaction (RT-PCR). The physiological functions of lysoPS were investigated, and experiments using small interfering RNA (siRNA) or inhibitors of the signaling pathways were conducted. Results: Among the three lysoPS receptors, GPR34 was highly expressed on all cell lines. LysoPS stimulated the chemotactic migratory ability. Wortmannin inhibited the migratory ability, as well as the GPR34 knock-down, strongly suggestive of the involvement of this receptor in the PI3K/Akt pathway. Conclusion: The involved receptor and pathways in the migratory ability in response to lysoPS was demonstrated, which opens premises for targeting as a new strategy for prevention and treatment of colorectal cancer.
  • Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigami H, Yamashita H, Yamaguchi H, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Kitayama J, Watanabe T, Koike K
    Journal of gastrointestinal cancer 45 3 307 - 311 2014年09月 [査読有り][通常論文]
  • Soichiro Ishihara, Tamuro Hayama, Hideki Yamada, Keijiro Nozawa, Keiji Matsuda, Hiroaki Miyata, Satomi Yoneyama, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Hioaki Nozawa, Takamitsu Kanazawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Yojiro Hashiguchi, Kenichi Sugihara, Toshiaki Watanabe
    ANNALS OF SURGICAL ONCOLOGY 21 9 2949 - 2955 2014年09月 [査読有り][通常論文]
     
    Background. Retrospective studies have shown that primary tumor resection improves the prognosis of patients with colorectal cancer with unresectable metastasis (mCRC). Prognostic significance of lymph node dissection (LND) in mCRC has not been examined previously. The aim of this study was to investigate the prognostic impact of primary tumor resection and LND in mCRC. Methods. A total of 1,982 patients with mCRC from January 1997 to December 2007 were retrospectively studied. The impact of primary tumor resection and LND on overall survival (OS) was analyzed using Cox proportional hazards model and propensity score analysis to mitigate the selection bias. Covariates in the models for propensity scores included treatment period, institution, age, sex, carcinoembryonic antigen, tumor location, histology, depth, lymph node metastasis, lymphovascular invasion, and number of metastatic organs. Results. In a multivariate analysis, primary tumor resection and treatment in the latter period were associated with an improved OS, and age over 70 years, female sex, lymph node metastasis, and multiple organ metastasis were associated with a decreased OS. In the propensity-matched cohort, patients treated with primary tumor resection showed a significantly better OS than those without tumor resection (median OS 13.8 vs. 6.3 months; p = 0.0001). Furthermore, among patients treated with primary tumor resection, patients treated with D3 LND showed a significantly better OS than those with less extensive LND (median OS 17.2 vs. 13.7 months; p < 0.0001). Conclusions. It was suggested that primary tumor resection with D3 LND improves the survival of patients with mCRC.
  • Shinya Abe, Hironori Yamaguchi, Koji Murono, Takamitsu Kanazawa, Souichirou Ishihara, Eiji Sunami, Toshiaki Watanabe
    INTERNATIONAL SURGERY 99 5 500 - 505 2014年09月 [査読有り][通常論文]
     
    Colon cast passage, which is the spontaneous passage of a full-thickness, infarcted colonic segment per rectum, is a rare occurrence. The main cause is acute ischemic colitis resulting from a circulation compromise. Most of the colon cast cases reported were secondary to abdominal aortic aneurysm repairs or colorectal surgery. We report a case of an 80-year-old woman with ischemic colitis who excreted a 20-cm colon cast. In most cases that involve a colon cast containing a muscle layer component, invasive therapy is required owing to colonic obstruction or stenosis. However, in the present case, the colon cast consisted only of a mucosa layer and was not associated with severe stenosis or obstruction; therefore, it was successfully treated by conservative therapy. Histologic examination of the colon segment may be crucial in determining the appropriate treatment.
  • Tsuyoshi Ozawa, Shinsuke Kazama, Takashi Akiyoshi, Koji Murono, Satomi Yoneyama, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Hiroaki Nozawa, Takamitsu Kanazawa, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Teppei Morikawa, Masashi Fukayama, Toshiaki Watanabe
    ANNALS OF SURGICAL ONCOLOGY 21 8 2650 - 2658 2014年08月 [査読有り][通常論文]
     
    The importance of Notch signaling in colorectal cancer (CRC) tumorigenesis has been recently recognized. However, the significance of Notch3 expression and its association with Notch1 expression in CRC is unclear. In the present study, we investigated Notch1 and Notch3 expression in Stage II and III CRC to assess their association with clinicopathological characteristics. The protein expression of Notch1 and Notch3 was examined using immunohistochemistry in 305 CRC specimens. Nuclear expression of Notch1 and Notch3 and their associations with clinicopathological characteristics and distant relapse-free survival (dRFS) were evaluated. Nuclear Notch1 was overexpressed in 37 % of specimen, and nuclear Notch3 in 38 %. Nuclear Notch3 expression correlated with tumor differentiation status (P = 0.0099). Nuclear expression of Notch1 and Notch3 was associated with tumor recurrence (P = 0.0311 and P = 0.0053, respectively). In multivariate analysis, nuclear Notch3 expression [hazard ratio (HR) = 1.71; 95 % confidence interval (CI), 1.06-2.78; P = 0.0271), lymph node metastasis, and venous involvement were independently correlated with dRFS. In subgroup analysis, nuclear Notch3 expression was strongly associated with dRFS in Stage II CRC (HR = 3.47; 95 % CI 1.44-9.22; P = 0.0055). Both nuclear Notch1 and Notch3 were positive in 67 specimens (22 %) and both were negative in 144 specimens (47 %). Coexpression of nuclear Notch1 and Notch3 had an additive effect toward poorer dRFS compared with a negative subtype (HR = 2.48; 95 % CI, 1.41-4.40; P = 0.0019). Nuclear Notch3 expression might be a novel predictive marker for recurrence in Stage II and III CRC.
  • Koji Murono, Kazushige Kawai, Nelson H. Tsuno, Soichiro Ishihara, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    DISEASES OF THE COLON & RECTUM 57 6 715 - 724 2014年06月 [査読有り][通常論文]
     
    BACKGROUND: Preoperative chemoradiotherapy has been widely used for the prevention of local recurrence of locally advanced rectal cancer, and the effect of chemoradiotherapy is known to be associated with overall survival. OBJECTIVE: We aimed to evaluate the association of the pathologic response grade with tumor recurrence rate after chemoradiotherapy, using radiographic analysis and the Response Evaluation Criteria in Solid Tumors as the parameters. DESIGN: This study was conducted at a single tertiary care institution in Japan. SETTING: This was a retrospective cohort study of patients undergoing preoperative chemoradiotherapy. PATIENTS: A total of 101 low rectal cancer patients receiving preoperative chemoradiotherapy from July 2004 to August 2012 were enrolled. MAIN OUTCOME MEASURES: The tumor reduction rate was measured with the use of traditional Response Evaluation Criteria in Solid Tumors, barium enema, and CT volumetry, and the correlation between the reduction rate and the pathologic response grade was examined. RESULTS: The tumor reduction rate assessed according to Response Evaluation Criteria in Solid Tumors showed no association with the pathologic response grade (p =0.61). In contrast, the radiographic response rate by both barium enema and CT volumetry strongly correlated with the pathologic response grade (p < 0.0001 and p = 0.001). In terms of local tumor recurrence, those diagnosed as high responders by the pathologic response grade, Response Evaluation Criteria in Solid Tumors, barium enema, and CT volumetry had a lower recurrence rate (p =0.03, p =0.03, p =0.0002, and p =0.001). The difference between high responders and low responders was especially prominent by barium enema and CT volumetry. LIMITATIONS: The study is limited by its retrospective nature. CONCLUSIONS: Double-contrast barium enema and CT volumetry were superior to Response Evaluation Criteria in Solid Tumors in evaluating the effect of chemoradiotherapy and predicting the likelihood of tumor recurrence.
  • Shigenobu Emoto, Hironori Yamaguchi, Takao Kamei, Hironori Ishigami, Takashi Suhara, Yukimitsu Suzuki, Taichi Ito, Joji Kitayama, Toshiaki Watanabe
    SURGERY TODAY 44 5 919 - 926 2014年05月 [査読有り][通常論文]
     
    To develop a drug-delivery system for the prolonged retention of intraperitoneally (i.p.) administered cisplatin (CDDP) to deliver intraperitoneal chemotherapy against peritoneal carcinomatosis effectively. CDDP was encapsulated inside an in situ cross-linkable hyaluronic acid (HA)-based hydrogel. The gelation and degradation kinetics of the hydrogel and the release kinetics of CDDP were investigated in vitro, and the antitumor effect was investigated in a mouse model of peritoneal dissemination of human gastric cancer. The gelation time varied according to the concentration of two polymers: HA-adipic dihydrazide and HA-aldehyde. CDDP was released from the hydrogel for more than 4 days. A cell proliferation assay showed that the polymers themselves were not cytotoxic toward MKN45P, a human gastric cancer cell line. By mixing the two polymers in the peritoneum, in situ gelation was achieved. The weight of peritoneal nodules decreased in the hydrogel-conjugated CDDP group, whereas no significant antitumor effect was observed in the free CDDP group. In situ cross-linkable HA hydrogels represent a promising biomaterial to prolong the retention and sustain the release of intraperitoneally administered CDDP in the peritoneal cavity and to enhance its antitumor effects against peritoneal dissemination.
  • Yuichiro Yokoyama, Kazushige Kawai, Shinsuke Kazama, Satomi Yoneyama, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Hiroaki Nozawa, Takamitsu Kanazawa, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    WORLD JOURNAL OF SURGICAL ONCOLOGY 12 141  2014年05月 [査読有り][通常論文]
     
    Published reports concerning internal hernias after extraperitoneal stoma construction are scarce. In our present report, we describe the case of a 56-year-old man who was referred to our hospital for the treatment of rectal cancer. He underwent abdominoperineal resection of the rectum with sigmoidostomy using an extraperitoneal route. On the ninth postoperative day, the patient experienced sudden and intense abdominal pain and was diagnosed with strangulation of the small intestine due to a stoma-associated internal hernia. Therefore, an emergency laparotomy was performed. The surgical findings showed that the small intestine protruded through the space between the sigmoid colon loop and the abdominal wall in a cranial-to-caudal direction. The strangulated portion of the small intestine was recovered, and the orifice of herniation was closed. No recurrence of internal herniation was observed during the follow-up period.
  • Joji Kitayama, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, Toshiaki Watanabe
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 73 3 605 - 612 2014年03月 [査読有り][通常論文]
     
    Intraperitoneal (IP) administration of paclitaxel (PTX) can enable direct infiltrate of high amount of PTX into peritoneal nodules and elicit remarkable clinical responses against peritoneal metastases. In this study, we examined the mechanisms leading to tumor shrinkage after IP PTX. We compared the microscopic features of peritoneal metastases before and after IP PTX in surgically removed human samples, as well as in a murine xenograft model using immunohistochemistry. We found that many microvessels exist in the peripheral areas of metastatic nodules in human samples before treatment. However, peripheral vessels were greatly reduced in number, and luminal obstructions were observed in lesions showing complete response after chemotherapy including IP PTX. Similar changes were observed in peripheral vessels of peritoneal tumors in MKN45-inoculated nude mice treated with IP-PTX. Moreover, pimonidazole staining revealed that highly hypoxic regions were produced by IP PTX at the tumor periphery. These findings strongly suggest that the remarkable efficacy of IP PTX in the treatment of peritoneal metastases is, at least in part, dependent on the destruction of peripheral microvessels by exposure to infiltrated PTX.
  • Joji Kitayama, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, Hiroharu Yamashita, Yasuyuki Seto, Keisuke Matsuzaki, Toshiaki Watanabe
    CELLULAR IMMUNOLOGY 288 1-2 8 - 14 2014年03月 [査読有り][通常論文]
     
    In this study, we analyzed intraperitoneal cells recovered from human samples and found that CD90(+)CD45(-) cells exist as a minor population but vigorously grow in culture, showing the morphological features of mesothelial cells (MC). Interestingly, the MC highly expressed arginase I and markedly suppressed T cell proliferation with the reduction of CD3 chain expression in T cells stimulated by coated anti-CD3 mAb. The addition of nor-NOHA (500 mu M), or L-arginine (1 mM) mostly restored the inhibitory effect of MC on T cell proliferation as well as the reduced expression of CD3 zeta chain. The expression level of CD3 zeta chain in T cells in the peritoneal cavity was significantly down-regulated from circulating T cells. These results suggest that intraperitoneal free MC have immunomodulatory functions through the control of L-arginine level, and thus may play significant roles in the pathogenesis of various diseases in the peritoneal cavity. (c) 2014 Elsevier Inc. All rights reserved.
  • Joji Kitayama, Hironori Ishigami, Hironori Yamaguchi, Hiroharu Yamashita, Shigenobu Emoto, Shoich Kaisaki, Toshiaki Watanabe
    ANNALS OF SURGICAL ONCOLOGY 21 2 539 - 546 2014年02月 [査読有り][通常論文]
     
    Background. Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes. Recently, we developed a combination chemotherapy that used intraperitoneal (IP) paclitaxel (PTX) and produced excellent antitumor effects against peritoneal lesions. However, no information is available about the benefit of gastrectomy in cases with malignant ascites. Methods. A total of 64 patients with severe peritoneal metastasis and ascites received IP PTX at 20 mg/m(2) via implanted subcutaneous peritoneal access ports as well as intravenous (IV) PTX at 50 mg/m(2) on days 1 and 8. S-1 was administered at 80 mg/m(2) day for 14 consecutive days, followed by 7 days of rest. In all patients, investigative laparoscopy was performed around the combination chemotherapy, and gastrectomy was performed on patients who showed apparent shrinkage of their peritoneal nodules as well as negative peritoneal cytology at the second laparoscopy. Results. Gastrectomy was performed in 34 patients. The median course of chemotherapy before surgery was 5 courses (range 2-16). R0 operation was achieved in 22 patients (65 %), and grade 2 and 3 histological responses were obtained in 7 (21 %) and 1 (3 %) patient(s), respectively. The median survival time and 1-year overall survival of the gastrectomized patients were 26.4 months and 82 %, and those of the 30 patients who did not receive gastrectomy were 12.1 months and 26 %, respectively. Morbidity was minimal, and there was no mortality. Conclusions. Salvage gastrectomy after chemotherapy of S-1 with IV and IP PTX is promising, even for patients with highly advanced gastric cancer and severe peritoneal metastasis and malignant ascites.
  • Joji Kitayama, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, Takao Kamei, Hiroharu Yamashita, Yasuyuki Seto, Keisuke Matsuzaki, Toshiaki Watanabe
    CYTOMETRY PART B-CLINICAL CYTOMETRY 86 1 56 - 62 2014年01月 [査読有り][通常論文]
     
    BackgroundPeritoneal metastasis (PM) is the most life-threatening type of metastasis in abdominal malignancy. To improve the diagnostic accuracy of cytologic detection (CY) of free tumor cells (FTC) in the peritoneal cavity, we tried to quantify the FTC to leukocyte ratio using flow cytometry in patients with peritoneal metastasis. MethodsCells were recovered from ascites or peritoneal lavages from 106 patients who underwent abdominal surgery and additional 89 samples which were obtained from peritoneal catheter or access port in patients with PM (+) gastric cancer. The cells were immunostained with monoclonal antibodies to CD45 and to CD326 (EpCAM). Using flow cytometry, CD326 (+) and CD45 (+) cells were classified as either tumor cells (T) or leukocytes (L) and the T/L ratio (TLR) was calculated. ResultsIn 106 samples obtained by laparotomy, Median (M) of the TLR of PM (+) patients was 1.39% (0-807.87%) which was significantly higher than PM (-) patients (M=0%, 0-2.14%, P<0.001). In PM (+) patients, 86 CY (+) samples showed higher TLR than 61 CY (-) samples (M=2.81%, 0.02-1868.44% vs. M=0%, 0-3.45%, p<0.0001). In all of the 24 patients who were monitored for TLR before and after intraperitoneal (IP) chemotherapy, the TLR was reduced which was more dramatic than the results of the change in cytology. ConclusionsTLR measured with FACS is an excellent reflection of the tumor spread in the peritoneal cavity and could be a reliable diagnostic biomarker to determine the severity of PM as well as effectiveness of IP chemotherapy. (c) 2013 International Clinical Cytometry Society
  • Joji Kitayama, Shigenobu Emoto, Hironori Yamaguchi, Hironori Ishigami, Toshiaki Watanabe
    PLOS ONE 9 1 e86516  2014年01月 [査読有り][通常論文]
     
    The peritoneal cavity is a common target of metastatic gastrointestinal and ovarian cancer cells, but the mechanisms leading to peritoneal metastasis have not been fully elucidated. In this study, we examined the roles of cells in peritoneal fluids on the development of peritoneal metastasis. We found that a minor subset of human intraperitoneal cells with CD90(+)/CD45(2) phenotype vigorously grew in culture with mesothelial-like appearance. The mesothelial-like cells (MLC) displayed the characteristics of mesenchymal stem cell, such as differentiating into adipocytes, osteocytes, and chondrocytes, and suppressing T cell proliferation. These cells highly expressed type I collagen, vimentin, alpha-smooth muscle actin and fibroblast activated protein-a by the stimulation with TGF-beta, which is characteristic of activated myofibroblasts. Intraperitoneal co-injection of MLCs with the human gastric cancer cell line, MKN45, significantly enhanced the rate of metastatic formation in the peritoneum of nude mice. Histological examination revealed that many MLCs were engrafted in metastatic nodules and were mainly located at the fibrous area. Dasatinib, a potent tyrosine kinase inhibitor, strongly inhibited the proliferation of MLCs but not MKN45 in vitro. Nevertheless, oral administration of Dasatinib significantly inhibited the development of peritoneal metastasis of MKN45, and resulted in reduced fibrillar formation of metastatic nodules. These results suggest floating MLCs in the peritoneal fluids support the development of peritoneal metastasis possibly through the production of the permissive microenvironment, and thus the functional blockade of MLCs is a reasonable strategy to treat recurrent abdominal malignancies.
  • Joji Kitayama, Hironori Ishigami, Hironori Yamaguchi, Shigenobu Emoto, Toshiaki Watanabe
    Case Reports in Oncology 7 1 58 - 64 2014年 [査読有り][通常論文]
     
    Background: Intraperitoneal administration of paclitaxel (PTX) can elicit a marked clinical response in peritoneal metastases of gastric cancer. Methods: In this study, we retrospectively analyzed the clinical outcome of 17 patients who underwent R0 resection with D2 dissection for advanced gastric cancer with macroscopic serosal exposure and received intraperitoneal PTX as adjuvant therapy. Results: A pathological study revealed that the depth of invasion of the primary tumor was pT4a or pT4b in 10 cases, and that the pN stage was more than pN2 in 8 cases. Genetic analysis of peritoneal lavage fluid was performed in 14 cases, all of which were positive for carcinoembryonic antigen mRNA. In these patients, PTX was intraperitoneally administered at 20-60 mg/m2 with oral S-1 for 3-36 months after surgery. In a median follow-up period of 66 months, recurrence occurred in the liver and peritoneum in 2 (11.7%) and 1 (5.9%) patients, respectively, and no nodal recurrence was observed. Five-year overall survival and disease-free survival were 88.2 and 82.3%, respectively. Conclusion: Since these patients are considered to be a high-risk group for peritoneal recurrence, this result strongly suggests that adjuvant chemotherapy including intraperitoneal PTX is a promising protocol to improve the outcome of patients with advanced gastric cancer with serosal exposure. © 2014 S. Karger AG, Basel.
  • Soichiro Ishihara, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Hioaki Nozawa, Takamitsu Kanazawa, Shinsuke Kazama, Hironori Yamaguchi, Eiji Sunami, Joji Kitayama, Yojiro Hashiguchi, Kenichi Sugihara, Toshiaki Watanabe
    INTERNATIONAL JOURNAL OF SURGERY 12 9 925 - 930 2014年 [査読有り][通常論文]
     
    Background: Right-sided colon cancer is considered to be biologically different from left-sided colon cancer; however, conflicting results have been reported regarding differences in prognosis. We aimed to clarify the prognostic impact of tumor location in stage IV colon cancer. Methods: Stage IV colon cancer treated from January 1997 to December 2007 (n = 2208) were retrospectively studied. Clinical and pathological features were compared between right-sided colon cancer (cecum, ascending, and transverse colon) and left-sided colon cancer (descending, sigmoid, and rectosigmoid colon). The impact of tumor location on cancer-specific survival (CSS) was analyzed in a multivariate analysis and propensity score analysis to mitigate the differences in background features. Results: Right-sided colon cancer was associated with older age, female sex, larger tumor size, poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma, a more advanced state within stage IV disease, and a worse CSS. In the cohort matched by propensity scores for background clinicopathological features, tumor location in the right-sided colon was associated with a significantly worse CSS (hazard ratio 1.2, 95% confidence interval 1.1-1.4, p = 0.008) in patients treated with palliative primary tumor resection, but not in those treated with R0 resection or no resection. Conclusion: Right-sided colon cancer were diagnosed at a more advanced state within stage IV disease and showed a significantly worse prognosis than left-sided colon cancer, suggesting that stage IV right-sided colon cancer is oncologically more aggressive than left-sided colon cancer. (C) 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
  • Hiroaki Nozawa, Takeshi Nishikawa, Toshiaki Tanaka, Junichiro Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Shinsuke Kazama, Hironori Yamaguchi, Soichiro Ishihara, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe
    CHEMOTHERAPY 60 5-6 360 - 367 2014年 [査読有り][通常論文]
     
    Background: The identification of responders is an important issue in chemotherapy for metastatic colorectal cancer (mCRC). 'Deepness of response' (DpR), defined as the maximum rate of reduction from the initial tumor burden, was recently proposed as a novel hypothetical parameter associated with overall survival (OS) in first-line chemotherapy plus cetuximab for mCRC. We determined whether this concept was universally applicable to diverse standard chemotherapeutic regimens for mCRC. Methods: We reviewed mCRC patients who received the first-line systemic chemotherapy regimens FOLFOX, CapeOX or FOLFIRI (with biologics) at our department between June 2005 and March 2015. Data such as clinicopathological parameters, metastasized organs, chemotherapeutic regimens, the best response by RECIST v1.1, progression-free survival (PFS) and OS were retrospectively retrieved for patients who exhibited tumor shrinkage. DpR was calculated as the uni-dimensional maximum reduction rate of measurable tumors. We addressed the association between DpR and survival. Results: Of the 156 patients receiving first-line chemotherapy regimens, tumor shrinkage was observed in 63 (41 of whom were men; median age 62 years). Complete remission was achieved in 6 patients, partial remission in 42 and stable disease in 15. The median DpR was 44.2% and was employed as the cutoff, in line with previous reports. DpR >= 45% (31 patients) was correlated with longer PFS (median 16.4 vs. 8.1 months for DpR <45%, p = 0.006) and OS (median 58.6 vs. 30.9 months for DpR <45%, p = 0.041). There was basically no difference in the subsequent chemotherapy between the DpR >= 45% and DpR <45% groups. Conclusion: DpR correlated with OS in various first-line systemic upfront chemotherapy regimens for mCRC. (C) 2015 S. Karger AG, Basel
  • Hironori Yamaguchi, Joji Kitayama, Hironori Ishigami, Shigenobu Emoto, Hiroharu Yamashita, Toshiaki Watanabe
    CANCER 119 18 3354 - 3358 2013年09月 [査読有り][通常論文]
     
    BACKGROUND The prognosis of patients with gastric cancer with peritoneal metastasis is extremely poor. This phase 2 study evaluated the benefits and tolerability of weekly intravenous and intraperitoneal paclitaxel (PTX) treatment combined with oral S-1 in patients with gastric cancer who had macroscopic peritoneal metastasis. METHODS Patients with gastric cancer who had primary tumors with macroscopic peritoneal metastasis were enrolled. PTX was administered intravenously at 50 mg/m(2) and intraperitoneally at 20 mg/m(2) on days 1 and 8, respectively. S-1 was administered at 80 mg/m(2) per day for 14 consecutive days, followed by 7 days of rest. The primary endpoint was the 1-year overall survival (OS) rate. The secondary endpoints were the response rate, efficacy against malignant ascites, and safety. RESULTS Thirty-five patients were enrolled. The median number of treatment courses was 11 (range, 2-35). The 1-year OS rate was 77.1% (95% confidence interval, 60.5-88.1). The overall response rate was 71% in 7 patients with target lesions. Malignant ascites disappeared or decreased in 15 of 22 (68%) patients. The frequent grade 3/4 toxic effects were neutropenia (34%), leukopenia (23%), and anemia (9%). CONCLUSIONS Combination chemotherapy consisting of intravenous and intraperitoneal PTX with S-1 is well-tolerated and effective in patients with gastric cancer who have macroscopic peritoneal metastasis. Cancer 2013;119:3354-8. (c) 2013 American Cancer Society.
  • Kitayama J, Emoto S, Yamaguchi H, Ishigami H, Kamei T, Yamashita H, Seto Y, Matsuzaki K, Watanabe T
    Cytometry. Part B, Clinical cytometry 2013年08月 [査読有り][通常論文]
     
    Background: Peritoneal metastasis (PM) is the most life-threatening type of metastasis in abdominal malignancy. To improve the diagnostic accuracy of cytologic detection (CY) of free tumor cells (FTC) in the peritoneal cavity, we tried to quantify the FTC to leukocyte ratio using flow cytometry in patients with peritoneal metastasis. Methods: Cells were recovered from ascites or peritoneal lavages from 106 patients who underwent abdominal surgery and additional 89 samples which were obtained from peritoneal catheter or access port in patients with PM (+) gastric cancer. The cells were immunostained with monoclonal antibodies to CD45 and to CD326 (EpCAM). Using flow cytometry, CD326 (+) and CD45 (+) cells were classified as either tumor cells (T) or leukocytes (L) and the T/L ratio (TLR) was calculated. Results: In 106 samples obtained by laparotomy, Median (M) of the TLR of PM (+) patients was 1.39% (0-807.87%) which was significantly higher than PM (-) patients (M=0%, 0-2.14%, p<0.001). In PM (+) patients, 86 CY (+) samples showed higher TLR than 61 CY (-) samples (M=2.81%, 0.02-1868.44% vs. M=0%, 0-3.45%, p<0.0001). In all of the 24 patients who were monitored for TLR before and after intraperitoneal chemotherapy, the TLR was reduced which was more dramatic than the results of the change in cytology. Conclusion: TLR measured with FACS is an excellent reflection of the tumor spread in the peritoneal cavity and could be a reliable diagnostic biomarker to determine the severity of PM as well as effectiveness of IP chemotherapy. © 2013 Clinical Cytometry Society.
  • Yousuke Nakai, Hironori Ishigami, Hiroyuki Isayama, Takashi Sasaki, Kazumichi Kawakubo, Hirofumi Kogure, Shigenobu Emoto, Hironori Yamaguchi, Joji Kitayama, Natsuyo Yamamoto, Naoki Sasahira, Kenji Hirano, Minoru Tada, Kazuhiko Koike
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 12 1796 - 1800 2012年12月 [査読有り][通常論文]
     
    Background and Aim: Gastrointestinal (GI) luminal obstruction or malignant biliary obstruction (MBO) is not a rare condition in gastric cancer patients with peritoneal metastasis. The role of endoscopic or percutaneous interventions is not fully elucidated in this setting. Methods: A total of 123 patients with unresectable or recurrent gastric adenocarcinoma with peritoneal metastasis receiving intravenous and intraperitoneal paclitaxel combined with S-1 were retrospectively studied. Safety and efficacy of interventions for GI luminal obstruction and MBO were evaluated. Results: A total of 27 patients (22%) underwent GI luminal and/or biliary interventions; GI luminal alone in 10, biliary alone in 10 and both in seven, with a technical success rate of 100%. Clinical success rate was 65% in self-expandable metallic stents (SEMS) placement for GI luminal obstruction. Eastern Cooperative Oncology Group (ECOG) performance status (PS) was prognostic of clinical success in GI luminal stenting (100% in PS of 1 vs 14% in PS of 23, P?<?0.001). Biliary drainage (endoscopic SEMS placement in four and percutaneous transhepatic biliary drainage in 12) relieved obstructive jaundice in 94%. Six complications were observed: four after GI luminal stenting (two occlusion and one aspiration pneumonia) and two after biliary stenting (one cholangitis and one cholecystitis). Median survival after the initial intervention was 5.7?months. PS at interventions was prognostic of survival after interventions (12.3?months in PS of 1 vs 2.2?months in PS of 2 or 3, P?<?0.001). Conclusion: Endoscopic or percutaneous interventions for GI luminal obstruction or MBO were feasible and effective in gastric cancer patients with peritoneal dissemination receiving combination chemotherapy.
  • Shigenobu Emoto, Hironori Ishigami, Akio Hidemura, Hironori Yamaguchi, Hiroharu Yamashita, Joji Kitayama, Toshiaki Watanabe
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 42 11 1013 - 1019 2012年11月 [査読有り][通常論文]
     
    The efficacy of intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis has been verified by clinical trials. To perform intraperitoneal chemotherapy safely and effectively, the appropriate management of intraperitoneal access ports is essential. The aim of this study was to investigate the occurrence of port complications during cyclically repeated intraperitoneal chemotherapy. The medical records of 131 gastric cancer patients with peritoneal metastases who received intraperitoneal paclitaxel between 2005 and 2011 were retrospectively analyzed. The median period of intraperitoneal chemotherapy using a port system was 12.9 months (range: 0.861.5 months), and a total of 27 (20.6) patients experienced port complications. Inflow obstruction (7.6) and infection (6.9) were the main complications, followed by reflux (3.1), subcutaneous masses (1.5) and fistulae (1.5). The median interval between port implantation and port complication was 5.4 months (range: 0.340.9 months). Complications were controllable and chemotherapy was not terminated by complications. Survival was not affected by the presence or absence of port complications (median survival time: 22.5 vs. 17.2 months, respectively; P 0.65). Intraperitoneal chemotherapy for gastric cancer using a port is safe and feasible under appropriate management.
  • Shigenobu Emoto, Hironori Yamaguchi, Junko Kishikawa, Hiroharu Yamashita, Hironori Ishigami, Joji Kitayama
    CANCER SCIENCE 103 7 1304 - 1310 2012年07月 [査読有り][通常論文]
     
    The intraperitoneal administration of paclitaxel has been shown to be a promising treatment strategy for peritoneal malignancy. The present study evaluated the effects of intraperitoneal administration of NK105, a paclitaxel-incorporating micellar nanoparticle, which has been shown to have a remarkable effect in a mouse model of gastric cancer. Intraperitoneal NK105 significantly reduced peritoneal tumors in vivo compared with the conventional paclitaxel formulation of paclitaxel solubilized in Cremophor EL and ethanol (PTX-Cre). Moreover, intraperitoneal NK105 significantly reduced the size of subcutaneously inoculated tumors, whereas no such effect was seen with PTX-Cre. Similar systemic toxic effects were observed following the intraperitoneal administration of both NK105 and PTX-Cre. Although NK105 disappeared rapidly almost within a day from the peritoneal cavity, the paclitaxel concentration in peritoneal nodules 4h after intraperitoneal administration was significantly higher in the NK105 group than in the PTX-Cre group (P<0.05), whereas there were no significant differences in liver paclitaxel concentrations between the two groups. We also evaluated the pharmacokinetics following intraperitoneal administration of NK105 and PTX-Cre. Serum paclitaxel concentrations 6, 12, 24, and 48h after the intraperitoneal administration of the drugs were significantly higher in the NK105 than the PTX-Cre group. Furthermore, the peak serum concentration was higher in the NK105 than PTX-Cre group (24100 +/- 3560 vs 108 +/- 25 similar to ng/mL, respectively; P<0.001), as was the area under the concentrationtime curve from 0 to 48h (191000 +/- 32100 vs 1500 +/- 108ng center dot h/mL, respectively; P<0.001). Therefore, intraperitoneal chemotherapy with nanoparticulate paclitaxel NK105 may offer a novel treatment strategy for improving drug delivery in gastric cancer with peritoneal dissemination because of enhanced drug penetration into peritoneal nodules and its prolonged presence in the systemic circulation. (Cancer Sci 2012; 103: 13041310)
  • Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S
    Gastrointestinal cancer research : GCR 5 3 Suppl 1 S10 - 3 2012年05月 [査読有り][通常論文]
     
    Peritoneal metastasis is the most frequent and life-threatening type of metastasis in patients with advanced gastric cancer. Despite recent advances in chemotherapeutic agents, any treatment, if administered only via the intravenous (IV) route, cannot satisfactorily control peritoneal metastasis in gastric cancer. Although intraperitoneal (IP) chemotherapy has been proposed as a treatment option, the clinical efficacy of IP chemotherapy for peritoneal lesions has not been examined in gastrointestinal cancer. One hundred patients with gastric cancer received combination chemotherapy of S-1 plus IV (50 mg/m(2)) and IP (20 mg/m(2)) paclitaxel (PTX) via a subcutaneously implanted peritoneal access port. S-1 was administered at 80 mg/m(2) per day for 14 consecutive days, followed by 7 days' rest. Radical gastrectomy was performed in a salvage setting when macroscopic curative resection was made feasible by the downstaging achieved by the combined chemotherapy. The median survival time (MST) of the patient sample was 23.6 months, with a 1-year survival of 80%. Combination chemotherapy of S-1 plus IV and IP PTX is well tolerated and very effective in patients with gastric cancer and peritoneal metastasis. Systemic chemotherapy combined with repeated IP administration of paclitaxel is a promising strategy for peritoneal carcinomatosis in gastrointestinal cancer.
  • Shigenobu Emoto, Hironori Ishigami, Hiroharu Yamashita, Hironori Yamaguchi, Shoichi Kaisaki, Joji Kitayama
    GASTRIC CANCER 15 2 154 - 161 2012年04月 [査読有り][通常論文]
     
    Serum tumor markers have been shown to correlate with the clinical status of patients with advanced gastric cancer. However, the clinical significance of each tumor marker in patients with peritoneal dissemination has not been fully verified. Four serum markers, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA125, and CA72-4, were periodically measured in 102 patients with peritoneal dissemination who received combination intravenous and intraperitoneal chemotherapy. The initial values at diagnosis and after treatment were analyzed in association with clinicopathological factors, response to chemotherapy, and overall survival. The sensitivities of CEA, CA19-9, CA125, and CA72-4 for peritoneal metastasis at the initial diagnosis were 19, 36, 46, and 45%, respectively. The CA125 level was significantly correlated with the degree of peritoneal dissemination and the existence of malignant ascites. Patients with ovarian metastasis showed significantly higher levels of CA72-4. The median survival time of patients with an elevated CA125 level was significantly shorter than that of patients with a normal CA125 level (36.7 vs. 16.6 months, p < 0.001). Multivariate analysis showed that the degree of peritoneal metastasis and an elevated CA125 level were independent prognostic factors. Normalization of the CA125 level after 3 courses of chemotherapy was correlated with reduced ascites and improved survival. Serum CA125 and CA72-4 are clinically useful markers in diagnosis, evaluating the efficacy of chemotherapy, and predicting the prognosis of patients with peritoneal dissemination. From an academic point of view, periodic measurements of these markers are warranted in gastric cancer patients with possible peritoneal dissemination.
  • Shigenobu Emoto, Hironori Ishigami, Hironori Yamaguchi, Hiroharu Yamashita, Shoichi Kaisaki, Joji Kitayama
    GASTRIC CANCER 14 4 390 - 395 2011年10月 [査読有り][通常論文]
     
    We detected 7 cases of leptomeningeal carcinomatosis in 126 patients with peritoneal dissemination of gastric cancer who received combined systemic and intraperitoneal chemotherapy. Leptomeningeal carcinomatosis was diagnosed 79-1540 days after the diagnosis of the primary gastric cancer. Patients presenting with various neurological symptoms were diagnosed by cerebrospinal fluid (CSF) cytology and radiological imaging. Irradiation to the whole brain and spine was performed in 4 patients, and provided palliation and increased survival for 1 patient. Intrathecal chemotherapy and drainage of CSF was performed in 1 patient each, but produced no significant clinical benefit in either of them. Survival after the diagnosis of leptomeningeal carcinomatosis was between 3 and 155 days. As patients with peritoneal dissemination of gastric cancer are living longer because of improved chemotherapy, clinicians must recognize the possibility of leptomeningeal carcinomatosis when patients complain of neurological symptoms.
  • Takao Kamei, Joji Kitayama, Hironori Yamaguchi, Daisuke Soma, Shigenobu Emoto, Tomohiro Konno, Kazuhiko Ishihara, Hironori Ishigami, Shoichi Kaisaki, Hirokazu Nagawa
    CANCER SCIENCE 102 1 200 - 205 2011年01月 [査読有り][通常論文]
     
    Intraperitoneal (i.p.) administration of paclitaxel nanoparticles (PTX-30W) prepared by solubulization with the amphiphilic copolymer of 2-methacryloxyethyl phosphorylcholine and n-butyl methacrylate can efficiently suppress the growth of peritoneal metastasis. In this study, we characterized the drug distribution of i.p. injected PTX-30W in peritoneal tumor and liver in a mouse model using MKN45, human gastric cancer cells. Oregon green-conjugated PTX-30W showed perivascular accumulation in MKN45 tumor in the peritoneum at 24 h after intravenous (i.v.) injection; however, the amount of PTX in tumor was markedly less than that in liver. In contrast, a larger amount of PTX accumulated in the peripheral area of disseminated nodules at 1 h after i.p. injection and the area gradually enlarged. The depth of PTX infiltration reached 1 mm from the tumor surface at 48 h after i.p. injection, and the fluorescence intensity was markedly greater than that in liver. Interestingly, i.p. injected PTX preferentially accumulated in relatively hypovascular areas, and many tumor cells in the vicinity of PTX accumulation showed apoptosis. This unique accumulation pattern and lesser washout in hypovascular areas are thought to be attributable to the superior penetrating activity of PTX-30W, and thus, PTX-30W is considered to be highly suitable for i.p. chemotherapy for peritoneal dissemination. (Cancer Sci 2011; 102: 200-205).
  • Hiroharu Yamashita, Keisuke Hata, Hironori Yamaguchi, Giichiro Tsurita, Kanako Wake, Soichi Watanabe, Masao Taki, Shoogo Ueno, Hirokazu Nagawa
    BIOELECTROMAGNETICS 31 7 573 - 575 2010年10月 [査読有り][通常論文]
     
    The aim of this study was to elucidate the possible effects of short-term exposure to a 1439-MHz electromagnetic field (EMF) employing time division multiple access (TDMA), which is the basis of the Japanese Personal Digital Cellular system, on estrogenic activity in rats. Sixty-four ovariectomized female Sprague-Dawley rats were divided into four groups: EMF exposure (EM), sham exposure, cage control, and 17 beta-estradiol injected (E2). The EM group was exposed, for 4 h per day on three consecutive days, to the 1439-MHz TDMA signal that produced 5.5-6.1 and 0.88-0.99 W/kg average specific absorption rates in the brain and the whole body, respectively. The uterine wet mass and serum estradiol level significantly increased in the E2 group, while there were no differences among the other three groups. Although negative effects of long-term EMF exposure must be thoroughly investigated before a final conclusion can be reached, our results do not support the assumption that the high frequency EMF used in cellular phones exerts estrogenic activity. Bioelectromagnetics 31: 573-575, 2010. (C) 2010 Wiley-Liss, Inc.
  • Shigenobu Emoto, Joji Kitayama, Hironori Yamaguchi, Hironori Ishigami, Shoichi Kaisaki, Hirokazu Nagawa
    Case Reports in Oncology 3 3 344 - 348 2010年09月 [査読有り][通常論文]
     
    Objective: Oxygen is one of the most important environmental factors for tumor development. In this study, we examined pO2 in malignant ascites in patients with peritoneal carcinomatosis. Methods: In 21 patients with peritoneal dissemination of gastric cancer, ascitic fluid was collected and its pH, pCO2 and pO2 were determined using a blood gas analyzer. Results: In 21 patients, pH of malignant ascites was significantly lower than that of arterial blood (7.39 ± 0.07, 7.44 ± 0.02, p < 0.05). Accordingly, pCO2 tended to be higher in ascites than in arterial blood. Unexpectedly, pO2 in malignant ascites showed relatively high values (90.4 ± 27.72 mm Hg), which were mostly the same as those of arterial blood (97.09 ± 10.33 mm Hg, p = 0.858). Even in 19 patients whose samples were collected at bedside in room air, pO2 of malignant ascites was 85.94 ± 23.94 mm Hg, which was patently higher than that in venous blood or in solid tumor tissues. Conclusion: Since the oxygen level critically affects the sensitivity of tumor cells to chemotherapeutic agents through metabolic transformation, the oxygenic condition in the peritoneal cavity may be beneficial for the progression of peritoneal metastasis, and also clinically important in considering the efficacy of chemotherapy. © 2010 S. Karger AG, Basel.
  • Hironori Yamaguchi, Masahiro Ishimaru, Hiroyuki Suzuki, Hiroharu Yamashita, Kazuhito Hatanaka, Toshimasa Uekusa, Hirokazu Nagawa
    American Journal of Surgery 199 1 e7 - e9 2010年01月 [査読有り][通常論文]
     
    A 47-year-old man with acute abdominal pain in the right lower quadrant underwent an appendectomy via McBurney's incision. Postoperative histology revealed a moderately differentiated adenocarcinoma in the appendix that invaded the submucosa along with lymphatic involvement. Forty-three days later, an ileocecal resection with radical lymph node dissection was performed through a midline incision. Three of the 30 resected lymph nodes were found to have adenocarcinoma metastasis. Five years later, an isolated abdominal wall recurrence occurred within the wound scar of the midline incision. A complete excision of the tumor and the invaded portion of the ileum was performed. To date, the patient has been well, with no evidence of recurrence for 5 years since the resection. The mechanism of abdominal wound recurrence is considered the leakage of carcinoma cells from transected lymph vessels during lymph node dissection, followed by the implantation of these cells into the abdominal wound. © 2010 Elsevier Inc. All rights reserved.
  • Masahiro Kato, Joji Kitayama, Hironori Yamaguchi, Junichi Sanuki, Shoichi Kaisaki, Hirokazu Nagawa
    Japanese Journal of Cancer and Chemotherapy 37 5 903 - 906 2010年 [査読有り][通常論文]
     
    We experienced 3 cases of recurrent breast cancer treated with S-1 therapy, delaying tumor progression and improving their quality of life (QOL). All the patients had been previously treated with both anthracyclines and/or taxanes prior to S-1 chemotherapy. All patients almost completed the full dose through the whole course of treatment, and the drug showed good tolerability. Long-term (more than 12 weeks) therapeutic efficacy and the patients' QOL have been maintained for all patients. No major side effects were seen. It is thought that less toxicity enabled patient 3 to undergo long-term therapy. It is especially important that one patient had therapeutic efficacy and QOL improvement from treatment with S-1 and aromatase inhibitor for over 3 years, after being treated with anthracyclines, taxanes and vinorelbine. We conclude that S-1 is effective and well tolerated in patients with metastatic breast cancer, and will accommodate a long-time progression with respect to efficacy and maintaining the patients' QOL. Further evaluation of S-1 is necessary to elucidate its clinical role in breast cancer treatment.
  • Hironori Ishigami, Joji Kitayama, Shoichi Kaisaki, Hironori Yamaguchi, Hiroharu Yamashita, Shigenobu Emoto, Hirokazu Nagawa
    ONCOLOGY 79 3-4 269 - 272 2010年 [査読有り][通常論文]
     
    Objectives: A phase I study of biweekly intravenous (IV) paclitaxel (PTX) plus intraperitoneal (IP) cisplatin (CDDP) and PTX was performed to determine the maximum tolerated dose (MTD) and recommended dose (RD) in gastric cancer patients. Methods: Nine gastric cancer patients with peritoneal metastasis were enrolled. PTX was administered intravenously at a dose of 100 mg/m(2) and intraperitoneally with an initial dose of 20 mg/m(2) (level 1), stepped up to 30 or 40 mg/m(2) depending on observed toxicity. CDDP was administered intraperitoneally at a dose of 30 mg/m(2) over 24 h. PTX and CDDP were administered on days 1 and 15 in 4-week cycles. Results: The MTD was determined to be dose level 1, as 2 of 3 patients experienced dose-limiting toxicities (DLTs), grade 4 leukopenia and grade 3 vomiting. Therefore, the doses of IV PTX, IP CDDP and IP PTX were reduced to 80, 25 and 20 mg/m2, respectively (level 0). Consequently, the RD was determined to be dose level 0, as only 1 of 6 patients experienced DLT, grade 3 nausea. Conclusions: Combination chemotherapy of IV PTX plus IP CDDP and PTX was shown to be a safe regimen that should be further explored in clinical trials. Copyright (C) 2011 S. Karger AG, Basel
  • Hironori Yamaguchi, Makoto Ishikawa, Kazuhito Hatanaka, Toshimasa Uekusa, Masahiro Ishimaru, Hirokazu Nagawa
    BREAST 15 2 259 - 262 2006年04月 [査読有り][通常論文]
     
    We report the case of a 52-year-old woman with occult breast cancer who presented with a hard metastatic nodule in the left axilla. Although histology identified a metastatic adenocarcinoma in the lymph nodes, numerous tests failed to detect the primary tumor. Immunohistochemistry showed that the resected lymph node was positive for both estrogen and progesterone receptors, suggesting the breast as the site of the primary tumor. Left modified radical mastectomy was performed. Pathology revealed an invasive ductal carcinoma (1.5 x 1 mm in size) with extensive lymphatic involvement, which strongly expressed both vascular endothetial growth factor-C (VEGF-C) and VEGF-D. (c) 2005 Elsevier Ltd. All rights reserved.
  • Hiroharu Yamashita, Masahiro Ishimaru, Hironori Yamaguchi, Haruo Yamauchi, Arishige Sugiura, Joji Kitayama, Hirokazu Nagawa
    Journal of Anesthesia 20 1 36 - 39 2006年02月 [査読有り][通常論文]
     
    Massive postoperative polyuria is rare, except in neurosurgery patients. Here we report excessive polyuria in a 59-year-old woman following total gastrectomy for advanced gastric cancer. The etiology of the patient's polyuria was unknown. Urine output was measured hourly and replaced with Ringer's lactate solution at 80% of measured volume. The rate of urine output during 9 postoperative days ranged from 900 to 2700 ml·h-1. Several administrations of an antidiuretic hormone (ADH) analogue were ineffective in reducing urine output, suggesting a possible relationship of the massive polyuria to nephrogenic diabetes insipidus. Following oral administration of a thiazide diuretic, known to exert an antidiuretic action in nephrogenic diabetes insipidus, urine output was dramatically reduced. We conclude that this case of massive polyuria probably resulted from postoperative nephrogenic diabetes insipidus. © JSA 2006.
  • H Yamashita, J Kitayama, D Shida, H Yamaguchi, K Mori, M Osada, S Aoki, Y Yatomi, Y Takuwa, H Nagawa
    JOURNAL OF SURGICAL RESEARCH 130 1 80 - 87 2006年01月 [査読有り][通常論文]
     
    Introduction. Sphingosine 1-phosphate (S1P) is a bioactive lysophospholipid, derived from activated platelet, that is known to induce diverse cellular responses through at least five G-protein-coupled receptors on various cell types. Abnormal platelet and coagulation activation is often seen in patients with gastric cancer. However, neither the effects of this platelet-derived mediator S1P nor the distribution of S1P receptors on the gastric cancer cell are fully understood. The aim of this study was to examine the possible role of S1P and its receptors in the progression of gastric cancer. Materials and methods. We characterized the expression profiles of S1P receptors in nine human gastric cancer cell lines and evaluated the relationship between the responses to S1P and its receptor expression on cell migration by modified Boyden chamber and cell proliferation by MTS assay. Results. Northern blotting analysis has revealed that S1P2 was expressed in all gastric cancer cell lines to varying degrees, and S1P3 was expressed in four cell lines. S1P1 expression was weak, and no significant expression of either S1P4 or S1P5 was detected. The addition of S1P markedly stimulated the migration of MKN1 and HCG-27 that dominantly expressed S1P3, and the effect was potently inhibited by pertussis toxin or wortmannin. In contrast, S1P significantly inhibited the migration of AZ-521 that expressed S1P2 exclusively. This indicates that the balance between S1P2- and S1P3-mediated signals might be critical in determining the metastatic response of gastric cancer cells to S1P. S1P elicited weak but significant antiproliferative effects on all of the three cell lines, although the effects were not major. In these cells, S1P induced extracellular signal-regulated kinase (ERK) phosphorylation with transient Akt dephosphorylation that may cause the weak effects on proliferation. Conclusions. Our results suggest that the S1P receptor expression may critically determine the biological behavior of gastric cancers and thus therapeutic interventions directed at each S1P receptor might be clinically effective in preventing metastasis in gastric cancer. (c) 2006 Elsevier Inc. All rights reserved.
  • Dai Shida, Joji Kitayama, Hironori Yamaguchi, Hiroharu Yamashita, Ken Mori, Toshiaki Watanabe, Hirokazu Nagawa
    WORLD JOURNAL OF GASTROENTEROLOGY 11 36 5638 - 5643 2005年09月 [査読有り][通常論文]
     
    AIM: To examine whether lysophosphatidic acid (LPA) induces phosphorylation of c-Met and epidermal growth factor receptor (EGFR), both of which have been proposed as prognostic markers of colorectal cancer, and whether LPA induces cyclooxygenase-2 (COX-2) expression in human colon cancer cells. METHODS: Using a human colon cancer cell line, LoVo cells, we performed immunoprecipitation analysis, followed by Western blot analysis. We also examined whether LPA induced COX-2 expression, by Western blot analysis. RESULTS: Immunoprecipitation analysis revealed that 10 mu mol/L LPA induced tyrosine phosphorylation of c-Met and EGFR in LoVo cells within a few minutes. We found that c-Met tyrosine phosphorylation induced by LPA was not attenuated by pertussis toxin or a matrix metalloproteinase inhibitor, in marked contrast to the results for EGFR. In addition, 0.2-40 mu mol/L LPA induced COX-2 expression in a dose-dependent manner. CONCLUSION: Our results suggest that LPA acts upstream of various receptor tyrosine kinases (RTKs) and COX-2, and thus may act as a potent stimulator of colorectal cancer. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
  • H Yamaguchi, H Yamashita, H Yamauchi, T Suzuki, M Ishimaru, H Nagawa
    SURGERY 137 6 661 - 662 2005年06月 [査読有り][通常論文]
  • D Shida, J Kitayama, H Yamaguchi, H Yamashita, K Mori, T Watanabe, H Nagawa
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 327 3 907 - 914 2005年02月 [査読有り][通常論文]
     
    The ligand-less receptor HER2/neu (erbB-2) has been proposed as a prognostic marker of gastric cancer that correlates with poor clinical outcome, indicating that HER2 signals play an important role in gastric cancer progression. This study demonstrated that two Major natural lysophospholipids, lysophosphatidic acid (LPA) and sphingosine I-phosphate (SIP), induce rapid and transient phosphorylation of HER2 in two human gastric cancer cell lines, MKN28 and MKN74 cells. We also revealed that tyrosine phosphorylation of HER2 induced by both lysophospholipids was significantly attenuated by two inhibitors, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, AG1478, and a broad-spectrum matrix metalloproteinase inhibitor, GM6001. This suggests that the pathway of HER2 transactivation induced by these lysophospholipids is dependent on the proteolytically released EGFR ligands. Our results indicate that LPA and SIP act upstream of HER2 in gastric cancer cells, and thus may act as potent stimulators of gastric cancer. (C) 2004 Elsevier Inc. All rights reserved.
  • K Hata, H Yamaguchi, G Tsurita, S Watanabe, K Wake, M Taki, S Ueno, H Nagawa
    BIOELECTROMAGNETICS 26 1 49 - 53 2005年01月 [査読有り][通常論文]
     
    The widespread use of the mobile phone has initiated many studies on the possible adverse effects of a high frequency electromagnetic field (EMF), which is used in mobile phones. A low frequency EMF is reported to suppress melatonin synthesis. The aim of this study was to clarify the effects on melatonin synthesis in rats after short term exposure to a 1439 MHz time division multiple access (TDMA) EMF. The average specific absorption ratio (SAR) of the brain was 7.5 W/kg, and the average SARs of the whole body were 1.9 and 2.0 W/kg for male and female rats, respectively. A total of 208 male and female rats were investigated. After acclimatization to a 12 h light-dark (LD) cycle, serum and pineal melatonin levels together with pineal serotonin level under a dark condition (less than I lux) were examined by radioimmunoassay. No significant differences in melatonin and serotonin levels were observed between the exposure, sham, and cage control groups. These results suggest that short term exposure to a 1439 MHz TDMA EMF, which is about four times stronger than that emitted by mobile phones, does not alter melatonin and serotonin synthesis in rats. Further investigations on the effects of long term exposure are warranted. (C) 2004 Wiley-Liss, Inc.
  • D Shida, J Kitayama, H Yamaguchi, K Hama, J Aoki, H Arai, H Yamashita, K Mori, A Sako, T Konishi, T Watanabe, T Sakai, R Suzuki, H Ohta, Y Takuwa, H Nagawa
    EXPERIMENTAL CELL RESEARCH 301 2 168 - 178 2004年12月 [査読有り][通常論文]
     
    Lysophosphatidic acid (LPA), which interacts with at least three G protein-coupled receptors (GPCRs), LPA I /Edg-2, LPA2/Edg-4, and LPA3/Edg-7, is a lipid mediator with diverse effects on various cells. Here, we investigated the expression profiles of LPA receptors and patterns of LPA-induced migration in gastric cancer cells. Northern blot analysis revealed that various gastric cancer cells expressed variable levels of LPA1, LPA2, and LPA3 without a consistent pattern. Using a Boyden chamber assay, LPA markedly increased cell migration of LPA1-expressing cells, the effects of which were almost totally abrogated by Kil6425, anLPA antagonist against LPA1 and LPA3. In contrast, LPA by itself did not significantly induce migration in MKN28 and MKN74 cells, which exclusively expressed LPA2. However, when hepatocyte growth factor (HGF) was placed with LPA in the lower chamber, LPA induced migration of these cells in a dose-dependent manner. Inummoprecipitation analysis revealed that LPA induced transient tyrosine phosphorylation of c-Met in LPA2-expressing cells, which suggests that the transactivation of c-Met by LPA causes a cooperative migratory response with HGF to these cells. Our results indicate that LPA regulates the migration of gastric cancer cells in a receptor-specific manner and suggest that the expression pattern of LPA receptors may affect the metastatic behavior of gastric cancer. (C) 2004 Elsevier Inc. All rights reserved.
  • D Shida, J Kitayama, H Yamaguchi, H Yamashita, K Mori, T Watanabe, Y Yatomi, H Nagawa
    FEBS LETTERS 577 3 333 - 338 2004年11月 [査読有り][通常論文]
     
    Receptor tyrosine kinases (RTKs) are transactivated by the stimulation of G protein-coupled receptors (GPCRs). Sphingosine I-phosphate (SIP), a ligand of GPCR, is known as a tumor-promoting lipid, but its signaling pathways are not fully understood. We here demonstrated that SIP induces rapid and transient tyrosine phosphorylation of epidermal growth factor receptor (EGFR) and c-Met in gastric cancer cells, both of which have been proposed as prognostic markers of gastric cancers. The pathway of SIP-induced c-Met transactivation is Gi-independent and matrix metalloproteinase-independent, which differs from that of EGFR transactivation. Our results indicate that SIP acts upstream of various RTKs and thus may act as a potent stimulator of gastric cancer. (C) 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
  • D Shida, T Watanabe, J Aoki, K Hama, J Kitayama, H Sonoda, Y Kishi, H Yamaguchi, S Sasaki, A Sako, T Konishi, H Arai, H Nagawa
    LABORATORY INVESTIGATION 84 10 1352 - 1362 2004年10月 [査読有り][通常論文]
     
    Lysophosphatidic acid (LPA) is a simple bioactive phospholipid with diverse effects on various cells, that interacts with three G protein-coupled transmembrane receptors, LPA1, LPA2, and LPA3. The expression pattern and functions of these LPA receptors in various tumors have not been fully examined, except in ovarian cancer. To evaluate the LPA receptor expression profile in human colorectal cancer and in normal mucosa, we used real-time reverse transcription-polymerase chain reaction (RT-PCR) and measured the expression levels of LPA1, LPA2, and LPA3 messenger RNA (mRNA) in 26 colorectal cancers and 16 corresponding normal tissue samples. Normal epithelium expressed both LPA1 and LPA2 mRNA at similar levels. In comparison, colorectal cancers expressed LPA1 mRNA at a significantly lower level (0.3-fold; P<0.05), and LPA2 mRNA at a significantly higher level (three-fold; P<0.05), as compared with normal tissues. Thus, the ratio of LPA2/LPA1 increased markedly during malignant transformation (18-fold increase). LPA3 mRNA was expressed at only a low level in both normal and cancer tissues. We also assessed LPA2 expression immunohistochemically using a rat anti-LPA2 monoclonal antibody, and confirmed high expression of LPA2 in colorectal cancer at the protein level. As for LPA1, we examined Western blot analysis for 16 matched normal and cancer tissues. It revealed a significant decrease in the expression of LPA1 protein in cancer tissues compared to normal mucosa in nine of 16 cases, and in the remaining seven cases the expression levels was much the same. These results suggested that alteration of LPA receptor expression might be an important event in the development of colorectal cancer, and therefore, LPA and its receptors could be a chemopreventive target against colorectal cancer.
  • A Sako, J Kitayama, H Yamaguchi, S Kaisaki, H Suzuki, K Fukatsu, S Fujii, H Nagawa
    JOURNAL OF SURGICAL RESEARCH 115 1 113 - 120 2003年11月 [査読有り][通常論文]
     
    Although peritoneal metastasis is an important factor determining the prognosis of patients with gastrointestinal cancer, the mechanisms have not yet been clearly defined. Human peritoneal mesothelial cells (HPMC) are the first line against disseminated tumor cells. Recent reports have shown that mesothelial cells are capable of secreting various cytokines and growth factors. In this study, we isolated human mesothelial cells from surgically resected omental tissue and examined the production and interaction of two major angiogenic factors, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2). Quiescent HPMC produced a considerable amount of VEGF at almost the same level as tumor cells. Interestingly, addition of FGF-2 to the culture significantly increased the mRNA synthesis and protein secretion of VEGF in a dose-dependent manner, as determined by Northern blot and ELISA. The addition of 0.5 ng/mL FGF-2 was enough to stimulate VEGF production, and the effect reached a plateau at 5 ng/mL. Reverse-transcribed polymerase chain reaction (RT-PCR) method clarified that the HPMC-derived VEGF consisted mostly of VEGF(121) and VEGF(165), which are both predominantly soluble forms. These data suggest that HPMC contribute to the development of metastases and the accumulation of malignant ascites due to the production of VEGF, especially in cancers that do not express enough amount of VEGF. (C) 2003 Elsevier Inc. All rights reserved.
  • Y Komuro, T Watanabe, J Kitayama, H Yamaguchi, N Tsuno, H Nagawa
    HEPATO-GASTROENTEROLOGY 50 54 1770 - 1773 2003年11月 [査読有り][通常論文]
     
    Background/Aims: The EDG-2 (endothelial cell differentiation gene-2) has been characterized as one of the high-affinity receptors of lysophosphatidic acid: an extracellular lipid mediator which can induce tumor progression. Recent studies have revealed that EDG-2 plays an important role in various pathological events including cell proliferation and tumor development. The investigation of EDG-2 is thus considered important for eliciting the mechanism of tumorigenesis. However, in colorectal tissue, the clinical significance of EDG-2 expression remains unclear. In the current study, we examined the immunohistochemical expression of EDG-2 in colorectal mucosa and adenoma, and clarified its relation with the clinicopathological features. Methodology: One hundred and sixty-one colorectal polyps were resected endoscopically or surgically at our institute from 2000 to 2001. According to the degree of dysplasia, adenomas were grouped into two categories: low-grade (mild or moderate dysplasia) and high-grade (severe dysplasia or carcinoma in situ). We investigated EDG-2 expression by immunohistochemistry. Results: EDG-2 was expressed almost exclusively in the cytoplasm in colorectal normal mucosa and adenoma. EDG-2 expression in normal mucosa and adenoma was 8% and 76%, respectively. EDG-2 expression was increased in low-grade adenoma compared with that in normal mucosa (P < 0.001). EDG-2 expression was significantly greater in adenomas with larger diameters (P < 0.001). Conclusions: We demonstrated that EDG-2 expression was increased in the early stage of adenoma. A significant correlation between EDG-2 expression and the size - of the adenomas suggests that EDG-2 may play an important role in the growth of these adenomas.
  • H Yamaguchi, J Kitayama, N Takuwa, K Arikawa, Inoki, I, K Takehara, H Nagawa, Y Takuwa
    BIOCHEMICAL JOURNAL 374 Pt 3 715 - 722 2003年09月 [査読有り][通常論文]
     
    We have recently reported that S1P (sphingosine-1-phosphate) differentially regulates cellular Rac activity and cell migration in either a positive or a negative direction via distinct G-protein-coupled receptor subtypes, i.e. S1P(1)/Edg1 (endothelial differentiation gene) and S1P(1)/Edg5 respectively, when each of the S1P receptor subtypes is expressed in CHO (Chinese-hamster ovary) cells. In B16F10 mouse melanoma cells, in which S1P(2), but not the other S1P-receptor subtypes, is endogenously expressed, S1P inhibited cell migration with concomitant inhibition of Rac and stimulation of RhoA in dose-dependent manners. Overexpression of S1P, in the melanoma cells resulted in potentiation of S1P inhibition of both Rac and cell migration. In contrast, overexpression of S1P(1) led to stimulation of cell migration, particularly at the lower S1P concentrations. Treatment of B16F10 cells with S1P inhibited lung metastasis 3 weeks after injection into mouse tail veins. Intriguingly, overexpression of S1P(2) greatly potentiated the inhibition of metastasis by S1P, whereas that of S1P(1) resulted in aggravation of metastasis. Suppression of cellular Rac activity by adenovirus-transduced expression of N(17)Rac, but not N(19)RhoA, strongly inhibited cell migration in vitro and lung metastasis in vivo. These results provide the first evidence that G-protein-coupled receptors could participate in the regulation of metastasis, in which ligand-dependent, subtype-specific regulation of the cellular Rac activity is probably critically involved as a mechanism.
  • K Arikawa, N Takuwa, H Yamaguchi, N Sugimoto, J Kitayama, H Nagawa, K Takehara, Y Takuwa
    JOURNAL OF BIOLOGICAL CHEMISTRY 278 35 32841 - 32851 2003年08月 [査読有り][通常論文]
     
    We investigated mechanisms for inhibition of B16 melanoma cell migration and invasion by sphingosine-1-phosphate (S1P), which is the ligand for the Edg family G protein-coupled receptors and also implicated as an intracellular second messenger. S1P, dihydro-S1P, and sphingosylphosphorylcholine inhibited B16 cell migration and invasion with the relative potencies expected as S1P(2) receptor agonists. The S1P(2)-selective antagonist JTE013 completely abolished the responses to these agonists. In addition, JTE013 abrogated the inhibition by sphingosine, which is the S1P precursor but not an agonist for S1P receptors, indicating that the sphingosine effects were mediated via S1P(2) stimulation, most likely by S1P that was converted from sphingosine. S1P induced inhibition and activation, respectively, of Rac and RhoA in B16 cells, which were abrogated by JTE013. Adenovirus-mediated expression of N(17)Rac mimicked S1P inhibition of migration, whereas C3 toxin pretreatment, but not Rho kinase inhibitors, reversed the S1P inhibition. Overexpression of S1P(2) sensitized, and that of either S1P(1) or S1P(3) desensitized, B16 cells to S1P inhibition of Rac and migration. In JTE013-pretreated, S1P(3)-overexpressing B16 cells, S1P stimulated cellular RhoA but failed to inhibit either Rac or migration, indicating that RhoA stimulation itself is not sufficient for inhibition of migration. These results provide compelling evidence that endogenously expressed S1P(2) negatively regulates cell motility and invasion through ligand dependent reciprocal regulation of cellular Rac and RhoA activities. In the presence of JTE013, S1P instead stimulated Rac and migration in B16 cells that overexpress either S1P(1) or S1P(3), unveiling counteractions between S1P(2) and S1P(1) or S1P(3) chemotactic receptor.
  • H Yamaguchi, G Tsurita, S Ueno, S Watanabe, K Wake, M Taki, H Nagawa
    BIOELECTROMAGNETICS 24 4 223 - 230 2003年05月 [査読有り][通常論文]
     
    This study sought to clarify the effects of exposure to electromagnetic waves (EMW) used in cellular phones on learning and memory processes. Sprague-Dawley rats were exposed for either 1 h daily for 4 days or for 4 weeks to a pulsed 1439 MHz time division multiple access (TDMA) field in a carousel type exposure system. At the brain, average specific absorption rate (SAR) was 7.5 W/kg, and the whole body average SAR was 1.7 W/kg. Other subjects were exposed at the brain average SAR of 25 W/kg and the whole body average SAR of 5.7 W/kg for 45 min daily for 4 days. Learning and memory were evaluated by reversal learning in a food rewarded T-maze, in which rats learned the location of food (right or left) by using environmental cues. The animals exposed to EMW with the brain average SAR of 25 W/kg for 4 days showed statistically significant decreases in the transition in number of correct choices in the reversal task, compared to sham exposed or cage control animals. However, rats exposed to the brain average SAR of 7.5 W/kg for either 4 days or for 4 weeks showed no T-maze performance impairments. Intraperitoneal temperatures, as measured by a fiber optic thermometer, increased in the rats exposed to the brain average SAR of 25 W/kg but remained the same for the brain average SAR of 7.5 W/kg. The SAR of a standard cellular phone is restricted to a maximum of 2 W/kg averaged over 10 g tissue. These results suggest that the exposure to a TDMA field at levels about four times stronger than emitted by cellular phones does not affect the learning and memory processes when there are no thermal effects.
  • D Shida, J Kitayama, H Yamaguchi, Y Okaji, NH Tsuno, T Watanabe, Y Takuwa, H Nagawa
    CANCER RESEARCH 63 7 1706 - 1711 2003年04月 [査読有り][通常論文]
     
    Lysophosphatidic acid (LPA) is a lipid mediator with diverse effects on various cells. Here, we investigated the effects of LPA on human colon carcinoma DLD1 cells. Northern blot analysis revealed that DLD1 highly expressed LPA1/Edg-2 but showed only low expression of LPA2/Edg-4 and no expression of LPA3/Edg-7 at the mRNA level. Western blot analysis revealed that DLD1 cells highly expressed LPA1 at the protein level. Using the Boyden chamber assay, LPA markedly increased DLD1 cell migration at concentrations as low as 10 nm, with maximum stimulation at 100 nm (3.6-fold increase). Checkerboard analysis indicated that LPA stimulated both the chemotactic and chemokinetic migration of DLD1 cells. LPA induced a dose-dependent increase in the proliferation of DLD1 cells (3.2-fold increase at 20 mum). Furthermore, LPA stimulated DLD1 cell adhesion to collagen type I (2.0-fold increase at 10 mum) and also stimulated the secretion of both vascular endothelial growth factor (1.4-fold increase at 20 mum) and interleukin 8 (19-fold increase at 20 mum) by ELISA. In contrast, as for matrix metalloproteinase, LPA had no significant effect on pro-matrix metalloproteinase-2 secretion and its activation, as measured by Western blot analysis. Thus, LPA, at concentrations that are present physiologically, enhanced DLD1 cell migration, proliferation, adhesion, and secretion of angiogenic factors, all of which are crucial for cancer metastasis. In comparison, other human colon carcinoma cells (HT29 and WiDR) exclusively expressed LPA2. LPA enhanced their proliferation and secretion of angiogenic factors, whereas LPA did not enhance migration or adhesion. Our results suggest that LPA acts as a potent stimulator of colon cancer progression, although the binding to LPA1 and LPA2 induces slightly different responses.
  • T Ishiguro, H Yamaguchi, H Nagawa
    HEPATO-GASTROENTEROLOGY 49 45 887 - 888 2002年05月 [査読有り][通常論文]
     
    Although the proportion of early gastric cancer is rising in the incidence of gastric cancer as a whole, its natural, history is still under discussion. We report a patient who was diagnosed with early gastric cancer and who had undergonebarium studies once a year for the three previous years.The exact, increasing size of the tumour could be measured at these four time points, and the data show, almost exactly, the line calculated by the formula S=0.3t(2) [S= size (cm(2)) of the cancerous lesion, t=time (yr) elapsed from the beginning of the gartric cancer].
  • E Sunami, NH Tsuno, J Kitayama, S Saito, T Osada, H Yamaguchi, S Tomozawa, T Tsuruo, Y Shibata, H Nagawa
    SURGERY TODAY 32 4 343 - 350 2002年 [査読有り][通常論文]
     
    Purpose. In the present study, we investigated the effect of troglitazone, a selective ligand and agonist of PPAR-gamma on the metastatic potential of human colon cancer cells. Methods. High- and low-PPAR-gamma expression clones of the colon cancer cell line, HT29, namely clones 21 and 3 respectively, were used. We investigated the effect of troglitazone on the proliferation, on the adhesion to extracellular matrix proteins and on the synthesis of matrix metalloproteinases (MMPs) of colon cancer cells. Results. Troglitazone inhibited the proliferation of both subclones, in a dose-dependent manner, and the inhibitory effect correlated with the level of PPAR-gamma expression. Troglitazone strongly inhibited the production of MMP-7, an enzyme associated with invasiveness of cancer cells, by both subclones. In addition, troglitazone caused a strong decrease in the adhesion of clone 21 to extracellular matrix (ECM) proteins, laminin and type IV collagen. This effect was independent of beta1-integrins expression. Conclusion. In addition to inhibition of cancer cell growth, troglitazone had an inhibitory effect on two important events associated with the metastatic potential of cancer cells, production of MMPs and adhesion to ECM proteins. Consequently, troglitazone is a promising agent for the treatment and prevention of colon cancer metastasis.

講演・口頭発表等

  • 晩期合併症・トランジション 先天性胆道拡張症術後晩期合併症の検討  [通常講演]
    吉田 淳, 笹沼 英紀, 宮戸 英世, 森嶋 計, 三木 厚, 兼田 裕司, 遠藤 和洋, 山口 博紀, 佐久間 康成, 川平 洋, 堀江 久永, 細谷 好則, 味村 俊樹, 北山 丈二, 佐田 尚宏
    日本膵・胆管合流異常研究会プロシーディングス 2019年09月
  • 通過障害を伴う進行胃癌に対し、PTEG造設後に腹腔内化学療法を行い奏功した1例  [通常講演]
    佐藤 孝弘, 高橋 和也, 春田 英律, 山口 博紀, 金丸 理人, 松本 志郎, 宇井 崇, 倉科 憲太郎, 齋藤 心, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 2019年08月
  • 腹腔内液中エクソソームを用いた胃癌腹膜播種症例のリキッドバイオプシー  [通常講演]
    大澤 英之, 齋藤 晶, 熊谷 祐子, 山口 博紀, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2019年07月
  • 開腹術後腹腔内滲出好中球上のPD-L1発現  [通常講演]
    金丸 理人, 大澤 英之, 高橋 和也, 松本 志郎, 春田 英律, 倉科 健太郎, 山口 博紀, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2019年07月
  • 当院における肥満外科手術の減量効果と代謝改善効果の中長期成績  [通常講演]
    春田 英律, 細谷 好則, 岡田 健太, 齋藤 心, 倉科 憲太郎, 金丸 理人, 石橋 俊, 山口 博紀, 北山 丈二, 佐田 尚宏
    日本消化器外科学会総会 2019年07月
  • 当院における75歳以上の切除不能進行再発大腸癌患者に対する全身化学療法の現状  [通常講演]
    清水 徹一郎, 堀江 久永, 佐田友 藍, 直井 大志, 田原 真紀子, 巷野 佳彦, 井上 賢之, 鯉沼 広治, 佐田 尚宏, 山口 博紀
    日本消化器外科学会総会 2019年07月
  • 【胃】胃癌腹膜播種に対する治療戦略 胃癌腹膜播種に対する全身・腹腔内投与併用化学療法  [通常講演]
    石神 浩徳, 藪崎 裕, 大森 健, 小寺 泰弘, 福島 亮治, 今野 元博, 有上 貴明, 富田 寿彦, 山口 博紀, 北山 丈二
    日本消化器外科学会総会 2019年07月
  • 【胃】胃癌腹膜播種に対する治療戦略 腹膜播種陽性胃癌に対するSOX+PTX腹腔内投与併用療法  [通常講演]
    齋藤 心, 山口 博紀, 細谷 好則, 金丸 理人, 春田 英律, 倉科 憲太郎, 堀江 久永, 佐久間 康成, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2019年07月
  • 食道神経内分泌癌(NEC)7例の検討  [通常講演]
    金子 勇貴, 齋藤 心, 山口 博紀, 春田 英律, 松本 四郎, 倉科 憲太郎, 細谷 好則, 北山 丈二, 仁木 利郎, 佐田 尚宏
    日本食道学会学術集会プログラム・抄録集 2019年06月
  • 術前DCF療法の治療効果に係る因子の検討  [通常講演]
    松本 志郎, 細谷 好則, 宇井 崇, 高橋 和也, 金丸 理人, 春田 英律, 倉科 憲太郎, 齋藤 心, 山口 博紀, 北山 丈二
    日本食道学会学術集会プログラム・抄録集 2019年06月
  • 胃管癌8例の臨床病理学的検討  [通常講演]
    齋藤 心, 細谷 好則, 松原 大祐, 春田 英律, 倉科 憲太郎, 松本 志郎, 北山 丈二, 山口 博紀, 佐久間 康成, 堀江 久永, 佐田 尚宏
    日本外科学会定期学術集会抄録集 2019年04月
  • 開腹術後腹腔内滲出好中球の臨床的意義  [通常講演]
    金丸 理人, 大澤 英之, 松本 志郎, 春田 英律, 倉科 憲太郎, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 2019年04月
  • 消化器癌手術患者における末梢血中低比重好中球の術中推移  [通常講演]
    熊谷 祐子, 金丸 理人, 大澤 英之, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 2019年04月
  • 放射線照射が癌細胞におけるアデノシン産生酵素CD73に与える影響について  [通常講演]
    津久井 秀則, 大澤 英之, 山口 博紀, 佐久間 康成, 細谷 好則, 堀江 久永, 藤井 博文, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 2019年04月
  • 腹腔内液中エクソソームを用いた胃癌腹膜播種治療におけるバイオマーカー探索  [通常講演]
    大澤 英之, 齋藤 晶, 熊谷 祐子, 佐久間 康成, 山口 博紀, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本外科学会定期学術集会抄録集 2019年04月
  • 胃癌における周術期化学療法の最先端 根治切除可能な漿膜浸潤陽性胃癌に対する腹腔内投与併用の周術期化学療法を検証する第II相試験(GAPS試験)  [通常講演]
    會澤 雅樹, 今野 元博, 藪崎 裕, 伊藤 誠二, 上之園 芳一, 廣野 靖夫, 上田 修吾, 松村 卓樹, 千葉 康敬, 千葉 佐知, 松木 淳, 有上 貴明, 伊藤 友一, 藤本 大裕, 石神 浩徳, 山口 博紀, 安田 卓司, 北山 丈二, 古河 洋
    日本外科学会定期学術集会抄録集 2019年04月
  • 当科における高度肥満症に対する腹腔鏡下スリーブ状胃切除術の取り組みと治療成績  [通常講演]
    春田 英律, 細谷 好則, 倉科 憲太郎, 斎藤 心, 宇井 崇, 松本 志郎, 金丸 理人, 高橋 和也, 山口 博紀, 佐久間 康成, 堀江 久永, 北山 丈二, 佐田 尚宏
    日本成人病(生活習慣病)学会会誌 2019年01月
  • 治癒切除を受けた消化器癌患者のメトホルミン内服による生存率改善について  [通常講演]
    熊谷 祐子, 大澤 英之, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本成人病(生活習慣病)学会会誌 2019年01月
  • 胃癌腹膜播種に対するSOX+PTX腹腔内投与併用化学療法の新規導入施設における治療成績  [通常講演]
    山口 博紀, 金丸 理人, 大澤 英之, 松本 志郎, 倉科 憲太郎, 春田 英律, 細谷 好則, 藤井 博文, 北山 丈二, 佐田 尚宏
    日本癌治療学会学術集会抄録集 2018年10月
  • 胃癌腹膜播種に対する全身化学療法と腹腔内化学療法および胃切除術による集学的治療  [通常講演]
    小林 大介, 石神 浩徳, 藪崎 裕, 大森 健, 小寺 泰弘, 福島 亮治, 今野 元博, 有上 貴明, 富田 寿彦, 岸 健太郎, 松村 卓樹, 三澤 一成, 廣野 靖夫, 山口 博紀, 北山 丈二, 腹腔内化学療法研究会
    日本癌治療学会学術集会抄録集 2018年10月
  • 根治切除可能であったTrousseau症候群を合併した進行胃癌の1例  [通常講演]
    齋藤 匠, 倉科 憲太郎, 細谷 好則, 山口 博紀, 益子 貴史, 春田 英律, 齋藤 心, 宇井 崇, 松本 志郎, 金丸 理人, 高橋 和也, 堀江 久永, 佐久間 康成, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 2018年10月
  • 外科の緩和ケア バランス麻酔のアプローチに学ぶ外科医のtotal distressマネジメント  [通常講演]
    清水 敦, 佐久間 康成, 細谷 好則, 堀江 久永, 藤田 崇史, 山口 博紀, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 2018年10月
  • 肥満に対する外科治療の最前線 当院における肥満外科手術の取り組みと治療成績  [通常講演]
    春田 英律, 細谷 好則, 倉科 憲太郎, 斎藤 心, 宇井 崇, 松本 志郎, 金丸 理人, 高橋 和也, 山口 博紀, 佐久間 康成, 堀江 久永, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 2018年10月
  • 消化器癌手術患者の末梢血中低比重好中球と術後転移再発との関連について(Low density neutrophils(LDN) in postoperative peripheral blood may assist the recurrence of gastrointestinal cancer)  [通常講演]
    熊谷 祐子, 金丸 理人, 大澤 英之, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本癌学会総会記事 2018年09月
  • 胃癌腹膜播種治療における腹腔内液中エクソソームマイクロRNA解析(Exosomal microRNA profiles in peritoneal fluids as a therapeutic biomarker for peritoneal metastasis of gastric cancer)  [通常講演]
    大澤 英之, 熊谷 祐子, 山口 博紀, 北山 丈二
    日本癌学会総会記事 2018年09月
  • 好中球細胞外トラップ(NETs)による開腹術後腹膜再発促進機構(Neutrophil extracellular traps(NETs) on postoperative peritoneal surface may support the tumor recurrence on peritoneum)  [通常講演]
    金丸 理人, 大澤 英之, 高橋 和也, 松本 志郎, 春田 英律, 倉科 憲太郎, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本癌学会総会記事 2018年09月
  • 担癌マウスリンパ節におけるアデノシン脱リン酸化酵素(CD39,CD73)発現についての解析(Expression of adenosine generating ecto-enzymes, CD39 and CD73, in lymphocytes in tumor bearing mouse)  [通常講演]
    津久井 秀則, 大澤 英之, 山口 博紀, 佐久間 康成, 細谷 好則, 堀江 久永, 藤井 博文, 佐田 尚宏, 北山 丈二
    日本癌学会総会記事 2018年09月
  • 腹腔環境の特殊性に基づいた新規腹膜播種治療(Treatment of peritoneal dissemination based on the unique microenvironment in peritoneal cavity)  [通常講演]
    北山 丈二, 金丸 理人, 大澤 英之, 熊谷 祐子, 山口 博紀, 細谷 好則, 松崎 圭祐, 佐田 尚宏
    日本癌学会総会記事 2018年09月
  • 腹膜播種の診断と治療の工夫 腹膜播種に対するパクリタキセル腹腔内化学療法におけるドラッグデリバリー向上の工夫  [通常講演]
    江本 成伸, 北山 丈二, 山口 博紀, 石神 浩徳, 室野 浩司, 田中 敏明, 畑 啓介, 川合 一茂, 野澤 宏彰
    日本消化器外科学会総会 2018年07月
  • 腹膜播種の診断と治療の工夫 腹膜播種陽性胃癌に対するSOX+PTX腹腔内投与併用化学療法の新規導入施設における治療成績  [通常講演]
    齋藤 心, 山口 博紀, 松本 志郎, 倉科 憲太郎, 佐久間 康成, 春田 英律, 堀江 久永, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本消化器外科学会総会 2018年07月
  • 開腹手術後の腹腔内滲出好中球由来細胞外トラップ(NETs)の臨床的意義  [通常講演]
    金丸 理人, 大澤 英之, 松本 志郎, 春田 英律, 倉科 憲太郎, 宮戸 秀世, 山口 博紀, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2018年07月
  • 集学的治療は微小転移を制御できるか? 胃癌腹膜微小転移に対するパクリタキセル腹腔内反復化学療法の有用性  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 腹腔内化学療法研究会
    日本消化器外科学会総会 2018年07月
  • 放射線化学療法(CRT)後の直腸癌組織におけるCD73の発現  [通常講演]
    津久井 秀則, 大澤 英之, 山口 博紀, 佐久間 康成, 細谷 好則, 堀江 久永, 藤井 博文, 若月 優, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2018年07月
  • 胃癌腹膜播種手術症例における予後因子としての腹腔洗浄液中CEA mRNA定量値  [通常講演]
    山口 博紀, 石神 浩徳, 松本 志郎, 宇井 崇, 春田 英律, 倉科 憲太郎, 齋藤 心, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2018年07月
  • 腹腔内液中エクソソームマイクロRNAを用いた胃癌腹膜播種症例のリキッドバイオプシー  [通常講演]
    大澤 英之, 熊谷 祐子, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2018年07月
  • 腹膜播種の診断と治療の工夫 腹膜播種に対するパクリタキセル腹腔内化学療法におけるドラッグデリバリー向上の工夫  [通常講演]
    江本 成伸, 北山 丈二, 山口 博紀, 石神 浩徳, 室野 浩司, 田中 敏明, 畑 啓介, 川合 一茂, 野澤 宏彰
    日本消化器外科学会総会 2018年07月
  • 腹膜播種の診断と治療の工夫 腹膜播種陽性胃癌に対するSOX+PTX腹腔内投与併用化学療法の新規導入施設における治療成績  [通常講演]
    齋藤 心, 山口 博紀, 松本 志郎, 倉科 憲太郎, 佐久間 康成, 春田 英律, 堀江 久永, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本消化器外科学会総会 2018年07月
  • 開腹手術後の腹腔内滲出好中球由来細胞外トラップ(NETs)の臨床的意義  [通常講演]
    金丸 理人, 大澤 英之, 松本 志郎, 春田 英律, 倉科 憲太郎, 宮戸 秀世, 山口 博紀, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2018年07月
  • 集学的治療は微小転移を制御できるか? 胃癌腹膜微小転移に対するパクリタキセル腹腔内反復化学療法の有用性  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 腹腔内化学療法研究会
    日本消化器外科学会総会 2018年07月
  • 放射線化学療法(CRT)後の直腸癌組織におけるCD73の発現  [通常講演]
    津久井 秀則, 大澤 英之, 山口 博紀, 佐久間 康成, 細谷 好則, 堀江 久永, 藤井 博文, 若月 優, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2018年07月
  • 胃癌腹膜播種手術症例における予後因子としての腹腔洗浄液中CEA mRNA定量値  [通常講演]
    山口 博紀, 石神 浩徳, 松本 志郎, 宇井 崇, 春田 英律, 倉科 憲太郎, 齋藤 心, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2018年07月
  • 腹腔内液中エクソソームマイクロRNAを用いた胃癌腹膜播種症例のリキッドバイオプシー  [通常講演]
    大澤 英之, 熊谷 祐子, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2018年07月
  • StageII・III食道癌の治療前BMIと術前化学療法中の体重減少は予後不良と関連する  [通常講演]
    倉科 憲太郎, 細谷 好則, 大澤 英之, 齋藤 心, 春田 英律, 松本 志郎, 山口 博紀, 藤井 博文, 北山 丈二, 佐田 尚宏
    日本食道学会学術集会プログラム・抄録集 2018年06月
  • 当院における腹腔鏡下スリーブ状胃切除術の治療成績  [通常講演]
    春田 英律, 細谷 好則, 岡田 健太, 倉科 憲太郎, 齋藤 心, 宇井 崇, 松本 志郎, 金丸 理人, 高橋 和也, 山口 博紀, 佐久間 康成, 堀江 久永, 北山 丈二, 佐田 尚宏
    日本肥満症治療学会学術集会プログラム・抄録集 2018年06月
  • 困難例に対する手術の工夫 胃全摘術後の総胆管結石に対し、腹腔鏡下胆管切石術(経胆嚢管法)を施行した2例  [通常講演]
    春田 英律, 齋藤 心, 倉科 憲太郎, 宇井 崇, 松本 志郎, 金丸 理人, 高橋 和也, 山口 博紀, 細谷 好則, 佐久間 康成, 北山 丈二, 佐田 尚宏
    小切開・鏡視外科学会雑誌 2018年06月
  • 当院における腹腔鏡下スリーブ状胃切除術の治療成績  [通常講演]
    春田 英律, 細谷 好則, 岡田 健太, 倉科 憲太郎, 齋藤 心, 宇井 崇, 松本 志郎, 金丸 理人, 高橋 和也, 山口 博紀, 佐久間 康成, 堀江 久永, 北山 丈二, 佐田 尚宏
    日本肥満症治療学会学術集会プログラム・抄録集 2018年06月
  • 切除不能進行食道癌に対しDCF療法後に食道切除を試みた症例の検討  [通常講演]
    宇井 崇, 藤井 博文, 細谷 好則, 山口 博紀, 森 美鈴, 齋藤 心, 倉科 憲太郎, 春田 英律, 松本 志郎, 佐田 尚宏
    日本食道学会学術集会プログラム・抄録集 2018年06月
  • 食道神経内分泌癌(NEC)6例の治療経験  [通常講演]
    齋藤 心, 細谷 好則, 藤井 博文, 山口 博紀, 森 美鈴, 福嶋 敬宜, 金丸 理人, 松本 志郎, 三浦 義正, 佐田 尚宏
    日本食道学会学術集会プログラム・抄録集 2018年06月
  • 胃癌腹膜播種治療における腹腔内液中エクソソームマイクロRNA解析  [通常講演]
    大澤 英之, 熊谷 裕子, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器病学会雑誌 2018年04月
  • 実臨床に即した切除不能・進行再発消化管がんに対する最適な治療戦略 消化器癌腹膜播種に対するタキサン腹腔内反復化学療法の可能性  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀
    日本消化器病学会雑誌 2018年04月
  • 胃癌腹膜播種治療におけるバイオマーカーとしての腹水中エクソソームマイクロRNA  [通常講演]
    大澤 英之, 熊谷 祐子, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本外科学会定期学術集会抄録集 2018年04月
  • 胃癌腹膜播種に対する腹腔内化学療法における腹腔洗浄液中CEA mRNA定量 手術適応決定のバイオマーカーとしての意義  [通常講演]
    山口 博紀, 石神 浩徳, 金丸 理人, 大澤 英之, 松本 志郎, 倉科 憲太郎, 春田 英律, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本外科学会定期学術集会抄録集 2018年04月
  • 高度進行胃癌に対する集学的治療 腹膜播種陽性または腹腔細胞診陽性胃癌に対する集学的治療  [通常講演]
    石神 浩徳, 山口 博紀, 山下 裕玄, 朝蔭 正宏, 北山 丈二
    日本外科学会定期学術集会抄録集 2018年04月
  • 胃癌切除症例における術前D-dimer値と病期・転帰の検討  [通常講演]
    倉科 憲太郎, 細谷 好則, 清水 徹一郎, 太田 学, 齋藤 心, 春田 英律, 宇井 崇, 松本 志郎, 金丸 理人, 三木 厚, 山口 博紀, 堀江 久永, 佐久間 康成, 北山 丈二, 佐田 尚宏
    日本胃癌学会総会記事 2018年03月
  • 当院における漿膜浸潤胃癌R0切除症例における術中出血量と生命予後の関係  [通常講演]
    金丸 理人, 大澤 英之, 高橋 和也, 松本 志郎, 宇井 崇, 春田 英律, 倉科 憲太郎, 宮戸 秀世, 斉藤 心, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本胃癌学会総会記事 2018年03月
  • 胃癌切除症例における術前D-dimer値と病期・転帰の検討  [通常講演]
    倉科 憲太郎, 細谷 好則, 清水 徹一郎, 太田 学, 齋藤 心, 春田 英律, 宇井 崇, 松本 志郎, 金丸 理人, 三木 厚, 山口 博紀, 堀江 久永, 佐久間 康成, 北山 丈二, 佐田 尚宏
    日本胃癌学会総会記事 2018年03月
  • 当院における漿膜浸潤胃癌R0切除症例における術中出血量と生命予後の関係  [通常講演]
    金丸 理人, 大澤 英之, 高橋 和也, 松本 志郎, 宇井 崇, 春田 英律, 倉科 憲太郎, 宮戸 秀世, 斉藤 心, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本胃癌学会総会記事 2018年03月
  • 腹腔内投与併用化学療法により病理学的完全奏功を得た腹膜播種陽性胃癌の2例(pCR in P1 gastric cancer using intraperitoneal and systemic chemotherapy: Report of two patients)  [通常講演]
    目黒 由行, 山口 博紀, 北山 丈二, 石神 浩徳, 奥野 貴之, 金丸 理人, 松本 志郎, 宇井 崇, 春田 英律, 倉科 憲太郎, 齋藤 心, 細谷 好則, 佐田 尚宏
    日本胃癌学会総会記事 2018年03月
  • 胃切除後胆道結石症の検討(Biliary tract stone after gastrectomy)  [通常講演]
    木村 有希, 細谷 好則, 小泉 大, 金丸 理人, 松本 史郎, 春田 英律, 宇井 崇, 倉科 健太郎, 宮戸 秀世, 齋藤 心, 佐久間 康成, 山口 博紀, 堀江 久永, 北山 丈二, アラン・レフォー, 佐田 尚宏
    日本胃癌学会総会記事 2018年03月
  • 憩室壁内に異所性膵を認めた空腸憩室穿通の1例  [通常講演]
    白鳥 広志, 西川 武司, 新谷 裕加子, 室野 浩司, 安田 幸嗣, 大谷 研介, 田中 敏明, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 深山 正久, 渡邉 聡明
    日本臨床外科学会雑誌 2018年03月
  • 腹腔内投与併用化学療法により病理学的完全奏功を得た腹膜播種陽性胃癌の2例(pCR in P1 gastric cancer using intraperitoneal and systemic chemotherapy: Report of two patients)  [通常講演]
    目黒 由行, 山口 博紀, 北山 丈二, 石神 浩徳, 奥野 貴之, 金丸 理人, 松本 志郎, 宇井 崇, 春田 英律, 倉科 憲太郎, 齋藤 心, 細谷 好則, 佐田 尚宏
    日本胃癌学会総会記事 2018年03月
  • 胃切除後胆道結石症の検討(Biliary tract stone after gastrectomy)  [通常講演]
    木村 有希, 細谷 好則, 小泉 大, 金丸 理人, 松本 史郎, 春田 英律, 宇井 崇, 倉科 健太郎, 宮戸 秀世, 齋藤 心, 佐久間 康成, 山口 博紀, 堀江 久永, 北山 丈二, アラン・レフォー, 佐田 尚宏
    日本胃癌学会総会記事 2018年03月
  • 大学病院における経皮内視鏡的胃瘻造設術の適応と早期合併症  [通常講演]
    倉科 憲太郎, 細谷 好則, 齋藤 心, 春田 英律, 宇井 崇, 松本 志郎, 金丸 理人, 安部 望, 高橋 和也, 山口 博紀, 堀江 久永, 佐久間 康成, 北山 丈二, 佐田 尚宏
    日本成人病(生活習慣病)学会会誌 2018年01月
  • 腹膜播種陽性胃癌に対するCape/CDDP+docetaxel腹腔内投与併用療法の第II相試験  [通常講演]
    戸澤 勝之, 石神 浩徳, 福島 亮治, 今野 元博, 小林 大介, 辻 靖, 秀村 晃生, 楠本 哲也, 大森 健, 藪崎 裕, 大橋 紀文, 太田 光彦, 山口 博紀, 北山 丈二, 腹腔内化学療法研究会
    日本癌治療学会学術集会抄録集 2017年10月
  • 「それぞれの癌」最善の治療とは? 腹膜播種治療の今 胃癌腹膜播種に対する全身・腹腔内投与併用化学療法  [通常講演]
    石神 浩徳, 山口 博紀, 北山 丈二
    日本癌治療学会学術集会抄録集 2017年10月
  • 食道癌の副腎転移と鑑別を要した副腎black adenomaの一例  [通常講演]
    吉田 陽, 松本 志郎, 春田 英律, 倉科 憲太郎, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 2017年10月
  • 食道癌の脳転移再発に対して手術および放射線療法で長期生存が得られた一例  [通常講演]
    松本 志郎, 細谷 好則, 春田 英律, 倉科 憲太郎, 宮戸 英世, 山口 博紀, 佐久間 康成, 堀江 久永, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 2017年10月
  • 腹腔鏡下胃全摘術におけるEEA Orvilを用いた食道空腸吻合の工夫  [通常講演]
    倉科 憲太郎, 細谷 好則, 春田 英律, 松本 志郎, 齋藤 心, 宇井 崇, 宮戸 秀世, 堀江 久永, 佐久間 康成, 山口 博紀, 北山 丈二, 佐田 尚宏
    日本臨床外科学会雑誌 2017年10月
  • 胃癌・大腸癌の腹膜播種に対する治療戦略 腹膜播種を伴う胃癌に対する腹腔内投与併用化学療法  [通常講演]
    石神 浩徳, 山口 博紀, 北山 丈二
    日本臨床外科学会雑誌 2017年10月
  • 胃癌Conversion surgery 腹膜播種を伴う胃癌に対する化学療法奏効後胃切除  [通常講演]
    石神 浩徳, 山口 博紀, 山下 裕玄, 朝蔭 正宏, 北山 丈二
    日本臨床外科学会雑誌 2017年10月
  • 消化器癌腹膜播種に対する新たなアプローチ 腹膜播種を伴う胃癌に対する腹腔内化学療法  [通常講演]
    石神 浩徳, 山口 博紀, 北山 丈二
    Gastroenterological Endoscopy 2017年09月
  • Stage IV胃癌への新たな治療戦略《アンサーパッド》 腹膜播種陽性胃癌に対する腹腔内化学療法と手術を組み合わせた治療戦略  [通常講演]
    山口 博紀, 石神 浩徳, 北山 丈二
    Gastroenterological Endoscopy 2017年09月
  • 消化器癌腹膜播種に対する新たなアプローチ 腹膜播種を伴う胃癌に対する腹腔内化学療法  [通常講演]
    石神 浩徳, 山口 博紀, 北山 丈二
    日本消化器病学会雑誌 2017年09月
  • Stage IV胃癌への新たな治療戦略《アンサーパッド》 腹膜播種陽性胃癌に対する腹腔内化学療法と手術を組み合わせた治療戦略  [通常講演]
    山口 博紀, 石神 浩徳, 北山 丈二
    日本消化器病学会雑誌 2017年09月
  • 胃癌腹膜播種治療におけるバイオマーカーとしての腹水中エクソソームマイクロRNA解析  [通常講演]
    大澤 英之, 三木 厚, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本癌学会総会記事 2017年09月
  • 開腹術後の腹膜再発における腹腔滲出性低比重好中球の意義  [通常講演]
    北山 丈二, 金丸 理人, 津久井 秀則, 大澤 英之, 山口 博紀, 松本 志朗, 倉科 憲太郎, 宮戸 秀世, 細谷 好則, 佐田 尚宏
    日本癌学会総会記事 2017年09月
  • 高度進行胃癌でのresectable metastasisに対する治療戦略 胃癌腹膜播種、腹腔内投与併用化学療法奏効例におけるConversion Surgery  [通常講演]
    山口 博紀, 石神 浩徳, 齋藤 心, 倉科 憲太郎, 大澤 英之, 松本 志郎, 藤井 博文, 細谷 好則, 北山 丈二, 佐田 尚宏
    日本消化器外科学会総会 2017年07月
  • 消化器癌の診断・治療を含めた新規分子腫瘍マーカーの意義と展望 胃癌腹膜播種治療における腹腔内液中バイオマーカーの意義  [通常講演]
    北山 丈二, 山口 博紀, 石神 浩則, 大澤 英之, 細谷 好則, 山下 裕玄, 瀬戸 泰之, 佐田 尚宏
    日本消化器外科学会総会 2017年07月
  • 消化器癌腹膜播種の病態解明と新たな治療戦略 腹膜播種に対するタキサン反復腹腔内化学療法の展望  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀
    日本消化器外科学会総会 2017年07月
  • 胃癌術後腹腔内Neutrophil Extracellular Traps(NETs)の腹膜播種再発の関与について  [通常講演]
    金丸 理人, 津久井 秀則, 斉藤 心, 倉科 憲太郎, 松本 志郎, 山口 博紀, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本消化器外科学会総会 2017年07月
  • 胃癌腹膜再発における開腹術後の腹腔内滲出液中low density granulocytes(LDG)の意義  [通常講演]
    金丸 理人, 津久井 秀則, 斉藤 心, 倉科 憲太郎, 宇井 崇, 春田 英律, 松本 志郎, 安部 望, 高橋 和也, 山口 博紀, 佐久間 康成, 堀江 久永, 細谷 好則, 佐田 尚宏, 北山 丈二
    日本外科学会定期学術集会抄録集 2017年04月
  • 高度進行胃癌に対するNeoadjuvant chemotherapyとConversion surgery 腹膜播種陽性胃癌に対するConversion surgery  [通常講演]
    石神 浩徳, 山口 博紀, 北山 丈二
    日本外科学会定期学術集会抄録集 2017年04月
  • 胃癌術後補助化学療法の新たな選択 漿膜浸潤陽性胃癌に対する補助療法としてのPaclitaxel腹腔内反復投与の可能性  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 金丸 理人, 松本 志郎, 倉科 憲太郎, 斎藤 心, 細谷 好則, 佐田 尚宏
    日本外科学会定期学術集会抄録集 2017年04月
  • 下部直腸癌に対する鏡視下括約筋間切除術の治療成績  [通常講演]
    石原 聡一郎, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2017年04月
  • Stage IV大腸癌根治切除症例における腹膜播種の意義  [通常講演]
    荒川 敬一, 川合 一茂, 石原 聡一郎, 山口 博紀, 野澤 宏彰, 畑 啓介, 清松 知充, 田中 潤一郎, 田中 敏明, 西川 武司, 大谷 研介, 安田 幸嗣, 渡邉 聡明, 杉原 健一
    日本大腸肛門病学会雑誌 2017年04月
  • 大腸癌患者における血漿遊離DNAメチル化レベルの定量と臨床的有用性の検討  [通常講演]
    永井 雄三, 須並 英二, 山本 陽子, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本大腸肛門病学会雑誌 2017年04月
  • 腹腔内洗浄細胞診陽性症例に対するパクリタキセル腹腔内投与+S-1/パクリタキセル静脈投与法の第II相臨床試験(Phase II study of ip paclitaxel plus S-1/iv paclitaxel in GC pts. with positive peritoneal cytology)  [通常講演]
    今野 元博, 石神 浩徳, 梨本 篤, 藪崎 裕, 今本 治彦, 山下 裕玄, 岸 健太郎, 小寺 泰弘, 上之園 芳一, 藤原 義之, 秀村 晃生, 田村 茂行, 福島 亮治, 山口 博紀, 北山 丈二
    日本胃癌学会総会記事 2017年03月
  • 腹腔内化学療法の経験のない施設における新規導入(Introduction of intraperitoneal chemotherapy at a hospital with inexperienced staff)  [通常講演]
    山口 博紀, 北山 丈二, 大澤 英之, 金丸 理人, 松本 志郎, 森 美鈴, 齋藤 心, 倉科 憲太郎, 上田 真寿, 細谷 好則, 藤井 博文, 佐田 尚宏
    日本胃癌学会総会記事 2017年03月
  • 腹膜播種を伴う胃癌に対するS-1+パクリタキセル経静脈・腹腔内併用療法/S-1+シスプラチン併用療法による第III相臨床試験(PHOENIX-GC traial)(IP PTX plus S-1/PTX compared with SP in gastric cancer with peritoneal metastasis: PHOENIX-GC trial)  [通常講演]
    小林 大介, 石神 浩徳, 藤原 義之, 福島 亮治, 梨本 篤, 藪崎 裕, 今本 治彦, 今野 元博, 小寺 泰弘, 上之園 芳一, 天貝 賢二, 門脇 重憲, 三輪 洋人, 山口 博紀, 山口 拓洋, 北山 丈二, 腹腔内化学療法研究会
    日本胃癌学会総会記事 2017年03月
  • 胃癌腹膜再発における開腹術後の腹腔内滲出液中low density granulocytes(LDG)の意義(Low density granulocytes in peritoneal exudates may assist peritoneal recurrence after gastrectomy)  [通常講演]
    北山 丈二, 金丸 理人, 津久井 秀則, 松本 志郎, 倉科 憲太郎, 斎藤 心, 細谷 好則, 山口 博紀, 石神 浩徳, 佐田 尚宏
    日本胃癌学会総会記事 2017年03月
  • Stage IV大腸癌根治切除後の予後予測Nomogram  [通常講演]
    川合 一茂, 石原 聡一郎, 山口 博紀, 須並 英二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2017年02月
  • 胃癌腹膜播種にPTX腹腔内投与を施行し3年間無再発生存ののち骨髄癌腫症を発症した1例  [通常講演]
    奥野 貴之, 山口 博紀, 石原 聡一郎, 石神 浩徳, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2016年09月
  • TRC法を用いた腹腔内洗浄液CEA mRNA定量検査の治療効果判定における有用性  [通常講演]
    佐藤 優実子, 山口 博紀, 高井 大哉, 北山 丈二, 大久保 滋夫, 矢冨 裕
    日本臨床検査自動化学会会誌 2016年08月
  • 粘膜下腫瘍様に発育し粘膜下層への高度浸潤とリンパ節転移を来した小型の大腸癌2症例  [通常講演]
    品川 貴秀, 石原 聡一郎, 野澤 宏彰, 川合 一茂, 山口 博紀, 林 玲匡, 田中 麻理子, 牛久 哲男, 深山 正久, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 直腸癌に対する術前CRTの功罪 下部局所進行直腸癌に対する術前化学放射線療法の有効性と今後の方向性についての検討  [通常講演]
    大谷 研介, 石原 聡一郎, 清松 知充, 西川 武司, 田中 敏明, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • KRAS遺伝子変異別にみた切除不能大腸癌に対する抗体製剤併用全身化学療法の成績  [通常講演]
    野澤 宏彰, 安田 幸嗣, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 川合 一茂, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 術前化学放射線療法後に低位前方切除術を施行した下部進行直腸癌患者における肛門機能の検討  [通常講演]
    柴田 淳一, 清松 知充, 西川 武司, 田中 敏明, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 3D画像ナビゲーションに基づいたロボット支援下直腸癌側方郭清  [通常講演]
    清松 知充, 石原 聡一郎, 大谷 研介, 西川 武司, 田中 敏明, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 下部進行直腸癌に対する術前化学放射線療法とロボット手術  [通常講演]
    川合 一茂, 山口 博紀, 石原 聡一郎, 野澤 宏彰, 畑 啓介, 清松 知充, 田中 敏明, 西川 武司, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 消化管外科手術におけるナビゲーションサージェリー 3D-CT angiographyによる左側結腸の腸間膜動脈分岐走行の検討  [通常講演]
    室野 浩司, 川合 一茂, 田中 敏明, 清松 知充, 畑 啓介, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 肛門温存のための下部直腸癌・肛門管癌外科治療 当科における下部直腸癌、肛門管癌に対する治療の検討  [通常講演]
    安田 幸嗣, 石原 聡一郎, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏影, 山口 博紀, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 潰瘍性大腸炎の炎症性発癌経路におけるCD133発現の免疫組織学的検討  [通常講演]
    風間 伸介, 山口 博紀, 石原 総一郎, 西村 洋治, 川島 吉之, 坂本 裕彦, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 潰瘍性大腸炎に対する大腸全摘・回腸嚢肛門管吻合術後合併症の検討  [通常講演]
    安西 紘幸, 畑 啓介, 石井 博章, 田中 敏明, 清松 知充, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 骨盤内臓器浸潤大腸癌における術前化学放射線療法の治療成績  [通常講演]
    西川 武司, 石原 聡一郎, 田中 敏明, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 山口 博紀, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 直腸癌術前化学放射線療法の治療効果、局所再発予測における18F-FDG PET/CTの有用性  [通常講演]
    奥野 貴之, 川合 一茂, 石原 聡一郎, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 野澤 宏彰, 山口 博紀, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 直腸癌に対する腹腔鏡下前方切除術における縫合不全リスク因子の検討  [通常講演]
    松崎 裕幸, 石原 聡一郎, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • Stage IV大腸がん根治術症例における術後CEA、CA19-9値の検討  [通常講演]
    阿部 真也, 川合 一茂, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 腹膜播種を伴う胃癌に対するS-1/シスプラチン+パクリタキセル腹腔内投与併用療法  [通常講演]
    小林 大介, 石神 浩徳, 神田 光郎, 田中 千恵, 山口 博紀, 北山 丈二, 小寺 泰弘
    日本消化器外科学会総会 2016年07月
  • 胃癌腹膜播種の新規バイオマーカーとしての腹腔洗浄液中CEA mRNA定量値の有用性  [通常講演]
    山口 博紀, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 胃癌腹膜播種の基礎と臨床 新たなエビデンスの創出に向けて 腹膜播種陽性胃癌に対する腹腔内化学療法  [通常講演]
    石神 浩徳, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2016年07月
  • 胃癌腹膜播種の基礎と臨床 新たなエビデンスの創出に向けて 胃癌腹膜再発予測のための腹腔内遊離癌細胞白血球比(Tumor leukocyte Ratio)の可能性  [通常講演]
    山下 裕玄, 北山 丈二, 山口 博紀, 八木 浩一, 愛甲 丞, 西田 正人, 竹中 芳治, 野村 幸世, 渡邉 聡明, 瀬戸 泰之
    日本消化器外科学会総会 2016年07月
  • 癌性腹膜炎をターゲットとしたPHOENIX-GC試験 腹腔内化学療法の一般化に向けた取り組み  [通常講演]
    山口 博紀, 北山 丈二, 石神 浩徳, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 進行胃癌に対する集学的治療の現状と展望 腹膜播種陽性胃癌に対する集学的治療  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 直腸癌側方リンパ節転移に対する術前化学放射線療法を併用した治療戦略とその成績  [通常講演]
    石原 聡一郎, 大谷 研介, 安田 幸嗣, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 直腸癌におけるLGR5,CD133免疫組織学的発現と臨床病理学的因子の検討  [通常講演]
    原田 有三, 風間 伸介, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 潤一郎, 田中 敏明, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 直腸癌に対する術前化学放射線療法とロボット手術  [通常講演]
    川合 一茂, 飯田 祐基, 山口 博紀, 野澤 宏彰, 畑 啓介, 清松 知充, 田中 敏明, 西川 武司, 安田 幸嗣, 大谷 研介, 室野 浩司, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 直腸癌に対する腹腔鏡下前方切除術は肥満患者においても低侵襲である  [通常講演]
    松崎 裕幸, 石原 聡一郎, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 胃癌腹膜播種における腹腔内化学療法奏功後の胃切除(Interval devalking gastrectomy)の意義  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 佐藤 優実子, 矢冨 裕, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 直腸癌における中直腸動脈の走行と側方画像シミュレーション ロボット手術への応用  [通常講演]
    清松 知充, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 切除不能大腸癌に対するVEGFまたはEGF-R阻害抗体併用による全身化学療法  [通常講演]
    野澤 宏彰, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 川合 一茂, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 潰瘍性大腸炎術後慢性回腸嚢炎のリスクファクターに対するメタアナリシス  [通常講演]
    畑 啓介, 石原 聡一郎, 野澤 宏彰, 山口 博紀, 川合 一茂, 清松 知充, 田中 敏明, 田中 潤一郎, 安田 幸嗣, 西川 武司, 大谷 研介, 北山 丈二, 石井 博章, 安西 紘幸, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2016年04月
  • 大腸癌に対する内視鏡的治療後追加腸切除症例の解析 sm浸潤距離以外の因子の検討  [通常講演]
    野澤 宏彰, 室野 浩司, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 清松 知充, 川合 一茂, 畑 啓介, 山口 博紀, 石原 聡一郎, 小田島 慎也, 藤城 光弘, 渡邉 聡明
    Gastroenterological Endoscopy 2016年04月
  • 腹膜播種に対するタキサン反復腹腔内化学療法の展望(Combination chemotherapy including repeated intraperitoneal taxane for peritoneal metastasis)  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀
    日本胃癌学会総会記事 2016年03月
  • 直腸癌手術における縫合不全リスク因子および肥満が短期成績に与える影響の検討  [通常講演]
    松崎 裕幸, 石原 聡一郎, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本成人病(生活習慣病)学会会誌 2016年01月
  • ロボット支援下直腸切除術における内腸骨系血管および骨盤内神経の視認性  [通常講演]
    清松 知充, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本内視鏡外科学会雑誌 2015年12月
  • 複数の吻合を行った腹腔鏡補助下大腸切除術の検討  [通常講演]
    野澤 宏彰, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本内視鏡外科学会雑誌 2015年12月
  • 閉塞性直腸癌と横行結腸癌の同時性多発癌に対して腹腔鏡下手術を施行した1例  [通常講演]
    奥野 貴之, 野澤 宏彰, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 潤一郎, 田中 敏明, 清松 知充, 畑 啓介, 川合 一茂, 山口 博紀, 石原 総一郎, 渡邉 聡明
    日本内視鏡外科学会雑誌 2015年12月
  • 血管疾患合併例における腹腔鏡下大腸手術の治療成績  [通常講演]
    永田 洋士, 野澤 宏彰, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本内視鏡外科学会雑誌 2015年12月
  • 直腸癌に対する腹腔鏡下DSTにおける縫合不全リスク因子の検討  [通常講演]
    松崎 裕幸, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本内視鏡外科学会雑誌 2015年12月
  • 腹腔鏡/ロボット支援手術における骨盤内リンパ節郭清の要点 ロボット支援下直腸癌手術における側方郭清の要点 安全に施行するための工夫  [通常講演]
    須並 英二, 清松 知充, 川合 一茂, 風間 伸介, 野澤 宏彰, 畑 啓介, 田中 潤一郎, 田中 敏明, 西川 武司, 大谷 研介, 安田 幸嗣, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本内視鏡外科学会雑誌 2015年12月
  • ロボット補助大腸手術の標準化 安全な導入に向けて 大腸癌に対するロボット支援手術の標準化  [通常講演]
    石原 聡一郎, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本内視鏡外科学会雑誌 2015年12月
  • 胃癌腹膜播種に対する奏功後胃切除の適応における腹腔液中CEAmRNAの定量の意義  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀
    日本癌学会総会記事 2015年10月
  • 当院における大腸癌腹膜播種の治療成績  [通常講演]
    永田 洋士, 石原 聡一郎, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏影, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 下部進行直腸癌に対する術前化学放射線療法と腹腔鏡下手術 Propensity scoreを用いた比較  [通常講演]
    川合 一茂, 須並 英二, 石原 聡一郎, 山口 博紀, 野澤 宏彰, 畑 啓介, 清松 知充, 田中 潤一郎, 田中 敏明, 西川 武司, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 直腸癌術後局所再発の治療戦略  [通常講演]
    西川 武司, 石原 聡一郎, 安田 幸嗣, 大谷 研介, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 縫合・吻合不全の予防と治療(小腸、結腸、直腸) 直腸癌に対する腹腔鏡下DSTにおける縫合不全リスク因子の検討  [通常講演]
    松崎 裕幸, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • IBDの治療戦略 潰瘍性大腸炎に対する腹腔鏡手術  [通常講演]
    畑 啓介, 石原 聡一郎, 須並 英二, 山口 博紀, 野澤 宏彰, 川合 一茂, 清松 知充, 田中 潤一郎, 田中 敏明, 西川 武司, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 外科医が行う臨床試験 その方法と問題点 腹膜播種に対する腹腔内化学療法に関する臨床試験 経過と問題点  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀
    日本臨床外科学会雑誌 2015年10月
  • Stage IV胃癌・大腸癌に対する治療戦略 Stage IV大腸癌治癒切除後長期生存例の検討  [通常講演]
    野澤 宏彰, 石原 聡一郎, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • Stage IV胃癌・大腸癌に対する治療戦略 腹膜播種を伴う胃癌に対する腹腔内化学療法後の胃切除  [通常講演]
    山口 博紀, 北山 丈二, 石神 浩徳, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • ダビンチを用いた手術初期のピットフォールとその防止策 直腸癌に対するロボット手術でのポート挿入位置の工夫  [通常講演]
    風間 伸介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 更なる治療成績の向上を目指した大腸癌治療 当科における大腸ステント留置後化学療法症例の外科手術の経験  [通常講演]
    田中 敏明, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一朗, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • ロボット支援手術の有用性を知る 直腸癌に対するロボット支援手術の安全性と有用性  [通常講演]
    石原 聡一郎, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 他臓器疾患を有する癌患者の外科治療 当科における併存症を有する大腸癌患者の周術期合併症の検討  [通常講演]
    阿部 真也, 川合 一茂, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 手術支援ロボット手術の実際 直腸癌に対するロボット支援下手術の現状  [通常講演]
    須並 英二, 清松 知充, 川合 一茂, 風間 伸介, 野澤 宏彰, 畑 啓介, 田中 潤一郎, 田中 敏明, 西川 武司, 大谷 研介, 安田 幸嗣, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 合併症ゼロを目指した再建、吻合手術手技(大腸) 縫合不全防止のための直腸再建時の工夫  [通常講演]
    田中 潤一郎, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 手術・処置・診断などのシミュレーションの現状と展望 ロボット支援下直腸癌手術における側方領域血管の3Dシミュレーション  [通常講演]
    清松 知充, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2015年10月
  • 大腸 直腸がんに対する腹腔鏡手術 鏡視下直腸癌手術における骨盤内解剖の画像シミュレーション 中直腸動脈のvariation  [通常講演]
    清松 知充, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本癌治療学会誌 2015年09月
  • 腹腔鏡手術導入による高齢者大腸癌手術の変遷  [通常講演]
    西川 武司, 石原 聡一郎, 安田 幸嗣, 大谷 研介, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本癌治療学会誌 2015年09月
  • 胃 胃がん腹膜播種へのアプローチ 腹膜播種を伴う胃癌に対する腹腔内投与併用化学療法の開発  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明
    日本癌治療学会誌 2015年09月
  • 外科的治療を行った腸管ベーチェット病の2例  [通常講演]
    品川 貴秀, 畑 啓介, 風間 伸介, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 術後2ヵ月で鼡径、側方リンパ節再発をきたした痔瘻癌の1例  [通常講演]
    奥野 貴之, 清松 知充, 西川 武司, 安田 幸嗣, 田中 敏明, 田中 潤一郎, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 原発性肺高血圧症患者のS状結腸癌術後に結腸浮腫を認めた一例  [通常講演]
    荒川 敬一, 川合 一茂, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 異時性多発肛門管癌の一例  [通常講演]
    瀧山 博年, 野澤 宏彰, 石原 聡一郎, 田中 潤一郎, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 川合 一茂, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 腹腔鏡補助下回盲部切除術を施行した単純性小腸潰瘍の一例  [通常講演]
    原田 有三, 清松 知充, 大谷 研介, 西川 武司, 安田 幸嗣, 田中 潤一郎, 田中 敏明, 川合 一茂, 畑 啓介, 風間 伸介, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 大腸癌患者における抗p53抗体の術後サーベイランスに関する検討  [通常講演]
    阿部 真也, 川合 一茂, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 50歳未満の若年で発症した大腸癌の臨床病理学的検討  [通常講演]
    永井 雄三, 畑 啓介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 回盲部およびS状結腸・直腸S状部同士の直接浸潤癌の2例  [通常講演]
    瀧山 亜希, 野澤 宏彰, 風間 伸介, 川合 一茂, 田中 潤一郎, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 大腸癌術前検査としてのCTコロノグラフィー検査の有用性  [通常講演]
    佐藤 一仁, 田中 敏明, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 当科における直腸癌局所再発の治療戦略  [通常講演]
    西川 武司, 石原 聡一郎, 安田 幸嗣, 大谷 研介, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 大腸癌に対する内視鏡的治療後追加腸切除症例の特徴 ESD症例とEMR症例の比較  [通常講演]
    野澤 宏彰, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • ISRの現状と展望 下部直腸癌に対する腹腔鏡下括約筋間切除術の治療成績  [通常講演]
    石原 聡一郎, 瀧山 亜希, 瀧山 博年, 原田 有三, 柴田 淳一, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • cT3N1下部直腸癌に対する治療戦略 cT3N1M0の下部進行直腸癌に対する術前放射線療法と術前化学放射線療法の効果に関する比較検討  [通常講演]
    安田 幸嗣, 石原 聡一郎, 大谷 研介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • IBDに対する癌サーベイランスの現状と今後の展望 潰瘍性大腸炎合併大腸癌の特徴  [通常講演]
    畑 啓介, 岸川 純子, 安西 紘幸, 大谷 研介, 安田 幸嗣, 西川 武史, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野沢 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • IBD治療における内科と外科の連携 潰瘍性大腸炎に対する大腸全摘、回腸嚢肛門管吻合術後合併症の検討  [通常講演]
    安西 紘幸, 畑 啓介, 石井 博章, 岸川 純子, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 大腸肛門機能の諸問題 術前化学放射線療法後に切除した下部進行直腸癌患者における術後肛門機能の検討  [通常講演]
    柴田 淳一, 石原 聡一郎, 清松 知充, 安西 紘幸, 瀧山 亜希, 瀧山 博年, 原田 有三, 大谷 研介, 安田 幸嗣, 西川 武司, 田中 敏明, 田中 潤一郎, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 大腸領域におけるロボット手術の現状と展望 当科における直腸癌ロボット手術の現状と課題  [通常講演]
    須並 英二, 清松 知充, 川合 一茂, 風間 伸介, 野澤 宏彰, 畑 啓介, 田中 潤一郎, 田中 敏明, 西川 武司, 大谷 研介, 安田 幸嗣, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • ストーマ合併症の現状と治療 当院におけるストーマ合併症例とその治療の検討  [通常講演]
    田中 潤一郎, 安田 幸嗣, 大谷 研介, 西川 武司, 田中 敏明, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 大腸癌に対する集学的治療 直腸 局所進行直腸癌に対する術前放射線療法と腹腔鏡手術  [通常講演]
    川合 一茂, 須並 英二, 山口 博紀, 石原 聡一郎, 風間 伸介, 野澤 宏彰, 畑 啓介, 清松 知充, 田中 潤一郎, 田中 敏明, 西川 武司, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年09月
  • 上行結腸癌術後異時性回腸癌を認めたリンチ症候群の1例  [通常講演]
    舘川 裕一, 山口 博紀, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 局所進行直腸癌に対する術前放射線療法と化学放射線療法  [通常講演]
    川合 一茂, 石原 聡一郎, 山口 博紀, 須並 英二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 胃癌腹膜播種の病態と診断・治療 腹膜播種を伴う胃癌に対する腹腔内投与併用化学療法  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • Colitis-associated cancerの診断と治療 当科における潰瘍性大腸炎サーベイランス内視鏡についての検討  [通常講演]
    安西 紘幸, 畑 啓介, 岸川 純子, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 進行性消化器癌の多職種連携治療 進行性消化器癌の治療の最近の動向 腹膜転移を伴う進行性の胃がんに対する集学的治療(Multidisciplinary Treatment of Progressive Gastroenterological Cancers: Update on Treatment of Progressive Gastroenterological Cancers Multidisciplinary treatment for advanced gastric cancer with pe  [通常講演]
    山口 博紀, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 腹腔内遊離細胞群の解析と臨床的意義 次世代の腹膜播種治療の確立に向けて  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 小野山 温那, 山下 裕玄, 瀬戸 泰之, 松崎 圭祐, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 腹腔鏡下直腸切除術の工夫 当科の腹腔鏡補助下直腸切除術における吻合の工夫  [通常講演]
    西川 武司, 須並 英二, 須並 英二, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 手術手技 特殊腹腔鏡下大腸手術 ロボット支援下括約筋間直腸切除術(ISR)の短期治療成績  [通常講演]
    石原 聡一郎, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 大腸癌患者におけるLINE-1を標的とした血漿遊離DNAメチル化レベルの定量と臨床的有用性の検討  [通常講演]
    永井 雄三, 須並 英二, 山本 陽子, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 直腸癌術前化学放射線療法の治療効果判定と再発予後予測におけるPET/CT検査の有用性  [通常講演]
    田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 風間 伸介, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 下部直腸癌に対する側方郭清の意義 JCOG0215の結果から得たもの 術前化学放射線療法による直腸癌側方リンパ節転移の制御  [通常講演]
    清松 知充, 川合 一茂, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 世界へ発信する大腸外科医療 当院における直腸がんに対するロボット手術(Colorectal Surgery, Expanding into the World Robotic surgery for rectal cancer in our institute)  [通常講演]
    須並 英二, 清松 知充, 川合 一茂, 風間 伸介, 野澤 宏彰, 畑 啓介, 田中 潤一郎, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 潰瘍性大腸炎術後の回腸嚢炎のリスクファクター  [通常講演]
    畑 啓介, 石井 博章, 風間 伸介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • 下部直腸GISTに対する術前imatinib療法  [通常講演]
    野澤 宏彰, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本消化器外科学会総会 2015年07月
  • FACSを用いた腹膜播種患者における腹腔内遊離癌細胞(floating tumor cell)定量の試み  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀
    Cytometry Research 2015年07月
  • 腹腔鏡補助下及び開腹大腸手術の術後合併症の比較  [通常講演]
    川合 一茂, 石原 聡一郎, 山口 博紀, 須並 英二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年06月
  • 生活習慣病が大腸腹腔鏡術後の合併症発生に及ぼす影響  [通常講演]
    石井 博章, 石原 聡一郎, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明, 松田 圭二
    成人病と生活習慣病 2015年05月
  • 同時性大腸癌と腹部大動脈瘤に対しEVAR後に、腹腔鏡下大腸切除術を施行した1例  [通常講演]
    清松 英充, 川合 一茂, 田中 潤一郎, 田中 敏明, 清松 知充, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明, 保坂 晃弘, 重松 邦弘
    成人病と生活習慣病 2015年05月
  • 併存疾患を有する大腸癌患者の周術期合併症の検討  [通常講演]
    阿部 真也, 川合 一茂, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    成人病と生活習慣病 2015年05月
  • stage III大腸癌患者における補助化学療法の検討 若年者と高齢者の比較  [通常講演]
    野澤 宏彰, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 風間 伸介, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年05月
  • 下部消化管 大腸癌肝転移症例におけるCD133発現の免疫組織学的検討  [通常講演]
    岸川 純子, 風間 伸介, 長谷川 潔, 山口 博紀, 石原 聡一郎, 須並 英二, 牛久 哲男, 北山 丈二, 深山 正久, 國土 典宏, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 下部消化管 Stage III大腸癌におけるCD133免疫組織学的発現と臨床病理学的因子の検討  [通常講演]
    風間 伸介, 岸川 純子, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 下部消化管 オキサリプラチンによる補助化学療法後の大腸癌再発に関わる因子の検討  [通常講演]
    野澤 宏彰, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 局所進行直腸癌に対する集学的治療戦略 下部消化管 局所進行直腸癌に対する術前放射線療法と化学放射線療法の比較  [通常講演]
    川合 一茂, 石原 聡一郎, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 胃癌の周術期化学療法 上部消化管 根治切除可能な漿膜浸潤を伴う胃癌に対する周術期化学療法 TS-1、パクリタキセル経静脈・腹腔内投与併用療法 第II相試験  [通常講演]
    今野 元博, 石神 浩徳, 藪崎 裕, 小林 大介, 伊藤 誠二, 上之園 芳一, 上田 修吾, 木村 豊, 山口 博紀, 今本 治彦, 梨本 篤, 古河 洋, 安田 卓司, 竹吉 泉, 福島 亮治, 小寺 泰弘, 北山 丈二
    日本外科学会定期学術集会抄録集 2015年04月
  • 下部消化管 直腸癌手術における周術期感染予防のための吻合法の工夫  [通常講演]
    西川 武司, 須並 英二, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 上部消化管 腹膜転移を伴う胃癌治療のためのパクリタキセルを用いた腹腔内化学療法(Intraperitoneal chemotherapy with paclitaxel for treatment of gastric cancer with peritoneal metastasis)  [通常講演]
    山口 博紀, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 下部消化管 直腸癌に対するロボット手術(Robotic surgery for rectal cancer in our institute)  [通常講演]
    須並 英二, 川合 一茂, 清松 知充, 風間 伸介, 野澤 宏彰, 畑 啓介, 田中 潤一郎, 田中 敏明, 西川 武司, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 下部消化管 直腸癌に対するロボット手術 CT解剖に基づく手術手技  [通常講演]
    清松 知充, 西川 武司, 田中 敏明, 田中 潤一郎, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 栄養・感染症・緩和 切除不能遠隔転移を伴う大腸癌に対する姑息的原発巣切除の意義 propensity score matching法による多施設データの解析  [通常講演]
    石原 聡一郎, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 金沢 孝満, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 杉原 健一, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 上部消化管 腹膜播種陽性または腹腔洗浄細胞診陽性胃癌に対する集学的治療  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明
    日本外科学会定期学術集会抄録集 2015年04月
  • 消化器疾患における線維化の病態と診療 腹腔内間葉系細胞による線維化を標的とした胃癌腹膜播種に対する新規治療戦略  [通常講演]
    北山 丈二, 山口 博紀, 石神 浩徳
    日本消化器病学会雑誌 2015年03月
  • 胃癌腹膜播種患者における腹腔内遊離癌細胞白血球比(Tumor Leukocyte Ratio)の臨床的意義  [通常講演]
    北山 丈二, 江本 成伸, 山口 博紀, 石神 浩徳, 小野山 温菜, 山下 裕玄, 松崎 圭佑, 瀬戸 泰之, 渡邉 聡明
    日本胃癌学会総会記事 2015年03月
  • 胃癌腹膜播種症例に対する新たな治療戦略 内科、外科の立場から 腹膜播種を伴う胃癌に対するカペシタビン/シスプラチン+ドセタキセル腹腔内投与併用療法  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明
    日本胃癌学会総会記事 2015年03月
  • 胃癌腹膜播種症例に対する新たな治療戦略 内科、外科の立場から 腹膜播種を伴う胃癌に対するS-1/オキサリプラチン+パクリタキセル腹腔内投与併用療法  [通常講演]
    上之園 芳一, 石神 浩徳, 藤原 義之, 富田 寿彦, 今本 治彦, 今野 元博, 梨本 篤, 藪崎 裕, 福島 亮治, 小寺 泰弘, 今村 和広, 上田 修吾, 山下 裕玄, 山口 博紀, 北山 丈二
    日本胃癌学会総会記事 2015年03月
  • 胃癌腹膜播種症例に対する新たな治療戦略 内科、外科の立場から 胃癌腹膜播種に対するS-1+PTX経静脈・腹腔内併用化学療法  [通常講演]
    山口 博紀, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本胃癌学会総会記事 2015年03月
  • 胃癌腹膜播種症例に対する新たな治療戦略 内科、外科の立場から 胃癌腹膜播種に対する腹腔内化学療法の展望 基礎的検討から  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 渡邉 聡明
    日本胃癌学会総会記事 2015年03月
  • conversion therapyの現状と将来展望 定義、適応と手術の時期 腹膜播種を伴う胃癌に対する腹腔内投与併用化学療法後胃切除  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明
    日本胃癌学会総会記事 2015年03月
  • 局所進行直腸癌に対する術前化学放射線療法術後の予後因子の検討  [通常講演]
    川合 一茂, 石原 聡一郎, 山口 博紀, 須並 英二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2015年02月
  • 生活習慣病が大腸腹腔鏡術後の合併症発生に及ぼす影響  [通常講演]
    石井 博章, 石原 聡一郎, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 須並 英二, 松田 圭二, 北山 丈二, 渡邉 聡明
    日本成人病(生活習慣病)学会会誌 2015年01月
  • 同時性大腸癌と腹部大動脈瘤に対しEVAR後に、腹腔鏡下大腸切除術を施行した1例  [通常講演]
    清松 英充, 川合 一茂, 田中 潤一郎, 田中 敏明, 清松 知充, 野澤 宏彰, 風間 伸介, 金沢 孝満, 保坂 晃弘, 山口 博紀, 石原 聡一郎, 須並 英二, 重松 邦弘, 渡邉 聡明
    日本成人病(生活習慣病)学会会誌 2015年01月
  • 併存疾患を有する大腸癌患者の周術期合併症の検討  [通常講演]
    阿部 真也, 川合 一茂, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本成人病(生活習慣病)学会会誌 2015年01月
  • 骨盤内動静脈奇形を合併したS状結腸癌の1切除例  [通常講演]
    瀧山 亜希, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年12月
  • 直腸癌術後人工肛門部に発生した異時性多発大腸癌に対して、局所切除を施行した一例  [通常講演]
    三田 英明, 安西 紘幸, 風間 伸介, 清松 知充, 川合 一茂, 田中 敏明, 米山 さとみ, 田中 潤一郎, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年11月
  • 大腸癌に対する腹腔鏡手術後の合併症に関与する患者因子の解析  [通常講演]
    石原 聡一郎, 松田 圭二, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 須並 英二, 北山 丈二, 橋口 陽二郎, 渡邉 聡明
    日本内視鏡外科学会雑誌 2014年10月
  • ロボット支援大腸手術 Pros and Cons 当科におけるロボット支援下大腸手術症例の検討  [通常講演]
    須並 英二, 石原 聡一郎, 川合 一茂, 清松 知充, 金沢 孝満, 風間 伸介, 野澤 宏彰, 畑 啓介, 田中 潤一郎, 田中 敏明, 西川 武司, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本内視鏡外科学会雑誌 2014年10月
  • 内視鏡外科の低侵襲性を評価する 利尿期への早期移行が示す腹腔鏡下直腸手術の低侵襲性  [通常講演]
    金沢 孝満, 田中 敏明, 西川 武司, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 風間 伸介, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本内視鏡外科学会雑誌 2014年10月
  • 直腸癌に対するロボット手術の工夫  [通常講演]
    風間 伸介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • 悪性大腸閉塞に対する経肛門減圧術について  [通常講演]
    田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 金沢 孝満, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • 下部直腸GISTに対する術前imatinib療法後の肛門温存手術  [通常講演]
    野澤 宏彰, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 風間 伸介, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • ロボット支援下直腸癌手術における側方郭清の3Dシミュレーション 血管走行に応じた処理の問題点  [通常講演]
    清松 知充, 田中 敏明, 田中 潤一郎, 川合 一茂, 畑 啓介, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • 内視鏡下手術における新たな工夫 局所進行直腸癌に対するロボット支援下側方郭清術  [通常講演]
    須並 英二, 風間 伸介, 清松 知充, 川合 一茂, 金沢 孝満, 野澤 宏彰, 田中 潤一郎, 田中 敏明, 畑 啓介, 西川 武司, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • 胃癌腹膜播種に対する治療戦略 パクリタキセルを用いた胃癌腹膜播種に対する腹腔内化学療法  [通常講演]
    山口 博紀, 石神 博紀, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • 下部直腸癌に対する括約筋切除術の適応と治療戦略 ロボット支援下括約筋間直腸切除術(ISR)の短期治療成績  [通常講演]
    石原 聡一郎, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 須並 英二, 松田 圭二, 北山 丈二, 橋口 陽二郎, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • Stage IV胃癌に対する外科治療 腹膜播種を伴う胃癌に対する集学的治療  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • 腹腔鏡下直腸癌手術における定型化のための工夫 直腸癌治療におけるロボット手術 定型化に向けた課題  [通常講演]
    渡邉 聡明, 須並 英二, 石原 聡一郎, 川合 一茂, 清松 知充, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 畑 啓介, 田中 潤一郎, 田中 敏明, 西川 武司, 北山 丈二
    日本臨床外科学会雑誌 2014年10月
  • 進行直腸癌に対する側方郭清の意義 術前化学放射線療法による直腸癌側方リンパ節転移の制御  [通常講演]
    川合 一茂, 石原 聡一郎, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • 本邦から発信する胃癌治療のエビデンス 胃癌腹膜播種に対するタキサン腹腔内化学療法  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • 膀胱全摘・尿管S状結腸吻合術後、両側の吻合部にS状結腸癌が発生した1例  [通常講演]
    荒川 敬一, 川合 一茂, 柴田 淳一, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2014年10月
  • 高度亀背を伴った直腸癌に対し腹腔鏡補助下直腸前方切除術を施行した一例  [通常講演]
    原田 有三, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • 直腸癌術後3ヵ月で発症した腹壁腫瘤の一例  [通常講演]
    佐藤 一仁, 田中 敏明, 金沢 孝満, 田中 潤一郎, 清松 知充, 野澤 宏彰, 山口 博紀, 風間 伸介, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • 早期癌で発見されたα-fetoprotein産生直腸癌の1切除例  [通常講演]
    安西 紘幸, 風間 伸介, 清松 知充, 西川 武司, 田中 敏明, 田中 潤一郎, 畑 啓介, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • 当科で経験した乳房外Paget病8症例の診断と治療  [通常講演]
    永井 雄三, 風間 伸介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 総一郎, 須並 英二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • 大腸癌における予後不良因子としてのTissue Factor発現の意義  [通常講演]
    川合 一茂, 須並 英二, 石原 聡一郎, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • Stage I〜III大腸癌における術後早期に再発をきたす症例の特徴  [通常講演]
    小澤 毅士, 風間 伸介, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • 大腸癌発癌過程におけるCD133発現の免疫組織学的検討  [通常講演]
    風間 伸介, 岸川 純子, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • 新しい腹腔鏡下大腸癌手術の手技と定型化 大腸癌治療におけるロボット手術 今後の普及に向けて  [通常講演]
    渡邉 聡明, 須並 英二, 石原 聡一郎, 金沢 孝満, 風間 伸介, 野澤 宏彰, 山口 博紀, 川合 一茂, 畑 圭介, 清松 知充, 田中 潤一郎, 田中 敏明, 西川 武司, 北山 丈二
    日本大腸肛門病学会雑誌 2014年09月
  • 大腸ステント留置例における術前口側検索の検討  [通常講演]
    田中 敏明, 西川 武司, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 野澤 宏彰, 金沢 孝満, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • IBD合併癌(Colitic Cancer)のサーベイランスと治療 当科における潰瘍性大腸炎サーベイランス内視鏡の有用性についての検討  [通常講演]
    岸川 純子, 風間 伸介, 畑 啓介, 安西 紘幸, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • 局所進行直腸癌に対する集学的治療の新展開 局所進行直腸癌に対する周術期補助療法  [通常講演]
    石原 聡一郎, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • 大腸癌治療におけるバイオマーカー 大腸癌腹膜播種治療における腹水洗浄細胞診の意義  [通常講演]
    須並 英二, 西川 武司, 風間 伸介, 金沢 孝満, 野澤 宏章, 畑 啓介, 清松 知充, 田中 潤一郎, 田中 敏明, 川合 一茂, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2014年09月
  • 安全で効果的なCARTを目指して! 胃癌癌性腹膜炎に対する集学的治療 CARTと腹腔内化学療法を併用した積極的治療  [通常講演]
    北山 丈二, 山口 博紀, 石神 浩徳, 渡邉 聡明, 花房 規夫
    日本アフェレシス学会雑誌 2014年09月
  • 腹腔内パクリタキセルの腹膜播種制御機序に関する免疫組織学的検討(Intraperitoneal Paclitaxel induces tumor shrinkage through direct infiltration in metastatic nodules on peritoneum)  [通常講演]
    江本 成伸, 山口 博紀, 石神 浩徳, 渡邉 聡明, 北山 丈二
    日本癌学会総会記事 2014年09月
  • 胃癌腹膜播種の成立に関わる腹腔内遊離間葉系幹細胞の役割(Mesenchymal cells promote peritoneal metastasis of gastric cancer by forming tumor permissive microenvironment)  [通常講演]
    北山 丈二, 山口 博紀, 石神 浩徳, 山下 裕玄, 小野山 温那, 瀬戸 泰之, 松崎 圭祐, 渡邉 聡明
    日本癌学会総会記事 2014年09月
  • 全身化学療法を行った切除不能大腸癌症例における"Deepness of response"と生存期間の相関  [通常講演]
    野澤 宏彰, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 畑 啓介, 風間 伸介, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本消化器病学会雑誌 2014年09月
  • 局所進行直腸癌に対する術前化学放射線療法の再発危険因子の解析  [通常講演]
    須並 英二, 川合 一茂, 清松 知充, 風間 伸介, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • 直腸切除術における縫合不全のリスク評価と対策  [通常講演]
    田中 潤一郎, 清松 知充, 川合 一茂, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • 進行胃癌に対する術前化学療法の適応と意義 腹膜転移を有する胃癌に対する腹腔内化学療法奏功後の胃切除  [通常講演]
    山口 博紀, 北山 丈二, 江本 成伸, 石神 浩徳, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • 胃癌腹膜播種に対する腹腔内投与併用化学療法  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • 直腸癌に対する個別化治療 術前化学放射線療法の治療効果と予測因子の探索  [通常講演]
    石原 聡一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • 術前補助化学放射線療法を施行した下部進行直腸癌手術症例におけるMUC2発現の臨床学的意義に関する検討  [通常講演]
    金子 建介, 川合 一茂, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • 大腸癌における術前Neutrophil/Lymphocyte ratioの意義の検討  [通常講演]
    川合 一茂, 須並 英二, 石原 聡一郎, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • ベンチからベッドへ 消化器癌の基礎研究成果 間葉系幹細胞による線維化を標的とした新たな腹膜播種治療法の開発  [通常講演]
    北山 丈二, 江本 成伸, 山口 博紀, 石神 浩徳, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • 閉塞性大腸癌に対するステント留置術ならびに腹腔鏡下大腸切除術後の成績  [通常講演]
    田中 敏明, 清松 知充, 川合 一茂, 野澤 宏彰, 金沢 孝満, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • 大腸切除術における術式の違いによる手術侵襲の検討 ロボット手術と腹腔鏡手術の比較  [通常講演]
    柴田 淳一, 石原 聡一郎, 川合 一茂, 清松 知充, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2014年07月
  • 胃癌腹膜播種に対する腹腔内化学療法におけるDDSの工夫  [通常講演]
    江本 成伸, 山口 博紀, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本DDS学会学術集会プログラム予稿集 2014年07月
  • 腹膜播種陽性胃癌に対する腹腔内投与併用化学療法  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明
    日本癌治療学会誌 2014年06月
  • 胃癌腹膜播種患者における腹腔内遊離癌細胞定量法の開発とその臨床的意義  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 江本 成伸, 松崎 圭祐, 山下 裕玄, 瀬戸 泰之, 渡邉 聡明
    日本癌治療学会誌 2014年06月
  • 直腸癌に対するロボット手術  [通常講演]
    渡邉 聡明, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二
    日本癌治療学会誌 2014年06月
  • スキルス胃癌の治療戦略 スキルス胃癌に対する集学的治療戦略  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本胃癌学会総会記事 2014年03月
  • CY1胃癌の治療戦略 P0CY1胃癌に対するS-1+Paclitaxel静脈内・腹腔内併用投与(Phoenix Regimen)の臨床成績  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本胃癌学会総会記事 2014年03月
  • 胃癌腹膜播種に対する治療の取り組みと展望 胃癌腹膜播種に対する腹腔内化学療法におけるドラッグデリバリーシステムの工夫  [通常講演]
    江本 成伸, 山口 博紀, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本胃癌学会総会記事 2014年03月
  • 胃癌腹膜播種に対する治療の取り組みと展望 腹膜播種を伴う胃癌に対する腹腔内投与併用化学療法  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本胃癌学会総会記事 2014年03月
  • 胃癌におけるトランスレーショナルリサーチの現状と将来 胃癌腹膜播種の成立における腹腔内間葉系幹細胞の役割とその臨床的意義  [通常講演]
    北山 丈二, 江本 成伸, 山口 博紀, 石神 浩徳, 渡邉 聡明
    日本胃癌学会総会記事 2014年03月
  • 切除不能進行胃癌に対するconversion surgery 腹膜播種陽性胃癌における腹腔内化学療法奏功後の外科切除  [通常講演]
    山口 博紀, 北山 丈二, 江本 成伸, 石神 浩徳, 渡邉 聡明
    日本胃癌学会総会記事 2014年03月
  • 胃癌腹膜播種の成立における腹腔内遊離間葉系幹細胞の役割とその臨床的意義  [通常講演]
    北山 丈二, 江本 成伸, 山口 博紀, 石神 浩徳, 渡邉 聡明, 松崎 圭祐
    日本消化器病学会雑誌 2014年03月
  • 術中内視鏡にて診断・切除し得た大腸多発腺癌・多発腺腫の1例  [通常講演]
    大矢 真里子, 阿部 真也, 飯田 祐基, 米山 さとみ, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 金沢 孝満, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • 腹腔鏡手術へのbridge to surgeryとしての大腸ステント留置術  [通常講演]
    田中 敏明, 田中 潤一郎, 米山 さとみ, 川合 一茂, 野澤 宏彰, 金沢 孝満, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • 超高齢者大腸癌における手術症例の検討  [通常講演]
    米山 さとみ, 田中 潤一郎, 田中 敏明, 清松 知充, 川合 一茂, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 石原 総一郎, 須並 英二, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • 下部進行直腸癌に対する化学放射線療法後のTNMstageによる評価と予後  [通常講演]
    川合 一茂, 須並 英二, 石原 聡一郎, 山口 博紀, 松田 圭二, 野澤 慶次郎, 橋口 陽二郎, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • 直腸癌術前化学放射線療法の効果判定におけるPET/CT検査の有用性の検討  [通常講演]
    田中 潤一郎, 米山 さとみ, 田中 敏明, 清松 知充, 川合 一茂, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • 胃癌腹膜播種の成立における腹腔内遊離間葉系幹細胞の役割とその臨床的意義  [通常講演]
    北山 丈二, 江本 成伸, 山口 博紀, 石神 浩徳, 山下 裕玄, 瀬戸 泰之, 松崎 圭祐, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • 大腸癌におけるNotch3蛋白発現と臨床病理学的因子の検討  [通常講演]
    小澤 毅士, 風間 伸介, 秋吉 高志, 米山 さとみ, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • StageIV大腸癌に対する切除の適応と限界 切除不能遠隔転移を伴う大腸癌に対する原発巣切除とリンパ節郭清の意義 propensity score matching法による多施設データの解析  [通常講演]
    石原 聡一郎, 米山 さとみ, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 金沢 孝満, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明, 杉原 健一
    日本外科学会雑誌 2014年03月
  • 進行胃癌に対する集学的治療 外科治療の位置づけ P1胃癌に対するパクリタキセルによる腹腔内化学療法の第2相臨床試験  [通常講演]
    山口 博紀, 北山 丈二, 石神 浩徳, 江本 成伸, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • 進行胃癌に対する集学的治療 外科治療の位置づけ 腹膜播種陽性胃癌に対する新規集学的治療戦略  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • 直腸癌に対する治療戦略 局所進行直腸癌に対する術前化学放射線療法に関する検討  [通常講演]
    須並 英二, 川合 一茂, 清松 知充, 風間 伸介, 野澤 宏彰, 金沢 孝満, 田中 潤一郎, 田中 敏明, 米山 さとみ, 室野 浩司, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本外科学会雑誌 2014年03月
  • 腹水濾過濃縮再静注法(CART)の新たな展開 胃癌癌性腹膜炎に対する集学的治療 CARTと腹腔内化学療法を併用した積極的治療  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本アフェレシス学会雑誌 2013年11月
  • 鏡視下直腸癌手術における中直腸動脈処理の術前シミュレーションとロボット手術における視認性  [通常講演]
    清松 知充, 須並 英二, 田中 敏明, 田中 潤一郎, 川合 一茂, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本内視鏡外科学会雑誌 2013年11月
  • 直腸癌に対するロボット手術の術後短期成績の検討  [通常講演]
    渡邉 聡明, 清松 知充, 川合 一茂, 風間 伸介, 金沢 孝満, 野澤 宏彰, 田中 潤一郎, 田中 敏明, 山口 博紀, 石原 聡一郎, 須並 英二
    日本内視鏡外科学会雑誌 2013年11月
  • キレート配位子修飾ヒアルロン酸in situ架橋ゲルを用いたシスプラチン送達システムの開発  [通常講演]
    平本 翔大, 太田 誠一, 江本 成伸, 山口 博紀, 石神 浩徳, 北山 丈二, 伊藤 大知
    日本バイオマテリアル学会大会予稿集 2013年11月
  • 直腸癌に対するロボット手術の導入  [通常講演]
    清松 知充, 石原 聡一郎, 川合 一茂, 山口 博紀, 須並 英二, 渡邉 聡明
    日本手術医学会誌 2013年10月
  • 白金製剤を用いた腹腔内化学療法におけるドラッグデリバリーシステムの工夫(Intraperitoneal chemotherapy for peritoneal carcinomatosis using platinum-containing drugs)  [通常講演]
    江本 成伸, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本癌学会総会記事 2013年10月
  • パクリタキセル内包ナノミセルの腹腔内化学療法への応用(Application of micellar nanoparticle paclitaxel drugs for intraperitoneal chemotherapy)  [通常講演]
    山口 博紀, 江本 成伸, 北山 丈二, 渡邉 聡明
    日本癌学会総会記事 2013年10月
  • 腹膜播種成立における腹腔内線維細胞(Intraperitoneal fibrocytes)の役割(Role of peritoneal fibrocytes on the development of peritoneal metastasis)  [通常講演]
    北山 丈二, 江本 成伸, 山口 博紀, 石神 浩徳, 山下 裕玄, 瀬戸 泰之, 渡邉 聡明
    日本癌学会総会記事 2013年10月
  • 直腸癌術前化学放射線療法の効果判定におけるPET/CT検査の有用性  [通常講演]
    田中 潤一郎, 米山 さとみ, 田中 敏明, 清松 知充, 川合 一茂, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • 大腸癌腹膜播種症例の治療成績  [通常講演]
    須並 英二, 室野 浩司, 野澤 宏彰, 風間 伸介, 金沢 孝満, 川合 一茂, 清松 知充, 田中 潤一郎, 田中 敏明, 米山 さとみ, 山口 博紀, 石原 聡一郎, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • Trocar配置と挿入のコツ ロボット支援下直腸癌手術におけるトロッカー配置の工夫  [通常講演]
    清松 知充, 須並 英二, 田中 敏明, 田中 潤一郎, 川合 一茂, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 石原 聡一郎, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • ロボット支援手術の手術手技 直腸癌に対するロボット手術の術後短期成績の検討  [通常講演]
    渡邉 聡明, 清松 知充, 川合 一茂, 風間 伸介, 金沢 孝満, 野澤 宏彰, 田中 潤一郎, 田中 敏明, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二
    日本臨床外科学会雑誌 2013年10月
  • 下部進行直腸癌の治療戦略 下部進行直腸癌に対する化学放射線療法の効果と予後の相関  [通常講演]
    川合 一茂, 須並 英二, 石原 聡一郎, 山口 博紀, 松田 圭二, 野澤 慶次郎, 橋口 陽二郎, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • 腹膜播種の治療戦略(胃) 腹膜播種を伴う胃癌に対する集学的治療戦略  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • IBDの治療戦略 当科における潰瘍性大腸炎合併癌の治療とその成績  [通常講演]
    小澤 毅士, 風間 伸介, 岸川 純子, 米山 さとみ, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • Stage IV臓器癌に対する治療戦略(大腸) Stage IV大腸癌の治療成績 多施設研究の結果から  [通常講演]
    石原 聡一郎, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 須並 英二, 北山 丈二, 橋口 陽二郎, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • 大腸癌イレウスに対する治療戦略 当科における大腸癌イレウスに対する経肛門減圧術(経肛門イレウス管v.s.ステント留置術)  [通常講演]
    田中 敏明, 吉田 俊太郎, 米山 さとみ, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 金沢 孝満, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • 再発癌の治療戦略(乳腺、食道、胃) 胃癌腹膜再発に対する腹腔内投与併用化学療法  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • 高齢者に対する癌治療方針(大腸) 高齢者大腸癌における腹腔鏡手術  [通常講演]
    金沢 孝満, 田中 敏明, 米山 さとみ, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 風間 伸介, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2013年10月
  • 腹膜播種患者における腹腔内遊離癌細胞定量法の確立とバイオマーカーとしての意義  [通常講演]
    北山 丈二, 江本 成伸, 山口 博紀, 石神 浩徳, 亀井 隆雄, 松崎 圭祐, 山下 祐玄, 瀬戸 泰之, 渡邉 聡明
    日本癌治療学会誌 2013年09月
  • 肉眼的腹膜播種陽性胃癌に対するパクリタキセル腹腔内投与 第II相臨床試験  [通常講演]
    山口 博紀, 北山 丈二, 石神 浩徳, 江本 成伸, 渡邉 聡明
    日本癌治療学会誌 2013年09月
  • 腹膜播種陽性または腹腔洗浄細胞診陽性胃癌におけるHER2発現  [通常講演]
    江本 成伸, 石神 浩徳, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本癌治療学会誌 2013年09月
  • 胃がん治療の最前線 胃がんの集学的治療 腹膜播種陽性胃がんに対する集学的治療  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本癌治療学会誌 2013年09月
  • 大腸がん治療の最前線 進行・再発大腸がんの治療戦略 局所進行直腸癌に対する術前化学放射線療法の治療効果に関する検討  [通常講演]
    須並 英二, 石原 聡一郎, 川合 一茂, 室野 浩司, 金沢 孝満, 風間 伸介, 野澤 宏明, 清松 知充, 田中 潤一郎, 田中 敏明, 米山 聡美, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本癌治療学会誌 2013年09月
  • 消化器癌腹膜播種の病態解明と新治療戦略 腹腔内化学療法効果発現の理論的根拠とこれに基づいた新規薬剤の開発  [通常講演]
    山口 博紀, 北山 丈二, 渡邉 聡明
    日本消化器病学会雑誌 2013年09月
  • 腹膜播種治療のためのヒアルロン酸ナノゲルの開発  [通常講演]
    太田 誠一, 平本 翔大, 江本 成伸, 山口 博紀, 石神 浩徳, 北山 丈二, 伊藤 大知
    人工臓器 2013年09月
  • 虫垂癌リンパ節郭清術後、創部腹壁転移の一例  [通常講演]
    山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2013年09月
  • colon castを伴った虚血性腸炎の一例  [通常講演]
    阿部 真也, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2013年09月
  • 尿管S状結腸吻合後長期経過中に発症した両側吻合部S状結腸癌の一例  [通常講演]
    柴田 淳一, 川合 一茂, 田中 敏明, 風間 伸介, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2013年09月
  • 当院における大腸カルチノイド外科的切除症例の検討  [通常講演]
    金子 建介, 川合 一茂, 田中 敏明, 米山 さとみ, 田中 潤一郎, 清松 知充, 野澤 宏彰, 風間 伸介, 金沢 孝満, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2013年09月
  • 大腸癌腹膜播種再発における腹腔洗浄液中CEA-mRNA定量の意義  [通常講演]
    室野 浩司, 風間 伸介, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 野澤 宏彰, 金沢 孝満, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2013年09月
  • 超高齢者大腸癌の治療の選択 高齢者大腸癌に対する腹腔鏡手術  [通常講演]
    金沢 孝満, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 風間 伸介, 野澤 宏彰, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明
    日本大腸肛門病学会雑誌 2013年09月
  • Flowcytometryを用いた腹腔内遊離癌細胞(Floating Tumor Cell;FTC)定量法の開発と臨床的意義  [通常講演]
    北山 丈二, 江本 成伸, 山口 博紀, 石神 浩徳, 亀井 隆雄, 渡邉 聡明
    日本消化器外科学会総会 2013年07月
  • 腹膜播種陽性胃癌に対するPaclitaxel腹腔内投与併用療法の有用性を検証する第III相試験(PHOENIX-GC試験)  [通常講演]
    會澤 雅樹, 石神 浩徳, 藤原 義之, 梨本 篤, 藪崎 裕, 福島 亮治, 小寺 泰弘, 山口 博紀, 北山 丈二
    日本消化器外科学会総会 2013年07月
  • 動脈相CTによる左側結腸の腸間膜動脈分岐走行の検討  [通常講演]
    室野 浩司, 川合 一茂, 清松 知充, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 須並 英二, 北山 丈二, 渡邊 聡明
    日本消化器外科学会総会 2013年07月
  • 胃癌腹膜播種症例における手術適応判定 腹腔洗浄液中CEA mRNA定量値は腹腔内化学療法の制御性を反映する  [通常講演]
    山口 博紀, 石神 浩徳, 江本 成伸, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2013年07月
  • 腹膜播種陽性胃癌における腹腔洗浄細胞診の臨床的意義  [通常講演]
    江本 成伸, 石神 浩徳, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本消化器外科学会総会 2013年07月
  • 高度進行胃癌に対する新たな治療戦略 術前化学療法と手術のタイミング、治療成績からみた検討 腹膜播種陽性胃癌に対する集学的治療戦略 S-1+Paclitaxel経静脈・腹腔内併用療法+胃切除  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本消化器外科学会総会 2013年07月
  • 大腸癌肝転移における脂肪肝との負の相関について  [通常講演]
    室野 浩司, 北山 丈二, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 須並 英二, 渡邉 聡明
    成人病と生活習慣病 2013年05月
  • 胃癌腹膜播種に対するナノ粒子化パクリタキセルの腹腔内投与  [通常講演]
    江本 成伸, 山口 博紀, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本外科学会雑誌 2013年03月
  • 腹膜播種を標的とした胃癌術前化学療法の展望  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本外科学会雑誌 2013年03月
  • 動脈相3D-CT angiographyによる腸間膜動脈分岐走行の検討  [通常講演]
    室野 浩司, 川合 一茂, 風間 伸介, 田中 敏明, 田中 潤一郎, 清松 知充, 金沢 孝満, 野澤 宏彰, 山口 博紀, 須並 英二, 北山 丈二, 渡邉 聡明
    日本外科学会雑誌 2013年03月
  • 胃癌腹膜播種に関する新たな知見と治療への応用 腹膜播種陽性胃癌に対する腹腔内投与併用化学療法の有用性を検証する第III相試験(PHOENIX-GC試験)  [通常講演]
    大橋 紀文, 石神 浩徳, 小寺 泰弘, 福島 亮治, 梨本 篤, 藪崎 裕, 今本 治彦, 今野 元博, 藤原 義之, 上之園 芳一, 山口 拓洋, 山口 博紀, 北山 丈二
    日本外科学会雑誌 2013年03月
  • 胃癌腹膜播種に関する新たな知見と治療への応用 胃癌腹膜播種に対する腹腔内投与併用療法 集学的治療の確立を目指して  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本外科学会雑誌 2013年03月
  • 胃癌腹膜播種に関する新たな知見と治療への応用 胃癌腹膜播種に対する腹腔内化学療法の効果予測と手術適応判定における腹腔洗浄液中CEA mRNA定量の有用性  [通常講演]
    山口 博紀, 江本 成伸, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本外科学会雑誌 2013年03月
  • 胃癌腹膜播種患者におけるFlowcytometryを用いた腹腔内遊離癌細胞定量の試み  [通常講演]
    北山 丈二, 江本 成伸, 山口 博紀, 石神 浩徳, 亀井 隆雄
    日本胃癌学会総会記事 2013年02月
  • 胃癌診療における審査腹腔鏡の実際 腹膜播種陽性胃癌症例における審査腹腔鏡  [通常講演]
    江本 成伸, 石神 浩徳, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本胃癌学会総会記事 2013年02月
  • 胃癌腹膜播種症例に対する治療戦略(CART治療の現状と問題点も含めて) 癌性腹水を伴う胃癌腹膜播種症例に対するS-1+Paclitaxel静脈内・腹腔内併用療法の臨床成績  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 江本 成伸, 花房 規男
    日本胃癌学会総会記事 2013年02月
  • 切除不能症例に対するConversion Therapy 化学療法後外科治療の適応と治療成績 腹膜転移を伴う胃癌に対するConversion surgery  [通常講演]
    石神 浩徳, 山口 博紀, 江本 成伸, 北山 丈二
    日本胃癌学会総会記事 2013年02月
  • 胃癌診療における新規バイオマーカー 腹腔内化学療法における腹腔洗浄液中CEA mRNA定量の意義  [通常講演]
    山口 博紀, 江本 成伸, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本胃癌学会総会記事 2013年02月
  • 腹膜播種を伴う胃癌に対する腹腔内投与併用化学療法の有用性を検証する第III相試験(PHOENIX-GC試験)  [通常講演]
    高張 大亮, 石神 浩徳, 福島 亮治, 梨本 篤, 藪崎 裕, 小寺 泰弘, 伊藤 誠二, 今本 治彦, 今野 元博, 藤原 義之, 田中 淳二, 上之園 芳一, 山口 拓洋, 山口 博紀, 北山 丈二
    日本消化器病学会雑誌 2013年02月
  • 大腸癌肝転移における脂肪肝との負の相関について  [通常講演]
    室野 浩司, 北山 丈二, 田中 敏明, 田中 潤一郎, 清松 知充, 川合 一茂, 風間 伸介, 金沢 孝満, 野澤 宏彰, 山口 博紀, 須並 英二, 渡邉 聡明
    日本成人病(生活習慣病)学会会誌 2013年01月
  • 腹膜播種に対するシスプラチン担持in situ架橋ゲルを用いた腹腔内化学療法  [通常講演]
    江本 成伸, 山口 博紀, 亀井 隆雄, 須原 宜史, 鈴木 幸光, 伊藤 大知, 石神 浩徳, 北山 丈二, 渡邉 聡明
    日本癌治療学会誌 2012年10月
  • 胃癌腹膜播種の手術適応判定における腹腔洗浄液中CEA mRNA定量の有用性  [通常講演]
    山口 博紀, 北山 丈二, 江本 成伸, 石神 浩徳, 渡邉 聡明
    日本癌治療学会誌 2012年10月
  • 癌性腹水を伴う進行膵癌に対するS-1+Paclitaxel経静脈・腹腔内併用療法  [通常講演]
    高原 楠昊, 伊佐山 浩通, 中井 陽介, 佐々木 隆, 石神 浩徳, 山口 博紀, 毛利 大, 木暮 宏史, 山本 夏代, 笹平 直樹, 平野 賢二, 多田 稔, 北山 丈二, 渡邉 聡明, 小池 和彦
    日本癌治療学会誌 2012年10月
  • 腹膜播種を伴う胃癌に対する腹腔内投与併用化学療法の有用性を検証する第III相試験  [通常講演]
    川崎 普司, 石神 浩徳, 福島 亮治, 小寺 泰弘, 今本 治彦, 今野 元博, 梨本 篤, 藪崎 裕, 上之園 芳一, 天貝 賢二, 田中 淳二, 藤原 義之, 山口 拓洋, 山口 博紀, 北山 丈二
    日本癌治療学会誌 2012年10月
  • 腹膜播種陽性胃癌に対する腹腔内投与併用療法 新規集学的治療体系の確立を目指して  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本癌治療学会誌 2012年10月
  • 腹腔内化学療法を含む集学的治療により5年生存が得られた胃癌腹膜播種の1例  [通常講演]
    江本 成伸, 石神 浩徳, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2012年10月
  • 腹膜播種陽性胃癌に対するパクリタキセル腹腔内投与併用化学療法の有用性を検証する第III相試験(PHOENIX-GC試験)  [通常講演]
    廣野 靖夫, 石神 浩徳, 小寺 泰弘, 福島 亮治, 今本 治彦, 今野 元博, 梨本 篤, 薮崎 裕, 上之園 芳一, 川崎 普司, 藤原 義之, 伊藤 誠二, 山口 博紀, 北山 丈二
    日本臨床外科学会雑誌 2012年10月
  • パクリタキセル腹腔内投与併用化学療法の肉眼的腹膜播種陽性胃癌に対する高度医療制度下第2相臨床試験  [通常講演]
    山口 博紀, 石神 浩徳, 江本 成伸, 北山 丈二, 渡邉 聡明
    日本臨床外科学会雑誌 2012年10月
  • 腹膜播種陽性胃癌に対する集学的治療戦略  [通常講演]
    石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明
    日本臨床外科学会雑誌 2012年10月
  • 胃癌腹膜播種症例に対する緩和処置としてのCART(Cell-free and Concentrated Ascites Reinfusion Therapy)と消化管ステントの有用性  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 江本 成伸, 花房 規男, 伊佐山 浩通, 佐々木 隆, 渡邉 聡明
    日本臨床外科学会雑誌 2012年10月
  • Stage IV胃癌に対する化学療法と手術の役割 胃癌腹膜播種に対する腹腔内化学療法後の手術適応の判定における腹腔洗浄液中CEA mRNA定量の意義  [通常講演]
    山口 博紀, 北山 丈二, 渡邉 聡明
    日本消化器病学会雑誌 2012年09月
  • ナノミセル化パクリタキセルの腹腔内投与の腹膜播種への抗腫瘍効果と薬物動態(Antitumor effect and pharmacokinetics of intraperitoneal nanomicellar paditaxel for peritoneal metastasis)  [通常講演]
    江本 成伸, 山口 博紀, 北山 丈二, 渡邉 聡明
    日本癌学会総会記事 2012年08月
  • ナノミセル化パクリタキセルを用いた癌性腹膜炎に対する腹腔内化学療法(Intraperitoneal chemotherapy with micellar nanoparticle paclitaxel for treating peritoneal carcinomatosis)  [通常講演]
    山口 博紀, 北山 丈二, 江本 成伸, 渡邉 聡明
    日本癌学会総会記事 2012年08月
  • 胃癌における術前、術後補助化学療法の位置づけ 漿膜浸潤陽性胃癌に対する術後アジュバントとしてのPaclitaxel腹腔内投与の可能性  [通常講演]
    北山 丈二, 石神 浩徳, 山口 博紀, 山下 裕玄, 江本 成伸
    日本消化器外科学会総会 2012年07月
  • 進行再発胃癌に対する治療戦略 腹膜播種を伴う胃癌に対する集学的治療戦略  [通常講演]
    石神 浩徳, 山口 博紀, 山下 裕玄, 江本 成伸, 北山 丈二
    日本消化器外科学会総会 2012年07月
  • 腹腔内化学療法の理論的根拠とこれに基づいた新規薬剤の開発  [通常講演]
    山口 博紀, 北山 丈二, 江本 成伸, 山下 裕玄, 石神 浩徳, 渡邉 聡明
    日本消化器外科学会総会 2012年07月
  • 胃癌腹膜播種による消化管狭窄に対する消化管ステントの有用性  [通常講演]
    江本 成伸, 北山 丈二, 石神 浩徳, 伊佐山 浩通, 佐々木 隆, 中井 陽介, 小池 和彦, 山下 裕玄, 山口 博紀, 渡邉 聡明
    日本消化器外科学会総会 2012年07月
  • ラット胎児造血器に対する電磁波の全身ばく露による影響について  [通常講演]
    室野 浩司, 佐々木 和人, 山口 博紀, 山下 裕玄, 王 建青, 上野 照剛, 名川 弘一, 北山 丈二
    日本生体磁気学会誌 2012年06月
  • 付属器切除により腹水コントロールしえた腹膜播種陽性の胃癌原発転移性卵巣腫瘍の1例  [通常講演]
    桐谷 翔, 山下 裕玄, 松崎 裕幸, 白須 拓郎, 森 健, 山口 博紀, 石神 浩徳, 北山 丈二
    日本臨床外科学会雑誌 2012年03月
  • パクリタキセル腹腔内投与の基礎研究と臨床応用 胃癌腹膜播種克服に向けて  [通常講演]
    山口 博紀, 江本 成伸, 山下 裕玄, 石神 浩徳, 北山 丈二
    日本外科学会雑誌 2012年03月
  • 胃癌腹膜播種に対するナノミセル化抗癌剤NK105の腹腔内投与による治療効果  [通常講演]
    江本 成伸, 山口 博紀, 石神 浩徳, 山下 裕玄, 北山 丈二
    日本外科学会雑誌 2012年03月
  • Stage IV胃癌に対する集学的治療 腹膜播種陽性胃癌に対する集学的治療  [通常講演]
    石神 浩徳, 山口 博紀, 山下 裕玄, 江本 成伸, 北山 丈二
    日本外科学会雑誌 2012年03月
  • 胃癌腹膜播種腹腔洗浄液中CEA mRNA定量値と細胞診の比較検討 腹膜播種の早期診断に向けて  [通常講演]
    山口 博紀, 江本 成伸, 山下 裕玄, 石神 浩徳, 北山 丈二
    日本胃癌学会総会記事 2012年02月
  • 胃癌治療におけるCART(cell-free and concentrated ascites reinfusion therapy) 当院における腹水濾過濃縮再静注法の現状  [通常講演]
    伊藤 哲也, 花房 規男, 岩瀬 哲, 野入 英世, 江本 成伸, 山下 裕玄, 畑尾 史彦, 山口 博紀, 石神 浩徳, 和田 郁雄, 清水 伸幸, 藤田 敏郎, 瀬戸 泰之, 北山 丈二, 宮川 清
    日本胃癌学会総会記事 2012年02月
  • 化学療法著効例に対する外科切除の意義(手術は必要か・いつ手術するか・どこまで切除するか) 腹腔内化学療法が奏効した腹膜播種陽性胃癌症例に対する外科切除  [通常講演]
    石神 浩徳, 甲斐崎 祥一, 山口 博紀, 山下 裕玄, 江本 成伸, 北山 丈二
    日本胃癌学会総会記事 2012年02月
  • 胃癌に対する化学療法の新展開 腹膜播種陽性胃癌に対する高度医療「パクリタキセル腹腔内投与併用療法」  [通常講演]
    石神 浩徳, 甲斐崎 祥一, 山口 博紀, 山下 裕玄, 江本 茂伸, 北山 丈二
    日本臨床外科学会雑誌 2011年10月
  • 腹膜播種と卵巣転移を伴う胃癌症例24例の検討  [通常講演]
    江本 成伸, 石神 浩徳, 山下 裕玄, 山口 博紀, 甲斐崎 祥一, 北山 丈二
    日本癌治療学会誌 2011年09月
  • 胃1 胃癌腹膜播種症例の腹腔洗浄細胞診と腹腔洗浄液中CEA mRNA定量値の比較検討  [通常講演]
    山口 博紀, 江本 成伸, 山下 裕玄, 石神 浩徳, 甲斐崎 祥一, 北山 丈二
    日本癌治療学会誌 2011年09月
  • 腹膜播種を伴う胃癌に対する高度医療「パクリタキセル腹腔内投与併用療法」  [通常講演]
    石神 浩徳, 甲斐崎 祥一, 山口 博紀, 山下 裕玄, 江本 成伸, 北山 丈二
    日本癌治療学会誌 2011年09月
  • ナノ粒子化パクリタキセルによる胃癌腹膜播種に対する腹腔内化学療法(Intraperitoneal chemotherapy with nanoparticulate paclitaxel for treating the peritoneal dissemination of gastric)  [通常講演]
    山口 博紀, 江本 成伸, 山下 裕玄, 石神 浩徳, 甲斐崎 祥一, 金野 智浩, 石原 一彦, 北山 丈二
    日本癌学会総会記事 2011年09月
  • 胃癌腹膜播種に対するナノミセル化抗癌剤NK105の腹腔内投与による治療効果  [通常講演]
    江本 成伸, 山口 博紀, 石神 浩徳, 山下 裕玄, 甲斐崎 祥一, 北山 丈二
    日本消化器外科学会総会 2011年07月
  • 腹膜播種陽性胃癌患者におけるフィブリノゲン値の予後予測因子としての有用性  [通常講演]
    山下 裕玄, 石神 浩徳, 山口 博紀, 江本 成伸, 甲斐崎 祥一, 北山 丈二
    日本消化器外科学会総会 2011年07月
  • 胃癌腹膜播種症例の腹水・腹腔洗浄液における細胞診とCEA mRNA定量値の比較 CY0とCY1の境界はどこか  [通常講演]
    山口 博紀, 江本 成伸, 山下 裕玄, 石神 浩徳, 甲斐崎 祥一, 北山 丈二
    日本消化器外科学会総会 2011年07月
  • 高度進行胃癌に対する術前補助化学療法(NAC)の意義 胃癌腹膜播種の完全制御を目指した腹腔内化学療法  [通常講演]
    石神 浩徳, 北山 丈二, 甲斐崎 祥一, 山口 博紀, 山下 裕玄, 江本 成伸, 國土 典宏
    日本消化器外科学会総会 2011年07月
  • 食道癌術後再建胃管の潰瘍穿通による胃管心嚢瘻の一例  [通常講演]
    中村 亜希, 山口 博紀, 江本 成伸, 山下 裕玄, 石神 浩徳, 甲斐崎 祥一, 北山 丈二
    日本臨床外科学会雑誌 2011年06月
  • 腹腔内化学療法と手術療法により長期生存が得られている胃癌腹膜播種の一症例  [通常講演]
    宮原 和洋, 山口 博紀, 江本 成伸, 石神 浩徳, 須並 英二, 甲斐崎 祥一, 北山 丈二, 名川 弘一
    日本臨床外科学会雑誌 2011年05月
  • 胃癌腹膜播種に対する腹腔内化学療法における腹腔ポート関連合併症に関する検討  [通常講演]
    江本 成伸, 石神 浩徳, 山口 博紀, 山下 裕玄, 甲斐崎 祥一, 北山 丈二, 名川 弘一
    日本外科学会雑誌 2011年05月
  • 大腸癌における腹水洗浄液中CEA-mRNA定量の試み  [通常講演]
    室野 浩司, 風間 伸介, 川合 一茂, 山口 博紀, 森 健, 谷澤 健太郎, 金沢 孝満, 斎藤 晋祐, 須並 英二, 北山 丈二, 名川 弘一
    日本外科学会雑誌 2011年05月
  • 腹膜播種陽性胃癌において炎症性マーカーは予後予測因子となりうるか?  [通常講演]
    山下 裕玄, 石神 浩徳, 山口 博紀, 江本 成伸, 甲斐崎 祥一, 北山 丈二, 名川 弘一
    日本外科学会雑誌 2011年05月
  • StageIV胃癌に対する外科治療の現状と方向性 胃癌腹膜播種に対する腹腔内化学療法と胃切除による集学的治療  [通常講演]
    山口 博紀, 北山 丈二, 江本 成伸, 山下 裕玄, 石神 浩徳, 甲斐崎 祥一, 名川 弘一
    日本外科学会雑誌 2011年05月
  • International consensus of the treatment strategy for peritoneal malignancy 胃癌腹膜播種に対する集学的治療(International consensus of the treatment strategy for peritoneal malignancy A novel multidisciplinary treatment strategy for gastric cancer with peritoneal metasta  [通常講演]
    石神 浩徳, 北山 丈二, 甲斐崎 祥一, 山口 博紀, 山下 裕玄, 江本 成伸, 名川 弘一
    日本外科学会雑誌 2011年05月
  • 腹膜播種陽性胃癌における腫瘍マーカーの臨床的意義の検討  [通常講演]
    江本 成伸, 石神 浩徳, 山下 裕玄, 山口 博紀, 甲斐崎 祥一, 北山 丈二, 名川 弘一
    日本胃癌学会総会記事 2011年03月
  • stageIV胃癌の集学的治療 腹膜播種を伴う胃癌に対する集学的治療  [通常講演]
    石神 浩徳, 北山 丈二, 甲斐崎 祥一, 山口 博紀, 山下 裕玄, 江本 成伸, 名川 弘一
    日本胃癌学会総会記事 2011年03月
  • 外科医が行う胃癌化学療法 胃癌腹膜播種に対するパクリタキセル腹腔内投与併用療法  [通常講演]
    石神 浩徳, 北山 丈二, 甲斐崎 祥一, 山口 博紀, 山下 裕玄, 江本 成伸, 國土 典宏, 名川 弘一
    日本臨床外科学会雑誌 2010年10月
  • 腹膜播種陽性胃癌に対して化学療法施行中に髄膜播種を発症した4例  [通常講演]
    江本 成伸, 石神 浩徳, 山口 博紀, 甲斐崎 祥一, 北山 丈二, 名川 弘一
    日本癌治療学会誌 2010年09月
  • 胃癌腹膜播種に対する新しい治療戦略 ナノ粒子化抗癌剤による腹腔内化学療法  [通常講演]
    山口 博紀, 北山 丈二, 石神 浩徳, 江本 成伸, 甲斐崎 祥一, 金野 智浩, 石原 一彦, 名川 弘一
    日本癌治療学会誌 2010年09月
  • 腹膜転移陽性胃がんの治療戦略 胃癌腹膜播種に対する腹腔内化学療法  [通常講演]
    石神 浩徳, 北山 丈二, 甲斐崎 祥一, 山口 博紀, 山下 裕玄, 江本 成伸, 國土 典宏, 名川 弘一
    日本癌治療学会誌 2010年09月
  • 進行胃がんに対する集学的治療の展望 腹膜播種を伴う胃癌に対する集学的治療  [通常講演]
    石神 浩徳, 北山 丈二, 甲斐崎 祥一, 山口 博紀, 山下 裕玄, 江本 成伸, 國土 典宏, 名川 弘一
    日本癌治療学会誌 2010年09月
  • ドラッグデリバリーシステム、その他 消化器がん腹膜播種に対する経静脈・腹腔内ルートを併用したbidirectional Chemotherapyの有用性(Drug delivery system, others Bidirectional chemotherapy using intraperitoneal approach for peritoneal dissemination of gastrointestinal cancer)  [通常講演]
    北山 丈二, 山口 博紀, 亀井 隆雄, 相馬 大介, 金野 智浩, 石原 一彦, 石神 浩則, 甲斐崎 祥一, 名川 弘一
    日本癌学会総会記事 2010年08月
  • 胃癌腹膜播種に対する新しい治療戦略 ナノ粒子化パクリタキセルによる腹腔内化学療法(Novel strategy for treating the peritoneal metastasis: intraperitoneal chemotherapy with nanoparticulate paclitaxel)  [通常講演]
    山口 博紀, 北山 丈二, 石神 浩徳, 江本 成伸, 甲斐崎 祥一, 金野 智浩, 石原 一彦, 名川 弘一
    日本癌学会総会記事 2010年08月
  • 胃癌組織内細動脈周囲の交感神経線維の消失は生物学的悪性度と相関する(Loss of sympathetic nerve fibers around intratumoral arterioles reflects the malignant potential of gastric cancer)  [通常講演]
    宮戸 秀世, 北山 丈二, 山口 博紀, 石神 浩徳, 甲斐崎 祥一, 名川 弘一
    日本癌学会総会記事 2010年08月
  • 腹腔洗浄液中CEA mRNA定量による胃癌腹膜播種病変のモニタリングと評価  [通常講演]
    山口 博紀, 北山 丈二, 亀井 隆雄, 大谷 研介, 加藤 昌弘, 石神 浩徳, 甲斐崎 祥一, 名川 弘一
    日本消化器外科学会総会 2010年07月
  • 高度進行胃癌に対する外科治療の有用性 腹膜播種を伴う胃癌に対する腹腔内化学療法奏効後胃切除  [通常講演]
    石神 浩徳, 北山 丈二, 甲斐崎 祥一, 加藤 昌弘, 山口 博紀, 大谷 研介, 亀井 隆雄, 名川 弘一
    日本消化器外科学会総会 2010年07月
  • DDSの臨床展開 腹膜播種に対するナノミセル化抗癌剤腹腔内投与の有用性  [通常講演]
    北山 丈二, 山口 博紀, 相馬 大介, 亀井 隆雄, 石神 浩徳, 金野 智浩, 石原 一彦, 名川 弘一
    Drug Delivery System 2010年05月
  • 腹膜播種に対する集学的治療 腹膜播種を伴う胃癌に対するS-1/Paclitaxel経静脈・腹腔内併用療法+胃切除  [通常講演]
    石神 浩徳, 北山 丈二, 甲斐崎 祥一, 加藤 昌弘, 山口 博紀, 大谷 研介, 亀井 隆雄, 名川 弘一
    日本胃癌学会総会記事 2010年03月
  • 胃癌術後腹膜播種再発に対するpaclitaxelを用いた腹腔内化学療法  [通常講演]
    山口 博紀, 北山 丈二, 石神 浩徳, 大谷 研介, 亀井 隆雄, 加藤 昌弘, 甲斐崎 祥一, 名川 弘一
    日本胃癌学会総会記事 2010年03月
  • Stage IV胃癌における外科治療の有用性 腹膜播種を伴う胃癌に対する集学的治療 S-1+Paclitaxel経静脈・腹腔内併用療法+胃切除  [通常講演]
    石神 浩徳, 北山 丈二, 甲斐崎 祥一, 加藤 昌弘, 山口 博紀, 大谷 研介, 亀井 隆雄, 名川 弘一
    日本外科学会雑誌 2010年03月
  • 消化器癌腹膜転移の治療 基礎と臨床 胃癌腹膜播種に対する新しい治療戦略 ナノ粒子化抗癌剤による腹腔内化学療法  [通常講演]
    山口 博紀, 北山 丈二, 大谷 研介, 亀井 隆雄, 相馬 大介, 加藤 昌弘, 石神 浩徳, 甲斐崎 祥一, 金野 智浩, 石原 一彦, 名川 弘一
    日本外科学会雑誌 2010年03月
  • 胃癌組織におけるAdiponectin受容体発現の検討(Adiponectin Receptors are Down-regulated in Gastric Cancer)  [通常講演]
    大谷 研介, 北山 丈二, 亀井 隆雄, 相馬 大介, 宮戸 秀世, 石神 浩徳, 秀村 晃生, 加藤 昌弘, 山口 博紀, 甲斐崎 祥一, 名川 弘一
    日本癌学会総会記事 2009年08月
  • Hyperfibrinogenemiaは胃癌におけるリンパ節転移の危険因子である  [通常講演]
    山下 裕玄, 北山 丈二, 石川 誠, 朝蔭 正宏, 山田 純, 石神 浩徳, 山口 博紀, 井上 知巳, 甲斐崎 祥一, 名川 弘一
    日本消化器病学会雑誌 2005年09月
  • スフィンゴシン1-リン酸(S1P)の胃癌細胞における細胞運動に及ぼす影響  [通常講演]
    山下 裕玄, 北山 丈二, 志田 大, 山口 博紀, 森 健, 多久和 陽, 名川 弘一
    日本癌学会総会記事 2005年09月
  • 頭頸部癌と食道癌を含む多重癌症例の検討-内視鏡検査によるスクリーニングの重要性について  [通常講演]
    山口 博紀, 北山 丈二, 朝蔭 正宏, 山下 裕玄, 名川 弘一
    日本外科学会雑誌 2005年04月
  • 胃吻門部癌の臨床病理的検討  [通常講演]
    朝蔭 正宏, 北山 丈二, 甲斐崎 祥一, 井上 知巳, 山口 博紀, 中山 洋, 酒向 晃弘, 石川 誠, 山下 裕玄, 山田 純, 名川 弘一
    日本外科学会雑誌 2005年04月
  • 大腸癌におけるリゾホスファチジン酸(LPA)のシグナル伝達についての検討  [通常講演]
    志田 大, 北山 丈二, 山口 博紀, 山下 裕玄, 森 健, 渡邉 聡明, 名川 弘一
    日本外科学会雑誌 2005年04月
  • 生理活性脂質スフィンゴシン-1-リン酸(S1P)による受容体サブタイプ特異的な細胞遊走・浸潤の制御  [通常講演]
    多久和 典子, 有川 佳代, 山口 博紀, 杉本 直俊, 多久和 陽
    日本生理学雑誌 2005年01月
  • 手術にて救命しえた胸部大動脈食道瘻の一例  [通常講演]
    芹澤 多佳子, 中山 洋, 北山 丈二, 石神 浩徳, 山口 博紀, 井上 陽介, 北野 健太郎, 竹谷 剛, 柴田 講, 師田 哲郎, 高本 眞一, 名川 弘一
    日本臨床外科学会雑誌 2004年12月
  • 脾過誤腫の1例  [通常講演]
    高橋 道郎, 石丸 正寛, 増田 晃一, 小室 安宏, 山口 博紀, 鈴木 卓, 畑中 一仁, 植草 利公
    日本臨床外科学会雑誌 2004年09月
  • 胃癌切除後腹膜再発例の検討-長期生存の因子  [通常講演]
    石丸 正寛, 増田 晃一, 山口 博紀, 高橋 道郎, 小室 安宏, 鈴木 卓, 太田 秀樹, 植草 利公
    日本消化器病学会雑誌 2004年09月
  • 閉鎖孔ヘルニア8例の検討  [通常講演]
    増田 晃一, 石丸 正寛, 高橋 道郎, 上 奈津子, 山口 博紀, 鈴木 卓
    日本臨床外科学会雑誌 2004年09月
  • イレウス症状にて発症したAAアミロイドーシス  [通常講演]
    高橋 道郎, 石丸 正寛, 増田 晃一, 小室 安宏, 山口 博紀, 鈴木 卓
    日本臨床外科学会雑誌 2004年09月
  • 多発大腸癌の一症例  [通常講演]
    上 奈津子, 増田 晃一, 高橋 道郎, 山口 博紀, 鈴木 卓, 石丸 正寛
    日本臨床外科学会雑誌 2004年09月
  • リンパ節に10個以上転移を認める胃癌切除例の検討  [通常講演]
    石丸 正寛, 増田 晃一, 上 奈津子, 山口 博紀, 高橋 道郎, 鈴木 卓, 植草 利公
    日本臨床外科学会雑誌 2004年09月
  • リゾホスファチジン酸(LPA)は大腸癌細胞のepidermal growth factor受容体(EGFR)をリン酸化する  [通常講演]
    志田 大, 北山 丈二, 山口 博紀, 山下 裕玄, 森 健, 渡邉 聡明, 名川 弘一
    日本癌学会総会記事 2004年09月
  • 胃癌細胞株の増殖能に対するスフィンゴシン1-リン酸(S1P)の影響  [通常講演]
    山下 裕玄, 北山 丈二, 志田 大, 山口 博紀, 森 健, 名川 弘一
    日本消化器外科学会雑誌 2004年07月
  • 超高齢者胃癌手術症例の臨床成績からみた外科治療方針  [通常講演]
    山口 博紀, 増田 晃一, 高橋 道郎, 小室 安宏, 鈴木 卓, 石丸 正寛
    日本消化器外科学会雑誌 2004年07月
  • 当院における開腹既往のある腹腔鏡下胆嚢摘出術の検討  [通常講演]
    高橋 道郎, 鈴木 卓, 増田 晃一, 小室 安宏, 山口 博紀, 石丸 正寛
    日本外科系連合学会誌 2004年06月
  • 生理活性脂質スフィンゴシン1リン酸の肺転移抑制作用  [通常講演]
    山口 博紀, 北山 丈二, 志田 大, 山下 裕玄, 多久 和陽, 名川 弘一
    日本外科学会雑誌 2004年03月
  • 大腸癌の進展に及ぼすリゾホスファチジン酸(LPA)の作用についての総合的検討  [通常講演]
    志田 大, 北山 丈二, 山口 博紀, 山下 裕玄, 森 健, 渡邉 聡明, 名川 弘一
    日本外科学会雑誌 2004年03月
  • 胃se癌切除例の検討  [通常講演]
    石丸 正寛, 増田 晃一, 山内 治雄, 山口 博紀, 山形 達史, 田尻 道彦, 鈴木 卓, 杉浦 有重, 植草 利公
    日本臨床外科学会雑誌 2003年10月
  • 腹腔内出血,出血性ショックにて発症した巨大陳旧性脾内血腫の一例  [通常講演]
    増田 晃一, 杉浦 有重, 山内 治雄, 山口 博紀, 鈴木 卓, 山形 達史, 田尻 道彦, 石丸 正寛, 植草 利公
    日本臨床外科学会雑誌 2003年10月
  • 2mmミニポートを用いた低侵襲腹腔鏡下胆嚢摘出術の有効性について  [通常講演]
    山内 治雄, 石丸 正寛, 鈴木 卓, 田尻 道彦, 山形 達史, 山口 博紀, 増田 晃一, 杉浦 有重
    日本臨床外科学会雑誌 2003年10月
  • 腸管癒着が誘因と考えられたPTP(press through package)誤飲による小腸穿孔の一例  [通常講演]
    山口 博紀, 山下 裕玄, 山内 治雄, 増田 晃一, 鈴木 卓, 石丸 正寛, 杉浦 有重, 植草 利公
    日本臨床外科学会雑誌 2003年10月
  • 若年者(30歳代)胃癌症例の特徴  [通常講演]
    石丸 正寛, 山内 治雄, 増田 晃一, 山口 博紀, 鈴木 卓, 杉浦 有重, 太田 秀樹, 植草 利公
    日本消化器病学会雑誌 2003年09月
  • 急性腹症にて緊急手術を行った小腸GISTの1切除例  [通常講演]
    山下 裕玄, 石丸 正寛, 山口 博紀, 山内 治雄, 鈴木 卓, 杉浦 有重, 植草 利公, 北山 丈二, 渡邉 聡明, 名川 弘一
    日本消化器病学会雑誌 2003年09月
  • リゾホスファチジン酸(LPA)はLPA1受容体を介し大腸癌・胃癌細胞株の運動能を促進する  [通常講演]
    志田 大, 北山 丈二, 山口 博紀, 渡邉 聡明, 名川 弘一
    日本癌学会総会記事 2003年08月
  • 原発性肺癌に対する胸腔鏡下肺葉切除術のアプローチ別手術成績 手術侵襲と予後について  [通常講演]
    田尻 道彦, 松浦 仁, 山下 裕玄, 山内 治雄, 山口 博紀, 鈴木 卓, 石丸 正寛, 杉浦 有重, 中山 治彦
    日本外科学会雑誌 2003年04月
  • リゾホスファチジン酸(LPA)の大腸癌細胞株増殖促進作用  [通常講演]
    志田 大, 北山 丈二, 山口 博紀, 渡邉 聡明, 名川 弘一
    日本外科学会雑誌 2003年04月
  • 胃癌出血による緊急手術症例の検討  [通常講演]
    石丸 正寛, 山下 裕玄, 山内 治雄, 山口 博紀, 松浦 仁, 田尻 道彦, 鈴木 卓, 杉浦 有重, 植草 利公
    日本臨床外科学会雑誌 2002年10月
  • type 4胃癌との鑑別の困難であった肥厚性幽門狭窄症の1例  [通常講演]
    山下 裕玄, 石丸 正寛, 山口 博紀, 山内 治雄, 松浦 仁, 田尻 道彦, 鈴木 卓, 杉浦 有重, 植草 利公
    日本臨床外科学会雑誌 2002年10月
  • リゾホスファチジン酸(LPA)の胃癌細胞株(MKN74)増殖促進作用  [通常講演]
    志田 大, 北山 丈二, 山口 博紀, 渡邉 聡明, 名川 弘一
    日本癌学会総会記事 2002年10月
  • スフィンゴシン-1-リン酸(S1P)受容体Edgイソフォームによるマウス悪性黒色腫B16細胞の遊走とマトリゲル内浸潤の二方向性制御とその分子機構  [通常講演]
    有川 佳代, 多久和 典子, 山口 博紀, 竹原 和彦, 多久和 陽
    生化学 2002年08月
  • スフィンゴシン-1-リン酸(S1P)受容体Edg5はマウス悪性黒色腫B16細胞の遊走とマトリゲル内浸潤の抑制をメディエイトする  [通常講演]
    有川 佳代, 多久和 典子, 山口 博紀, 竹原 和彦, 多久和 陽
    日本研究皮膚科学会年次学術大会・総会プログラム 2002年08月
  • ヒト乳癌組織におけるケモカインレセプターCXCR4の発現  [通常講演]
    加藤 昌弘, 北山 丈二, 石川 誠, 酒向 晃弘, 秀村 晃生, 山口 博紀, 風間 伸介, 鈴木 宏幸, 甲斐崎 祥一, 名川 弘一
    日本外科学会雑誌 2002年03月
  • 脂質メディエータースフィンゴシン1リン酸によるB16メラノーマ肺転移及び走化性運動の抑制  [通常講演]
    山口 博紀, 北山 丈二, 名川 弘一, 多久和 典子, 多久和 陽
    日本癌学会総会記事 2001年09月
  • スフィンゴシン-1-リン酸(S1P)受容体EDG5はマウス悪性黒色腫B16細胞マトリゲル浸潤の抑制をメディエイトする  [通常講演]
    有川 佳代, 多久和 典子, 山口 博紀, 竹原 和彦, 多久和 陽
    生化学 2001年08月
  • 血行再建は成功したにも拘わらず足部切断を余儀なくされた糖尿病性腎不全のASOの1例  [通常講演]
    阿保 義久, 斎藤 琢治, 山口 博紀, 金沢 孝満, 石黒 達昌, 畠山 卓也, 宮田 哲郎, 安原 洋, 重松 宏, 武藤 徹一郎
    血管外科 1999年09月
  • アニサキスが原因と考えられたMeckel憩室炎による絞扼性イレウスの1例  [通常講演]
    山口 博紀, 櫻井 直彦, 黒木 尚, 後藤 振一郎, 仙波 大右, 蛇澤 晶
    日本臨床外科学会雑誌 1999年02月
  • 大腸癌を伴った丘疹-紅皮症(太藤)の1例  [通常講演]
    菊地 さやか, 小宮根 真弓, 神田 奈緒子, 菊池 かな子, 玉置 邦彦, 石黒 達昌, 山口 博紀, 正木 忠彦, 古宇田 信浩
    日本皮膚科学会雑誌 1999年02月
  • 胸腺原発Hodgkin病の1切除例  [通常講演]
    山口 博紀
    茨城県臨床医学雑誌 1997年08月
  • 穿孔性腹膜炎によって発症したCrohn病の1切除例 本邦報告例の文献的考察  [通常講演]
    山口 博紀
    日本臨床外科医学会雑誌 1997年06月
  • 小腸間膜より発生した巨大腹腔内デスモイド腫瘍の1例  [通常講演]
    山口 博紀
    日立医学会誌 1996年07月
  • 小腸間膜より発生した腹腔内巨大デスモイドの一例  [通常講演]
    山口 博紀
    日本消化器外科学会雑誌 1996年06月
  • 総胆管癌合併例2例を含む先天性胆管拡張症手術例5例の臨床病理学的検討  [通常講演]
    山口 博紀
    日本消化器外科学会雑誌 1995年02月
  • リンパ管腫症(胃・肝・脾・小腸間膜)の一例  [通常講演]
    山口 博紀
    日本臨床外科医学会雑誌 1994年12月

MISC

  • 【がん診療における心血管合併症:onco-cardiologyアップデート】内科で診る機会の多い腫瘍の化学療法と心血管合併症について知る 消化管癌の化学療法と心血管合併症
    山口 博紀 診断と治療 106 (8) 950 -956 2018年08月 [査読無し][通常論文]
     
    <Headline>1 食道癌では根治的化学放射線療法が行われるが、放射線照射の晩期毒性として心膜炎による心嚢水貯留や収縮性心膜炎があり、胸部へ放射線照射後の心不全症状発現時にはこれらを念頭におく必要がある。2 胃癌における化学療法では、トラスツズマブによる心機能低下はよく知られているが、新規薬剤である免疫チェックポイント阻害薬ニボルマブによる心筋炎の発生にも留意が必要である。3 大腸癌における化学療法では、血管新生阻害薬による心血管毒性として、高血圧症、動脈血栓塞栓症、静脈血栓塞栓症があり、静脈血栓塞栓症に引き続く肺血栓塞栓症を未然に防ぐことが重要である。(著者抄録)
  • 【最新版 "腸閉塞"を極める!】疾患別 診断と治療 胃癌腹膜播種による腸閉塞
    山口 博紀, 北山 丈二 臨床外科 73 (7) 826 -829 2018年07月 [査読無し][通常論文]
     
    <文献概要>ポイント ◆外科的治療に際しては,術前に狭窄部位を詳細に把握するよう努め,十分なインフォームド・コンセントのもとに手術適応を決定する◆内科的治療には減圧ドレナージチューブ留置,消化管ステント留置,オクトレオチド投与がある.◆経口摂取不能な胃癌腹膜播種症例に対する臨床試験が複数進行中である.
  • 【腹膜と腹水を究める-新しい考え方と治療法】腹膜播種に対する腹腔内化学療法の基礎と臨床
    山口 博紀, 石神 浩徳, 北山 丈二 外科 80 (6) 630 -634 2018年05月 [査読無し][通常論文]
     
    <文献概要>腹腔内に投与されたpaclitaxelは腹腔内に停留し,播種病変に直接浸透して抗腫瘍効果を発現する.胃癌腹膜播種に対し,S-1+paclitaxel静脈投与・腹腔内投与併用療法の第I相から第III相臨床試験を行い,安全性を確認し有望な治療成績を得た.膵癌腹膜播種においても臨床試験がすすめられている.今後は新規バイオマーカーにより腹腔内に遊離癌細胞の検出感度を高め,腹膜播種再発の予防を目的とした腹腔内化学療法を行いたい.
  • TRC法を用いた腹腔内洗浄液CEA mRNA定量検査の治療効果判定における有用性
    佐藤 優実子, 山口 博紀, 高井 大哉, 北山 丈二, 大久保 滋夫, 矢冨 裕 日本臨床検査自動化学会会誌 40 (5) 603 -609 2015年11月 [査読無し][通常論文]
     
    核酸増幅法のTRC法によるCEA mRNA定量検査の基礎的検討と、臨床的有用性を評価した。胃癌症例の腹腔内洗浄液から抽出したRNAの品質指標となるRNA Integrity Number(RIN値)は平均7.76であり、このRIN値と内部標準遺伝子(PBGD mRNA)発現量との間に相関は認めなかった。TRC法の性能評価では、希釈直線性はCEA mRNA、PBGD mRNAとも良好であった。同時再現性は陽性判定時間の変動係数:CVはCEA mRNAで0.8〜6.1%、PBGD mRNAで0.5〜3.2%であり、日差再現性のCVはそれぞれ6.9〜9.6%、2.9〜9.1%であった。TRC法とRT-PCR法との間に正の相関を認めた(r=0.937)。胃癌腹膜播種例の腹腔内洗浄液245検体中細胞診陽性が54検体で、そのCEA mRNA陽性率は88.9%であった。CEA mRNA陽性検体のROC曲線下のAUCは0.83で、カットオフ値をCEA mRNA発現量5400copiesとすると感度69%、特異度84%で細胞診陽性を予測できた。
  • 【腹膜悪性腫瘍】転移性腹膜腫瘍の治療 腹膜播種陽性胃癌に対する腹腔内化学療法
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明 外科 77 (10) 1148 -1152 2015年10月 [査読無し][通常論文]
     
    腹膜播種陽性胃癌に対して,全身化学療法に強力な局所療法である腹腔内化学療法と胃切除を付加した集学的治療は有望な治療法の一つである.当科ではS-1+paclitaxel(PTX)経静脈・腹腔内併用療法を考案し,第II相試験において生存期間中央値(MST)23.6ヵ月という成績を得た.また,初発例100例中64例に化学療法奏効後に胃切除を施行し,MST 30.5ヵ月という成績を得た.現在,本併用化学療法の有効性を検証するための第III相試験を実施中である.(著者抄録)
  • 【胃癌の診療】胃癌の治療 胃癌に対する腹腔内化学療法
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明 臨床消化器内科 30 (7) 899 -902 2015年05月 [査読無し][通常論文]
  • 【炎症性腸疾患-病態研究から標的治療への展開-】病態研究から標的治療へ 炎症性腸疾患のがんサーベイランスと炎症に由来する発がん機構解明
    安西 紘幸, 畑 啓介, 風間 伸介, 岸川 純子, 石井 博章, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明 最新医学 70 (2) 229 -235 2015年02月 [査読無し][通常論文]
     
    潰瘍性大腸炎とクローン病の長期罹患は大腸がんの危険因子と考えられており,dysplasiaをマーカーとしたサーベイランス内視鏡が推奨されている.近年,炎症に由来する発がん機構が解明されつつあり,また新しい内視鏡技術のサーベイランスへの応用も検討されている.本稿では炎症性腸疾患合併がんの疫学や特徴,炎症に由来する発がん機構,そしてサーベイランスについて概説する.(著者抄録)
  • 【直腸癌治療の最前線】直腸癌の低侵襲手術
    柴田 淳一, 石原 聡一郎, 西川 武司, 田中 敏明, 田中 潤一郎, 清松 知充, 畑 啓介, 川合 一茂, 野澤 宏彰, 金沢 孝満, 風間 伸介, 山口 博紀, 須並 英二, 渡邉 聡明 日本消化器病学会雑誌 111 (11) 2105 -2112 2014年11月 [査読無し][通常論文]
     
    結腸癌に対する腹腔鏡下手術は、創が小さく術後疼痛が軽減することや、腸蠕動の回復が良好で早期の経口摂取が可能となるなど従来の開腹手術に比べて侵襲が少ないとされる。一方、直腸癌に対しては、腫瘍が深く狭い骨盤腔内に存在しworking spaceが限られるため、直線的な鉗子操作のみで行われる腹腔鏡下手術では難易度が高いとされていたが、デバイスの進歩などとともに徐々に普及しつつある。また最近では、直腸癌領域においてロボット支援下手術が行われるようになってきており、3D視野効果や、多関節鉗子による自由度の高い操作性により、より繊細で正確な手術が可能となっている。(著者抄録)
  • 癌性腹膜炎を伴う胃癌に対する集学的治療 CARTと腹腔内化学療法を併用した積極的治療戦略
    石神 浩徳, 北山 丈二, 山口 博紀, 渡邉 聡明 日本アフェレシス学会雑誌 33 (3) 162 -166 2014年10月 [査読無し][通常論文]
  • 胃癌腹膜播種
    山口 博紀, 石神 浩徳, 渡邉 聡明, 北山 丈二 消化器の臨床 17 (5) 397 -402 2014年10月 [査読無し][通常論文]
     
    胃癌腹膜播種は、胃癌手術において根治手術を妨げる最大の要因であると同時に、胃癌根治術後の半数近くを占める再発形式であり、胃癌術後の死因の最多を占める。難治性疾患である胃癌腹膜播種病変に対してはいまだ標準治療は存在していないが、S-1+パクリタキセル静脈投与・腹腔内投与併用療法は胃癌腹膜播種に対して強力な抗腫瘍効果を示し、第II相臨床試験では1年生存率77〜78%と良好な成績が得られている。腹腔内に直接投与された脂溶性抗癌剤であるパクリタキセルは、腹腔内に長時間停留し、腹膜播種結節の表面から直接浸透することにより抗腫瘍効果を発揮する。現在S-1+シスプラチン併用療法と比較する第III相臨床試験が進行中である。(著者抄録)
  • 【外科医が知っておくべき小腸疾患】手術 クローン病
    岸川 純子, 風間 伸介, 畑 啓介, 山口 博紀, 石原 聡一郎, 須並 英二, 渡邉 聡明 臨床外科 69 (9) 1092 -1097 2014年09月 [査読無し][通常論文]
     
    <ポイント>クローン病(CD)において絶対的手術適応となるのは,炎症が増悪して深掘れ潰瘍を呈し,穿孔や穿通に続く膿瘍,あるいは大量出血の原因となりうる場合である.また,内科的治療に反応せず炎症の増悪・寛解に伴い腸管の創傷治癒を繰り返した場合には瘢痕性狭窄や瘻孔形成をきたし,相対的な手術適応となる.再手術率が高く,短腸症候群が問題となることから,CDの小腸病変では可及的に腸管を温存することが重要であり,狭窄形成術または小範囲切除が行われる.再発予防として内科治療ではメサラジンやニトロイミダゾール系抗菌薬,プリン誘導体,また近年は抗TNF-α製剤であるインフリキシマブの有用性が示されており,禁煙の重要性も報告されている.(著者抄録)
  • 【colitic cancerの初期病変-遡及例の検討を含めて】colitic cancer早期発見,診断のためのサーベイランス法 ランダム生検と狙撃生検の比較
    岸川 純子, 風間 伸介, 畑 啓介, 安西 紘幸, 小澤 毅士, 山口 博紀, 石原 聡一郎, 須並 英二, 北山 丈二, 渡邉 聡明 胃と腸 49 (10) 1479 -1486 2014年09月 [査読無し][通常論文]
     
    潰瘍性大腸炎の長期経過例では,慢性持続炎症を背景とした大腸癌の合併リスクが高いことから,大腸内視鏡検査によるサーベイランスが推奨されている.しかし,その病変は,通常の散発性大腸癌と比較して内視鏡的に同定困難であるとされてきた.このため,これまでは盲目的な生検で大腸癌や前癌病変であるdysplasiaを確率的にとらえようとするランダム生検が行われてきたが,侵襲の大きさと同定率の低さが費用対効果に見合わないことが問題であった.近年,内視鏡の解像度の向上に加え,色素内視鏡や拡大観察などの応用で以前より病変の視認性が向上してきていることを背景に,狙撃生検の有用性が示唆されるようになってきた.現在本邦で行われているランダム生検と狙撃生検の無作為ランダム化比較試験の結果が待たれるところである.(著者抄録)
  • 【消化器癌化学療法の最前線】腹腔内化学療法の基礎と臨床応用
    山口 博紀, 渡邉 聡明 BIO Clinica 29 (2) 146 -150 2014年02月 [査読無し][通常論文]
     
    腹腔内に直接投与された脂溶性抗癌剤であるパクリタキセルは、腹腔内に長時間停留し、腹膜播種結節の表面から直接浸透することにより抗腫瘍効果を発揮する。一回の投与におけるパクリタキセルの浸透距離は腫瘍結節表面から100-200μm程度であり、十分な効果を得るためには腹腔内投与を繰り返す必要がある。S-1+パクリタキセル静脈投与・腹腔内投与併用療法は胃癌腹膜播種に対して強力な抗腫瘍効果を示し、第II相臨床試験では1年生存率77-78%と良好な成績を得た。現在S-1+シスプラチン併用療法と比較する第III相臨床試験が進行中である。(著者抄録)
  • 石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明 癌と化学療法 40 (10) 1269 -1273 2013年10月 [査読無し][通常論文]
     
    腹膜播種陽性胃癌に対して高いエビデンスを有する標準治療は存在せず、その病態を考慮した新規治療法の開発が急務である。強力な局所療法であるpaclitaxel(PTX)腹腔内投与と全身化学療法、胃切除を組み合わせた集学的治療は有望な治療法の一つである。当科ではS-1+PTX経静脈・腹腔内併用療法を考案し、第I相試験により推奨投与量を決定し、第II相試験において1年全生存割合78%、生存期間中央値(MST)23.6ヵ月という成績を得た。また、2011年までに本療法を実施した100例の初発例のうち、腹膜播種に著効が確認された62例に対して胃切除を施行し、安全性を確認するとともに、MST34.5ヵ月という成績を得た。現在、本療法をS-1+CDDP併用療法と比較する第III相試験(PHOENIX-GC試験)を実施中である。全生存期間における優越性が証明され、PTX腹腔内投与の保険収載につながることが期待される。(著者抄録)
  • 【大腸癌腹膜播種を極める-最近の進歩と今後の展望】腹膜播種を考える 大腸癌と胃癌の違い
    山口 博紀, 渡邉 聡明 臨床外科 68 (9) 1014 -1018 2013年09月 [査読無し][通常論文]
     
    <ポイント>癌取扱い規約,治療ガイドラインにおいて,大腸癌と胃癌の腹膜播種の分類と治療方針には大きな違いがある.大腸癌根治術後の腹膜播種再発の頻度は胃癌に比べて圧倒的に少ない.その理由として,大腸癌は未分化型の頻度が少なく,また,腹腔内に癌細胞が遊離しても腹膜転移形成能が低いことが考えられる.(著者抄録)
  • 石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明 臨床外科 68 (6) 675 -679 2013年06月 [査読無し][通常論文]
     
    <ポイント>パクリタキセル腹腔内投与を併用した化学療法により,胃癌腹膜転移の強力な制御が可能である.化学療法により腹水細胞診が陰性化し,腹膜播種が消失または著明に縮小した場合に手術適応と判断した.腹膜転移100例中60例に手術を施行し,生存期間中央値は34.5ヵ月であり,重篤な術後合併症を認めなかった.(著者抄録)
  • 石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明 胃がんperspective 6 (1) 22 -29 2013年03月 [査読無し][通常論文]
  • 石神 浩徳, 北山 丈二, 山口 博紀, 江本 成伸, 渡邉 聡明 癌と化学療法 39 (13) 2460 -2463 2012年12月 [査読無し][通常論文]
     
    腹膜播種陽性胃癌に対する標準治療は全身化学療法であり、切除不能な進行再発胃癌を対象とした臨床試験の結果に基づき、S-1+cisplatin(CDDP)併用療法が一般に行われている。一方で近年、taxane系抗癌剤腹腔内投与および化学療法と手術を組み合わせた集学的治療の有用性が報告されている。当院ではS-1+paclitaxel(PTX)経静脈・腹腔内併用療法を考案し、第II相試験において1年全生存率78%、生存期間中央値(MST)23.6ヵ月という成績を得た。また、腹膜播種に対する奏効が確認された60例に対して胃切除を施行し、安全性を確認するとともに、MST34.5ヵ月という成績を得た。これらの治療成績より、腹腔内投与併用化学療法と胃切除による集学的治療は生存期間の延長をもたらすことが示唆された。本療法とS-1+CDDP併用療法を比較することを目的として、2011年より高度医療評価制度下に第III相試験(PHOENIX-GC試験)を実施中である。(著者抄録)
  • 【播種治療の展望】胃癌播種病変に対する腹腔内化学療法 効果発現の根拠
    山口 博紀, 北山 丈二, 名川 弘一 Surgery Frontier 19 (2) 139,106 -143,106 2012年06月 [査読無し][通常論文]
     
    近年胃癌腹膜播種に対し、腹腔内にパクリタキセル(PTX)を直接投与する腹腔内化学療法を行うことにより、比較的良好な成績が報告されている。腹腔内に投与された水溶性・低分子物質は腹腔内を覆っている腹膜中皮よりただちに吸収されるが、脂溶性・高分子物質はストマータや乳斑と呼ばれるリンパ管開口部より吸収されるため、腹腔内に比較的長時間停留する。脂溶性抗癌剤であるPTXは界面活性剤であるクレモフォールELによりミセル化され製剤化されており、ほかの抗癌剤と比べ著しく腹腔内停留時間が長い。腹腔内に投与されたPTXは腹膜播種結節の表面から内部に向かい直接浸透することによって抗腫瘍効果を発揮する。1回の投与におけるPTXの浸透距離は腫瘍結節表面から数百μm程度であり、十分な効果を得るためには腹腔内投与を繰り返す必要がある。また、肉眼的に播種が消失し、腹腔洗浄細胞診が陰性化しても、洗浄液中のCEA mRNAは多くの場合陰性とならないため、可能な限り腹腔内化学療法を継続する必要がある。(著者抄録)
  • 外科学の古典を読む[第9回] Kocher授動の原典
    山口 博紀, 名川 弘一, 北山 丈二 外科 73 (9) 983 -986 2011年09月 [査読無し][通常論文]
  • 【ナノテクノロジーの外科領域への応用】抗癌剤内包ナノミセルの腹腔内化学療法への応用
    山口 博紀, 北山 丈二, 名川 弘一 Surgery Frontier 17 (2) 124 -130 2010年06月 [査読無し][通常論文]
     
    消化器癌の死亡原因の大きな割合を占める腹膜播種に対し、最近さまざまな治療がなされるようになってきたが、いまだ満足できる成績は得られておらず、新たな治療法が必要とされている。抗癌剤をナノキャリアを用いて高分子ミセル化させ、抗癌剤が腹膜から緩徐に吸収されることにより長時間にわたり腹腔内に滞留させることを可能としたDDSが開発されている。脂溶性である抗癌剤パクリタキセル(PTX)を高分子ポリマーに内包させることにより分子量の大きい水溶性製剤とし、腹膜播種を生じたマウス腹腔内に投与したところ、界面活性剤であるクレモフォールELに溶解させたパクリタキセルを投与した群に比較し、強い抗腫瘍効果と生存期間の延長を認めた。また、腹腔内投与されたナノミセル化パクリタキセルは播種結節のより深部に浸透しており、抗腫瘍効果増強の機序として示唆された。抗癌剤内包ナノミセルはすでにわが国において臨床応用が始められており、各種抗癌剤に治療抵抗性を示してきた腹膜播種病変に対する新たな治療戦略の一翼を担うものとして期待される。(著者抄録)
  • S-1とAromatase Inhibitorが有効であった再発乳癌の3症例
    加藤 昌弘, 北山 丈二, 山口 博紀, 佐貫 潤一, 甲斐崎 祥一, 名川 弘一 癌と化学療法 37 (5) 903 -906 2010年05月 [査読無し][通常論文]
     
    今回われわれは、進行・再発乳癌に対しS-1による加療を行い、1年以上にわたり病気の進行を軽減し、QOLを維持した治療が施行できた3症例を経験した。いずれもanthracycline系やtaxane系の前治療を受けている症例であった。3症例すべてにおいて特に重篤な副作用の発現は認められておらず、減量および投与スケジュールを変更することなく治療継続が可能であった。特に1症例では、anthracycline系、taxane系薬剤だけでなく、vinorelbineなども投与された症例であり、S-1とaromatase inhibitorで約3年を超えて治療継続が可能であった点は非常に重要なことであると考えられる。経口剤であり、比較的副作用が軽微であるS-1は進行・再発乳癌の症例に対してQOLを維持した治療に大きく寄与できる可能性があると考えられる。(著者抄録)
  • 【血液脳関門研究の最近の進歩】血液脳関門と電磁波
    釣田 義一郎, 山口 博紀, 名川 弘一, 上野 照剛 生体の科学 52 (6) 548 -551 2001年12月 [査読無し][通常論文]
  • 下顎転移を起こした胃癌の1症例
    鈴木 弥生, 中川 暁子, 戸島 均, 和田 全玄, 星本 和種, 山口 博紀, 奥村 稔, 鴨志田 敏郎, 高橋 敦 耳鼻咽喉科・頭頸部外科 73 (3) 235 -238 2001年03月 [査読無し][通常論文]
     
    胃腺癌が下顎歯肉に転移した69歳男で,治療として下顎腫瘍を局所切除した.術後口腔内出血は消失し,咀嚼機能が回復した
  • 結核性膿胸及び胸郭形成術後の胸壁原発悪性リンパ腫の1例
    河崎 勉, 大坂 顯通, 山口 博紀, 高橋 敦, 北川 昌伸, 今井 康文 日立医学会誌 35 (2) 109 -114 1998年12月 [査読無し][通常論文]
     
    78歳女.58年前に左肺結核のために胸郭形成術が施行された.左側胸部痛と胸壁の腫瘤病変が認められ,生検によってび漫性免疫芽球型B細胞性悪性リンパ腫と診断された.化学療法が施行されたが治療抵抗性で,発症から約5ヵ月後に敗血症性ショックのために死亡した
  • 【混合型肝癌など胆管成分をもつ肝癌】当院で経験した混合型肝癌の2例
    小島 博, 矢倉 道泰, 村居 晴洋, 時田 元, 上司 裕史, 原田 英治, 山口 博紀, 櫻井 直彦, 黒木 尚, 後藤 振一郎, 仙波 大右, 蛇澤 晶 Liver Cancer 4 (2) 94 -98 1998年10月 [査読無し][通常論文]
     
    75歳女,70歳男.combined typeの混合型肝癌の2例.1例は自己免疫性肝炎に合併した混合型肝癌であり,他の1例は肝細胞癌術後,約5年後に混合型肝癌が発生した極めてまれな症例である
  • 穿孔性腹膜炎にて発症した小腸Crohn病の1例
    中坪 直樹, 山口 博紀, 佐藤 宗勝 日本臨床外科学会雑誌 59 (5) 1295 -1299 1998年05月 [査読無し][通常論文]
     
    34歳男.前駆症状を認めず,突然の腹痛,発熱で発症し穿孔性腹膜炎の診断で緊急手術を施行した際,Crohn病が疑われた.本症の急性腹症としての意義を含め,文献的検討を行った
  • 下血で発症した肺癌小腸転移の1例
    中坪 直樹, 山口 博紀, 佐藤 宗勝 日本臨床外科医学会雑誌 58 (12) 2904 -2908 1997年12月 [査読無し][通常論文]
     
    54歳男,1993年2月に左B6原発の肺癌(rtLU)に対し左肺全摘術(P-T2N2M0,stageIIIA)が行われた.1996年5月より下血が出現し当科を受診した.高度の貧血が認められたため内視鏡検査を施行したが上部消化管,大腸に出血部位は認められなかった.小腸造影検査で空腸に狭窄所見が認められ転移性小腸腫瘍の疑いで手術を施行した.トライツ靱帯より100から130cmの空腸間膜に径7cmの腫瘤を認めた.腫瘤は一部腸管壁を巻き込む形で存在していた.腫瘤を含め約40cmの小腸切除を行い端々吻合を施行した.組織学的には中分化型腺癌であり,肺癌からの転移と診断された
  • リンパ管腫症(胃,肝,脾,腸間膜,リンパ節)の1例
    山口 博紀, 吉澤 浩次, 星本 和種 日立医学会誌 34 (1) 26 -31 1997年02月 [査読無し][通常論文]
     
    58歳男.健康診断によって胃腫瘍,及び脾,肝の多発性嚢胞性病変を指摘された.精査の結果,胃の粘膜下腫瘍,肝,脾の嚢胞性病変及び腹腔内リンパ節転移が疑われた.胃全摘,脾摘,小腸間膜嚢腫切除,肝生検,傍大動脈リンパ節生検が施行された.病理組織学的に胃,肝,脾,小腸間膜,リンパ節に発生したリンパ管腫症と診断された
  • 当院の腹腔鏡下胆嚢摘出術の現況 186例の臨床的検討と今後の課題
    奥村 稔, 山口 博紀, 友澤 滋 つくばシンポジウム 11 12 -16 1995年12月 [査読無し][通常論文]
     
    男94例,女92例,内訳は胆石症140例,胆嚢ポリープ23例,総胆管結石症16例,胆石症+胆嚢ポリープ6例,胆嚢腺筋症1例である.操作性の良好な吊り上げ法の利点により,総胆管結石症16例に対し,13例に総胆管切開+Tチューブドレナージを,3例に経胆嚢管的切石を一期的にL.C.に併施し加療した.又,胆石症1例,胆嚢ポリープ2例に癌の合併があり,1例は後日開腹し肝床切除+リンパ節郭清を,2例は病理学的所見より経過観察としている.術後合併症では,術後腹腔内出血1例,脳梗塞1例,総胆管遺残結石2例,膵炎・肝機能異常1例であった


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.